

## Health Technology Assessment

Volume 25 • Issue 19 • March 2021

ISSN 1366-5278

# Assistive technology and telecare to maintain independent living at home for people with dementia: the ATTILA RCT

*Rebecca Gathercole, Rosie Bradley, Emma Harper, Lucy Davies, Lynn Pank, Natalie Lam, Anna Davies, Emma Talbot, Emma Hooper, Rachel Winson, Bethany Scutt, Victoria Ordonez Montano, Samantha Nunn, Grace Lavelle, Matthew Lariviere, Shashivadan Hirani, Stefano Brini, Andrew Bateman, Peter Bentham, Alistair Burns, Barbara Dunk, Kirsty Forsyth, Chris Fox, Catherine Henderson, Martin Knapp, Iracema Leroi, Stanton Newman, John O'Brien, Fiona Poland, John Woolham, Richard Gray and Robert Howard*





# Assistive technology and telecare to maintain independent living at home for people with dementia: the ATTILA RCT

Rebecca Gathercole<sup>1\*</sup>, Rosie Bradley<sup>2</sup>, Emma Harper<sup>2</sup>,  
Lucy Davies<sup>2</sup>, Lynn Pank<sup>2</sup>, Natalie Lam<sup>2</sup>, Anna Davies<sup>3,4</sup>,  
Emma Talbot<sup>5</sup>, Emma Hooper<sup>6,7</sup>, Rachel Winson<sup>8</sup>,  
Bethany Scutt<sup>1</sup>, Victoria Ordonez Montano<sup>9</sup>,  
Samantha Nunn<sup>10</sup>, Grace Lavelle<sup>1</sup>, Matthew Lariviere<sup>11</sup>,  
Shashivadan Hirani<sup>3</sup>, Stefano Brini<sup>3</sup>, Andrew Bateman<sup>12</sup>,  
Peter Bentham<sup>13</sup>, Alistair Burns<sup>7</sup>, Barbara Dunk<sup>14</sup>,  
Kirsty Forsyth<sup>15</sup>, Chris Fox<sup>16</sup>, Catherine Henderson<sup>17</sup>,  
Martin Knapp<sup>17</sup>, Iracema Leroi<sup>18</sup>, Stanton Newman<sup>3</sup>,  
John O'Brien<sup>19</sup>, Fiona Poland<sup>20</sup>, John Woolham<sup>21</sup>,  
Richard Gray<sup>2</sup> and Robert Howard<sup>22</sup>

<sup>1</sup>Department of Old Age Psychiatry, King's College London, London, UK

<sup>2</sup>Medical Research Council Population Health Research Unit, University of Oxford, Oxford, UK

<sup>3</sup>School of Health Sciences, City, University of London, London, UK

<sup>4</sup>Population Health Sciences, University of Bristol, Bristol, UK

<sup>5</sup>Norfolk and Suffolk NHS Foundation Trust, Stowmarket, UK

<sup>6</sup>Lancashire Care NHS Foundation Trust, Preston, UK

<sup>7</sup>Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

<sup>8</sup>Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK

<sup>9</sup>Hertfordshire Community NHS Trust, Watford, UK

<sup>10</sup>Cambridgeshire Community Services NHS Trust, Cambridge, UK

<sup>11</sup>Centre for International Research on Care, Labour and Equalities, University of Sheffield, Sheffield, UK

<sup>12</sup>School of Health and Social Care, University of Essex, Colchester, UK

<sup>13</sup>Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, UK

<sup>14</sup>South London and Maudsley NHS Foundation Trust, London, UK

<sup>15</sup>School of Health Sciences, Queen Margaret University, Edinburgh, UK

<sup>16</sup>Norwich Medical School, University of East Anglia, Norwich, UK

<sup>17</sup>Care Policy and Evaluation Centre, London School of Economics and Political Science, London, UK

<sup>18</sup>Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland

<sup>19</sup>Department of Psychiatry, University of Cambridge, Cambridge, UK

<sup>20</sup>School of Health Sciences, University of East Anglia, Norwich, UK

<sup>21</sup>National Institute for Health Research (NIHR) Health & Social Care Workforce Research Unit, King's College London, London, UK

<sup>22</sup>Division of Psychiatry, University College London, London, UK

\*Corresponding author



**Declared competing interests of authors:** Samantha Nunn reports that a National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme grant was awarded to King's College London, and that study activity at Cambridgeshire Community Services NHS Trust was funded by this grant. Peter Bentham reports personal fees from TauRx Therapeutics Ltd (Aberdeen, UK) outside the submitted work. Catherine Henderson reports grants from the NIHR HTA programme during the conduct of the study. John O'Brien reports personal fees from TauRx Therapeutics Ltd, AXON Neuroscience SE (Larnaca, Cyprus), GE Healthcare (Chicago, IL, USA) and Eisai Co., Ltd (Tokyo, Japan), grants and personal fees from Avid Radiopharmaceuticals (Eli Lilly and Company, Indianapolis, IN, USA) and grants from Alliance Medical (Warwick, UK) outside the submitted work. Richard Gray reports grants from the NIHR HTA programme during the conduct of the study. Robert Howard reports grants from the NIHR HTA programme during the conduct of the study. He also reports that he was a member of the HTA programme Commissioning Sub-board (Expressions of Interest) (2009–11) and of the HTA Programme Commissioning Committee (2013–18).

Published March 2021

DOI: 10.3310/hta25190

This report should be referenced as follows:

Gathercole R, Bradley R, Harper E, Davies L, Pank L, Lam N, *et al.* Assistive technology and telecare to maintain independent living at home for people with dementia: the ATTILA RCT. *Health Technol Assess* 2021;**25**(19).

*Health Technology Assessment* is indexed and abstracted in *Index Medicus/MEDLINE*, *Excerpta Medica/EMBASE*, *Science Citation Index Expanded (SciSearch®)* and *Current Contents®/Clinical Medicine*.



# Health Technology Assessment

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 3.370

*Health Technology Assessment* is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) ([www.publicationethics.org/](http://www.publicationethics.org/)).

Editorial contact: [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

The full HTA archive is freely available to view online at [www.journalslibrary.nihr.ac.uk/hta](http://www.journalslibrary.nihr.ac.uk/hta). Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: [www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

## Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

## HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

## This report

The research reported in this issue of the journal was funded by the HTA programme as project number 10/50/02. The contractual start date was in January 2013. The draft report began editorial review in September 2019 and was accepted for publication in December 2019. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

Copyright © 2021 Gathercole *et al.* This work was produced by Gathercole *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. See: <https://creativecommons.org/licenses/by/4.0/>. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

Published by the NIHR Journals Library ([www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)), produced by Prepress Projects Ltd, Perth, Scotland ([www.prepress-projects.co.uk](http://www.prepress-projects.co.uk)).

## NIHR Journals Library Editor-in-Chief

---

**Professor Ken Stein** Professor of Public Health, University of Exeter Medical School, UK

## NIHR Journals Library Editors

---

**Professor John Powell** Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

**Professor Andrée Le May** Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

**Professor Matthias Beck** Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly** Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin** Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson** Consultant Advisor, Wessex Institute, University of Southampton, UK

**Ms Tara Lamont** Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

**Dr Catriona McDaid** Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire** Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads** Emeritus Professor of Wellbeing Research, University of Winchester, UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma** Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts** Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

**Professor Jonathan Ross** Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Ken Stein** Professor of Public Health, University of Exeter Medical School, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: [www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

**Editorial contact:** [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)



# Abstract

## Assistive technology and telecare to maintain independent living at home for people with dementia: the ATTLA RCT

Rebecca Gathercole<sup>1\*</sup>, Rosie Bradley<sup>2</sup>, Emma Harper<sup>2</sup>,  
Lucy Davies<sup>2</sup>, Lynn Pank<sup>2</sup>, Natalie Lam<sup>2</sup>, Anna Davies<sup>3,4</sup>,  
Emma Talbot<sup>5</sup>, Emma Hooper<sup>6,7</sup>, Rachel Winson<sup>8</sup>, Bethany Scutt<sup>1</sup>,  
Victoria Ordonez Montano<sup>9</sup>, Samantha Nunn<sup>10</sup>, Grace Lavelle<sup>1</sup>,  
Matthew Lariviere<sup>11</sup>, Shashivadan Hirani<sup>3</sup>, Stefano Brini<sup>3</sup>,  
Andrew Bateman<sup>12</sup>, Peter Bentham<sup>13</sup>, Alistair Burns<sup>7</sup>,  
Barbara Dunk<sup>14</sup>, Kirsty Forsyth<sup>15</sup>, Chris Fox<sup>16</sup>,  
Catherine Henderson<sup>17</sup>, Martin Knapp<sup>17</sup>, Iracema Leroi<sup>18</sup>,  
Stanton Newman<sup>3</sup>, John O'Brien<sup>19</sup>, Fiona Poland<sup>20</sup>,  
John Woolham<sup>21</sup>, Richard Gray<sup>2</sup> and Robert Howard<sup>22</sup>

<sup>1</sup>Department of Old Age Psychiatry, King's College London, London, UK

<sup>2</sup>Medical Research Council Population Health Research Unit, University of Oxford, Oxford, UK

<sup>3</sup>School of Health Sciences, City, University of London, London, UK

<sup>4</sup>Population Health Sciences, University of Bristol, Bristol, UK

<sup>5</sup>Norfolk and Suffolk NHS Foundation Trust, Stowmarket, UK

<sup>6</sup>Lancashire Care NHS Foundation Trust, Preston, UK

<sup>7</sup>Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

<sup>8</sup>Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK

<sup>9</sup>Hertfordshire Community NHS Trust, Watford, UK

<sup>10</sup>Cambridgeshire Community Services NHS Trust, Cambridge, UK

<sup>11</sup>Centre for International Research on Care, Labour and Equalities, University of Sheffield, Sheffield, UK

<sup>12</sup>School of Health and Social Care, University of Essex, Colchester, UK

<sup>13</sup>Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, UK

<sup>14</sup>South London and Maudsley NHS Foundation Trust, London, UK

<sup>15</sup>School of Health Sciences, Queen Margaret University, Edinburgh, UK

<sup>16</sup>Norwich Medical School, University of East Anglia, Norwich, UK

<sup>17</sup>Care Policy and Evaluation Centre, London School of Economics and Political Science, London, UK

<sup>18</sup>Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland

<sup>19</sup>Department of Psychiatry, University of Cambridge, Cambridge, UK

<sup>20</sup>School of Health Sciences, University of East Anglia, Norwich, UK

<sup>21</sup>National Institute for Health Research (NIHR) Health & Social Care Workforce Research Unit, King's College London, London, UK

<sup>22</sup>Division of Psychiatry, University College London, London, UK

\*Corresponding author [rebecca.gathercole@kcl.ac.uk](mailto:rebecca.gathercole@kcl.ac.uk)

**Background:** Assistive technology and telecare have been promoted to manage the risks associated with independent living for people with dementia, but there is limited evidence of their effectiveness.

**Objectives:** This trial aimed to establish whether or not assistive technology and telecare assessments and interventions extend the time that people with dementia can continue to live independently at home and whether or not they are cost-effective. Caregiver burden, the quality of life of caregivers and of people with dementia and whether or not assistive technology and telecare reduce safety risks were also investigated.

**Design:** This was a pragmatic, randomised controlled trial. Blinding was not undertaken as it was not feasible to do so. All consenting participants were included in an intention-to-treat analysis.

**Setting:** This trial was set in 12 councils in England with adult social services responsibilities.

**Participants:** Participants were people with dementia living in the community who had an identified need that might benefit from assistive technology and telecare.

**Interventions:** Participants were randomly assigned to receive either assistive technology and telecare recommended by a health or social care professional to meet their assessed needs (a full assistive technology and telecare package) or a pendant alarm, non-monitored smoke and carbon monoxide detectors and a key safe (a basic assistive technology and telecare package).

**Main outcome measures:** The primary outcomes were time to admission to care and cost-effectiveness. Secondary outcomes assessed caregivers using the 10-item Center for Epidemiological Studies Depression Scale, the State-Trait Anxiety Inventory 6-item scale and the Zarit Burden Interview.

**Results:** Of 495 participants, 248 were randomised to receive full assistive technology and telecare and 247 received the limited control. Comparing the assistive technology and telecare group with the control group, the hazard ratio for institutionalisation was 0.76 (95% confidence interval 0.58 to 1.01;  $p = 0.054$ ). After adjusting for an imbalance in the baseline activities of daily living score between trial arms, the hazard ratio was 0.84 (95% confidence interval 0.63 to 1.12;  $p = 0.20$ ). At 104 weeks, there were no significant differences between groups in health and social care resource use costs (intervention group – control group difference: mean –£909, 95% confidence interval –£5336 to £3345) or in societal costs (intervention group – control group difference: mean –£3545; 95% confidence interval –£13,914 to £6581). At 104 weeks, based on quality-adjusted life-years derived from the participant-rated EuroQol-5 Dimensions questionnaire, the intervention group had 0.105 (95% confidence interval –0.204 to –0.007) fewer quality-adjusted life-years than the control group. The number of quality-adjusted life-years derived from the proxy-rated EuroQol-5 Dimensions questionnaire did not differ between groups. Caregiver outcomes did not differ between groups over 24 weeks.

**Limitations:** Compliance with the assigned trial arm was variable, as was the quality of assistive technology and telecare needs assessments. Attrition from assessments led to data loss additional to that attributable to care home admission and censoring events.

**Conclusions:** A full package of assistive technology and telecare did not increase the length of time that participants with dementia remained in the community, and nor did it decrease caregiver burden, depression or anxiety, relative to a basic package of assistive technology and telecare. Use of the full assistive technology and telecare package did not increase participants' health and social care or societal costs. Quality-adjusted life-years based on participants' EuroQol-5 Dimensions questionnaire responses were reduced in the intervention group compared with the control group; groups did not differ in the number of quality-adjusted life-years based on the proxy-rated EuroQol-5 Dimensions questionnaire.

**Future work:** Future work could examine whether or not improved assessment that is more personalised to an individual is beneficial.

**Trial registration:** Current Controlled Trials ISRCTN86537017.

**Funding:** This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 25, No. 19. See the NIHR Journals Library website for further project information.



# Contents

List of tables	xv
List of figures	xix
List of boxes	xxi
List of abbreviations	xxiii
Plain English summary	xxv
Scientific summary	xxvii
<b>Chapter 1 Introduction</b>	<b>1</b>
Scientific background	1
Aims and objectives of the trial	2
Structure of the report	3
Deviations from the protocol	3
<b>Chapter 2 Methods</b>	<b>5</b>
Trial objectives	5
Trial design	5
Site identification and recruitment	6
Participants	6
Screening for eligibility and the preliminary information visit	6
<i>Inclusion criteria</i>	6
<i>Exclusion criteria</i>	7
Selection and recruitment	7
Outcome measures	7
<i>Time in days from randomisation to institutionalisation</i>	9
<i>Cost-effectiveness</i>	9
Secondary efficacy parameters	9
<i>Caregiver burden</i>	9
<i>Number and severity of serious adverse events</i>	9
<i>Quantitative and qualitative data</i>	10
Sample size	10
Trial interventions	11
Randomisation	11
Blinding	11
Patient and public involvement	12
Ethics approval	12
Sponsorship	12
<b>Chapter 3 Describing the intervention</b>	<b>13</b>
Introduction	13
Method	13
<i>Assistive technology and telecare delivery systems</i>	13
<i>Assistive technology and telecare</i>	13
<i>Assistive technology and telecare installations</i>	16

## CONTENTS

Results	16
<i>Participants</i>	16
<i>Assessment</i>	17
<i>Assistive technology and telecare recommendations</i>	19
<i>Assistive technology and telecare installations</i>	19
Summary	25
<b>Chapter 4 Primary outcome results</b>	<b>27</b>
Recruitment	27
Primary outcomes	30
<i>Time to institutionalisation</i>	30
<i>Deaths while in the community</i>	33
<i>Serious adverse events</i>	34
<b>Chapter 5 Economic evaluation</b>	<b>37</b>
Methods	37
<i>Outcomes</i>	37
<i>Perspective</i>	37
<i>Time horizon</i>	37
<i>Costs</i>	37
<i>Intervention costs</i>	38
<i>Valuing assessment time</i>	38
<i>Valuing the assistive technology and telecare package</i>	39
<i>Missing data</i>	39
Analyses	41
Cost-effectiveness analyses	41
Results	42
<i>Sample numbers</i>	42
<i>Use of care and support services</i>	42
Outcomes	44
<i>Costs of care and support services</i>	44
Cost-effectiveness analyses	49
<i>Model results: outcomes and costs</i>	49
<i>EuroQol-5 Dimensions</i>	50
<i>Quality-adjusted life-years</i>	52
<i>Incremental cost-effectiveness ratios and probability of cost-effectiveness</i>	53
Sensitivity analysis: replacement cost of unpaid care	54
<i>Institutionalisation-free days</i>	54
<i>EuroQol-5 Dimensions</i>	54
<i>Quality-adjusted life-years</i>	54
Discussion	55
Conclusions	56
<b>Chapter 6 Impact of assistive technology for people with dementia on burden and psychological well-being in unpaid caregivers</b>	<b>57</b>
Aims	58
Methods	58
<i>Design and participants</i>	58
<i>Intervention and control conditions</i>	59
<i>Recruitment</i>	59
<i>Sample size</i>	59
<i>Procedure</i>	59

<i>Data collection</i>	59
<i>Caregiver outcome data</i>	59
<i>Analyses</i>	60
Results	60
<i>Caregiver participants</i>	61
Section 1: findings for all caregivers	61
<i>Caregiver burden</i>	61
<i>Caregiver mood</i>	62
Section 2: spousal caregivers who were living with the person with dementia (co-resident)	62
<i>Caregiver burden</i>	64
<i>Caregiver mood</i>	65
Section 3: caregivers who were the spouse or partner of the person with dementia	65
<i>Caregiver burden</i>	65
<i>Caregiver mood</i>	65
Discussion	66
Strengths, limitations and suggestions for future research	67
Conclusions and implications for practice	67
<b>Chapter 7</b> Practices of people with dementia and caregivers using assistive technologies and telecare at home: a community-based ethnographic study	<b>69</b>
Aims and research questions	69
Methods	69
Design	69
Sample	70
Settings	70
Recruitment	71
Participant observation	71
Analysis	71
Findings	72
<i>Placing technology in care</i>	73
<i>Technology replacing care</i>	74
<i>Technology displacing care and everyday life</i>	76
Discussion	77
<i>Strengths and limitations</i>	77
Conclusions and implications	77
<b>Chapter 8</b> Discussion	<b>79</b>
Main outcomes	79
<i>Conclusions from Chapter 6</i>	79
<i>How ethnographic findings complement ATTILA trial findings</i>	80
Limitations	80
Future research	81
Implications	81
<b>Acknowledgements</b>	<b>83</b>
<b>References</b>	<b>87</b>
<b>Appendix 1</b> Costing the intervention	<b>99</b>
<b>Appendix 2</b> Rating of assistive technology and telecare need	<b>105</b>

## CONTENTS

<b>Appendix 3</b> Unit costs table	<b>115</b>
<b>Appendix 4</b> Baseline demographic characteristics of the sample with dyads participating in full baseline assessments	<b>129</b>
<b>Appendix 5</b> Use of health, social and unpaid care over the previous 3 months	<b>131</b>
<b>Appendix 6</b> Mean cumulative costs	<b>141</b>
<b>Appendix 7</b> Economic evaluation and caregiver data supplementary tables and figures	<b>143</b>



# List of tables

<b>TABLE 1</b> Schedule of trial assessments	8
<b>TABLE 2</b> The ATT assessment standard: current practice across sites	14
<b>TABLE 3</b> Fidelity with ATT assessment standard and identified ATT needs, by assessment areas	17
<b>TABLE 4</b> Fidelity with ATT assessment standard and identified ATT needs, by participant and assessment characteristics	18
<b>TABLE 5</b> Recommended ATT devices matched to ATT devices installed at 24 weeks (intervention arm only)	22
<b>TABLE 6</b> The ATT installations, 12–104 weeks (intervention arm only)	24
<b>TABLE 7</b> Current ATT practice with people with dementia, using the TIDieR format	25
<b>TABLE 8</b> Yearly recruitment per site	27
<b>TABLE 9</b> Participant status at the end of the ATTILA trial	29
<b>TABLE 10</b> Participant baseline characteristics	29
<b>TABLE 11</b> Reasons for admission to care categorised	32
<b>TABLE 12</b> Causes of death categorised	34
<b>TABLE 13</b> Counts of categorised SAEs	35
<b>TABLE 14</b> Number of participants reporting categorised SAEs	35
<b>TABLE 15</b> Mean EQ-5D index scores and SEs, at baseline and at the 12-, 24-, 52- and 104-week assessment points	45
<b>TABLE 16</b> Mean costs (SEs): health and social care services for participant, caregiver costs, out-of-pocket costs, total health and social care and societal costs over the previous 3 months, at baseline and at the 12-, 24-, 52- and 104-week assessments (2016–17 Great British pounds)	45
<b>TABLE 17</b> Institutionalisation-free days and costs at 104 weeks (450 participants)	49
<b>TABLE 18</b> Difference-in-difference estimates: differences in between-group differences on participant and proxy-rated EQ-5D scores and 3-month costs. Sample: available cases	50
<b>TABLE 19</b> Quality-adjusted life-years and costs at 24, 52 and 104 weeks (450 participants)	52

<b>TABLE 20</b> Incremental cost-effectiveness ratio: 24-, 52- and 104-week QALYs (EQ-5D)	53
<b>TABLE 21</b> Caregiver and care recipient demographics (whole sample, N = 495)	61
<b>TABLE 22</b> Caregiver relationship to care recipient and residential status	61
<b>TABLE 23</b> The ZBI: burden for all caregivers for total score and for three principal components	62
<b>TABLE 24</b> Zarit Burden Interview mean and component scores, SEs and 95% CIs for each group at each time point	63
<b>TABLE 25</b> The CES-D-10 and STAI-6 scores according to group and time point for all caregivers	63
<b>TABLE 26</b> Anxiety and Depression mean scores, SEs and 95% CIs for each group at each time point	64
<b>TABLE 27</b> Demographic characteristics of participants with dementia in the subgroup analysis including only caregivers who lived with the cared-for person (n = 195)	64
<b>TABLE 28</b> Demographic characteristics of participants with dementia in the subgroup analysis including only caregivers who were the spouse or partner of the care recipient (n = 240)	65
<b>TABLE 29</b> Description of ethnographic cases	72
<b>TABLE 30</b> Difference-in-difference model estimates: average 3-month costs at baseline and across the 24-week follow-up period	143
<b>TABLE 31</b> Difference-in-difference model estimates: average 3-month EQ-5D index scores at baseline and across the 24-week follow-up period	143
<b>TABLE 32</b> Difference-in-difference model estimates: average 3-month costs at baseline and across the 52-week follow-up period	144
<b>TABLE 33</b> Difference-in-difference model estimates: average 3-month EQ-5D index scores at baseline and across the 52-week follow-up period	144
<b>TABLE 34</b> Difference-in-difference model estimates: average 3-month costs at baseline and across 104-week follow-up period	144
<b>TABLE 35</b> Difference-in-difference model estimates: average 3-month EQ-5D index scores at baseline and across the 104-week follow-up period	145
<b>TABLE 36</b> Mean costs (SEs): unpaid care and total costs from the societal perspective with unpaid care valued at replacement cost over the previous 3 months, at baseline and at the 12-, 24-, 52- and 104-week assessments (£, 2016–17)	148

<b>TABLE 37</b> Difference-in-difference estimates at 104 weeks: differences in between-group differences on participant and proxy-rated EQ-5D scores and 3-month costs (unpaid care valued at replacement cost)	<b>149</b>
<b>TABLE 38</b> Institutionalisation-free days and societal costs (unpaid care valued at replacement cost) at 104 weeks (£, 2016–17) ( <i>n</i> = 450)	<b>150</b>
<b>TABLE 39</b> Societal costs and QALYs (unpaid care valued at replacement cost) at 104 weeks (£, 2016–17) ( <i>n</i> = 450)	<b>150</b>
<b>TABLE 40</b> Principal component analysis of caregivers' responses on the ZBI	<b>151</b>
<b>TABLE 41</b> The ZBI scores for co-resident caregivers, by time point and trial arm	<b>152</b>
<b>TABLE 42</b> The ZBI mean and component scores for co-resident caregivers, by time point and trial arm	<b>153</b>
<b>TABLE 43</b> The STAI-6 and CES-D-10 for co-resident caregivers, by time point and trial arm	<b>153</b>
<b>TABLE 44</b> The Anxiety and Depression mean scores for co-resident caregivers, by time point and trial arm	<b>154</b>
<b>TABLE 45</b> The ZBI scores for spousal caregivers, by time point and trial arm for total burden and principal components	<b>154</b>
<b>TABLE 46</b> The ZBI mean and component scores for spousal caregivers, by time point and trial arm	<b>155</b>
<b>TABLE 47</b> The CES-D-10 and STAI-6 scores for spousal caregivers, by time point and trial arm	<b>155</b>
<b>TABLE 48</b> The Anxiety and Depression mean scores for spousal caregivers, by time point and trial arm	<b>156</b>



# List of figures

<b>FIGURE 1</b> Public assessor value networks	20
<b>FIGURE 2</b> Not-for-profit value networks	21
<b>FIGURE 3</b> The Consolidated Standards of Reporting Trials flow diagram	28
<b>FIGURE 4</b> Kaplan–Meier survival curve: time to admission to care by randomised arm, unadjusted analysis	31
<b>FIGURE 5</b> Kaplan–Meier survival curve: time to admission to care by baseline BADLS score	31
<b>FIGURE 6</b> Forest plot: admission to care by randomised arm, adjusted for baseline BADLS score	32
<b>FIGURE 7</b> Subgroup analyses of admission to care for the ATT group vs. the control group, by baseline characteristics	33
<b>FIGURE 8</b> Kaplan–Meier survival curve: time to death while community resident, by randomised arm	34
<b>FIGURE 9</b> Forest plot of the incidence of SAEs	36
<b>FIGURE 10</b> The ATTILA trial flow of dyads	43
<b>FIGURE 11</b> Map of sitting room in Violet Draper’s home	73
<b>FIGURE 12</b> Map of Christopher Smith’s bungalow	75
<b>FIGURE 13</b> Cost-effectiveness acceptability curve: institutionalisation-free days and total costs at the 104-week follow-up	145
<b>FIGURE 14</b> The CEAC at the 24-week follow-up: EQ-5D-proxy index scores and health and social care costs	145
<b>FIGURE 15</b> The CEAC at 52-week follow-up: EQ-5D-proxy index scores and health and social care costs	146
<b>FIGURE 16</b> The CEAC at 104-week follow-up: EQ-5D-proxy index scores and health and social care costs	146
<b>FIGURE 17</b> Cost-effectiveness acceptability curve: person with dementia QALY derived from the EQ-5D-proxy and total costs at the 24-week follow-up	146
<b>FIGURE 18</b> Cost-effectiveness acceptability curve: person with dementia QALY derived from the EQ-5D-proxy and total costs at the 52-week follow-up	147
<b>FIGURE 19</b> Cost-effectiveness acceptability curve: person with dementia QALY derived from the EQ-5D-proxy and total costs at the 104-week follow-up	147



# List of boxes

**BOX 1** Methods of cost-effectiveness analysis

**100**





## List of abbreviations

ACCOMODATE	A Collaborative COMMunity-based ethnography Of people with Dementia using Assistive technology and Telecare at home in England	GPS	Global Positioning System
ADL	activities of daily living	ICER	incremental cost-effectiveness ratio
AE	adverse event	ICH-GCP	International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use – Good Clinical Practice
ASCD	Adult Social Care Department	ICT	information and communications technology
ATT	assistive technology and telecare	LMM	linear mixed modelling
ATTILA	Assistive Technology and Telecare to maintain Independent Living At home for people with dementia	MOHOST	Model of Human Occupation Screening Tool
BADLS	Bristol Activities of Daily Living Scale	NHC	Northern Housing Consortium
CASSR	council with adult social services responsibilities	NICE	National Institute for Health and Care Excellence
CCTV	closed-circuit television	QALY	quality-adjusted life-year
CEAC	cost-effectiveness acceptability curve	RCT	randomised controlled trial
CES-D-10	10-item Center for Epidemiological Studies Depression Scale	SAE	serious adverse event
CI	confidence interval	SD	standard deviation
CSRI	Client Service Receipt Inventory	SE	standard error
DHSC	Department of Health and Social Care	SMMSE	Standardised Mini-Mental State Examination
EQ-5D	EuroQol-5 Dimensions	STAI-6	State-Trait Anxiety Inventory-6 items
EQ-5D-5L	EuroQol-5 Dimensions, five-level version	TECS	Technology Enabled Care Services
GP	general practitioner	TIDieR	Template for Intervention Description and Replication
		WSD	Whole System Demonstrator
		WTP	willingness to pay
		ZBI	Zarit Burden Interview



## Plain English summary

**M**any people with dementia living at home are recommended assistive technology and telecare to help them remain living safely and independently in the community. These devices are meant to assist and support activities such as taking medication or cooking, or to raise an alert when there is an issue, such as a fire; however, there is currently little evidence to support such claims. This trial investigated whether or not assistive technology and telecare could delay people moving into residential care and keep them any safer than alternatives, and whether or not they were cost-effective.

We recruited 495 people with dementia and their unpaid caregivers, who were randomly assigned to receive either a package of assistive technology and telecare recommended by a health or social care professional or alternative support involving only basic assistive technology and telecare. We monitored the residential status, the use of health-care services and the health and well-being of participants with dementia and their caregivers over a 2-year period. Researchers also spent time with participants to see how they were living with the technology.

The trial found no difference in the time that people with dementia with full assistive technology and telecare remained at home, nor any reduction in the number of safety incidents, compared with the participants who received basic assistive technology and telecare only. Full assistive technology and telecare did not increase health and social care costs. It did not improve the well-being of people with dementia or that of their caregivers. People with dementia who had full assistive technology and telecare rated their quality of life poorer than those with basic assistive technology and telecare did, but their caregivers rated their quality of life as about the same as caregivers of people with basic assistive technology and telecare. The technology sometimes averted crises but also disrupted people's everyday lives.

These results suggest that assistive technology and telecare for people with dementia provided in real-world conditions may not be as beneficial as previously claimed. The way that assistive technology and telecare services are organised bears further investigation to see how these services could be improved.



# Scientific summary

## Background

There are approximately 850,000 people with dementia in the UK, most of whom will require accommodation in nursing or residential care homes when their illness has progressed to the point at which they can no longer live safely and independently in their own homes. The financial cost of caring for people with dementia is considerable, as are the social and psychological costs to unpaid caregivers, who are usually family. Caregiver breakdown is a common reason for the unplanned admission of older people to permanent nursing or residential care. Assistive technology and telecare offer a relatively new means of delivering care and support to people with social care needs by helping to manage the risks facing people with dementia who wish to remain living independently at home. Despite growing implementation of assistive technology and telecare, the evidence to support their use is limited, with many studies having poor methodology or contradictory results. This trial was designed to answer questions about the efficacy and cost-effectiveness of assistive technology and telecare, with particular relevance for those who commission and provide care for people with dementia.

## Objectives

The Assistive Technology and Telecare to maintain Independent Living At home for people with dementia (ATTILA) trial aimed to test the following hypotheses that:

- the application of assistive technology and telecare will significantly extend the time that people with dementia can continue to live independently and safely in their own homes
- assistive technology and telecare interventions are cost-effective in the management of risk and in maintaining independence among people with dementia living in their own homes
- the provision of assistive technology and telecare interventions to people with dementia living at home will significantly reduce the number of incidents involving serious risks to safety and independent living, particularly those involving acute admissions to hospital
- assistive technology and telecare interventions will reduce burden and stress in family and other unpaid caregivers and increase quality of life for people with dementia.

## Method

The ATTILA trial was a pragmatic randomised controlled trial comparing the outcomes of people with dementia who received assistive technology and telecare with the outcomes of people who received equivalent traditional community services but not assistive technology and telecare.

Participants were adults with suspected or diagnosed dementia living in the community who had been recommended assistive technology and telecare to help manage challenges at home caused by their dementia-related cognitive decline. Inclusion criteria were any dementia diagnosis or evidence of memory difficulties or possible dementia, a professionally assessed need for assistive technology and telecare from a health or social care professional, living in the community and living in a dwelling suitable for the installation of assistive technology and telecare. Exclusion criteria were already receiving an assistive technology and telecare intervention (excluding a non-linked smoke detector or carbon monoxide detector, a key safe or a pendant alarm) or having been previously provided assistive technology and telecare but not using it; being unlikely to comply with follow-up, for example owing to an unstable medical or psychiatric condition; participating in another clinical trial involving an

intervention for dementia; having an urgent need for a care package owing to immediate and severe risks to self or others; the absence of an appropriate unpaid caregiver; and living in accommodation unsuitable for the provision of assistive technology and telecare.

All aspects of the intervention (assistive technology and telecare assessment, funding, choice of devices, or ordering and installation of devices) were determined by staff from participating local authorities or telecare providers. Each participant underwent an assessment with the assistive technology and telecare provider to determine the level of need and what services were required. The intervention involved the installation of simple, battery-operated, standalone technologies and/or telecare (a range of devices and sensors that communicate and relay messages to an external call centre where an appropriate response is arranged). The installation and selection of the technology to be deployed was the responsibility of the local authorities involved. Those in the control arm were limited to a pendant alarm, non-monitored smoke and carbon monoxide detectors and a key safe, as recommended by the health or social care professional assessing their needs. Both arms could use additional support services, such as paid care, meals on wheels and attendance at day centres.

Participants were followed up for a minimum of 2 years or until they either moved into residential care or died. Over these 2 years, participants had five follow-up assessments, if they were still living in the community. After this time, they were invited to have a telephone assessment every 6 months until the end of the trial, for a maximum of 3 years or until the point of care home admission or death.

There were two co-primary outcomes to establish whether or not assistive technology and interventions (1) can extend the time that people with dementia can continue to live independently and safely in the community and (2) are cost-effective in the management of risk and in maintaining independence in people with dementia living in their own homes. Secondary outcomes were as follows:

- to establish whether or not these technologies can –
  - significantly reduce the number of incidents involving serious risks to safety and independent living, including acute admissions to hospital
  - reduce stress in family and other unpaid caregivers
  - increase quality of life for those with dementia and their caregivers
- to collect qualitative and quantitative data from people living with dementia and their formal and unpaid caregivers about their experiences of using these technologies.

All participants were included in an intention-to-treat analysis.

## Results

Out of 495 participants, 248 were randomised to receive the full assistive technology and telecare package and 247 were randomised to the limited control package. We sought to describe the assistive technology and telecare intervention using the Template for Intervention Description and Replication (TIDieR) framework. We found a poor fit between the assistive technology and telecare needs and the assessment recommendations ( $\tau = 0.242$ ;  $p < 0.000$ ) and a moderate fit between the assistive technology and telecare recommendations and the installations ( $\tau = -0.470$ ;  $p < 0.000$ ). Furthermore, 62% of devices were installed for assistive technology and telecare needs that had not been identified in the assessment process, and 53% of devices recommended as a result of assessment were not installed by week 24. Median survival outside a care home was 127 weeks in the assistive technology and telecare group and 128 weeks in the control group (hazard ratio for institutionalisation over 3 years 0.76, 95% confidence interval 0.58 to 1.01;  $p = 0.054$ ). After adjusting for an imbalance in baseline activities of daily living scores between trial arms, the hazard ratio was 0.84 (95% confidence

interval 0.63 to 1.12;  $p = 0.20$ ). At 104 weeks, there were no significant differences between groups in health and social care resource use costs (intervention group – control group difference: mean –£909, 95% confidence interval –£5336 to £3345) or societal costs (intervention group – control group difference: mean –£3545, 95% confidence interval –£13,914 to £6581). At 104 weeks, based on quality-adjusted life-years derived from the participant-rated EuroQol-5 Dimensions questionnaire, the intervention group had 0.105 (95% confidence interval –0.204 to –0.007) fewer quality-adjusted life-years than the control group. The number of quality-adjusted life-years derived from the proxy-rated EuroQol-5 Dimensions questionnaire did not differ between groups.

Carer outcomes did not differ between groups over 24 weeks. Ethnographic research examining the way in which participants with dementia and carers were living with the technology found that technological mediation through assistive technology and telecare could replace, displace and disrupt co-located, face-to-face interactions.

## Conclusions

A full package of assistive technology and telecare did not result in a significant increase to the length of time a person with dementia could remain living in the community, nor did it achieve decreases in caregiver burden, depression or anxiety. Use of the full assistive technology and telecare package did not increase participants' health and social care or societal costs. Quality-adjusted life-years based on participants' EuroQol-5 Dimensions questionnaire responses were reduced in the intervention, compared with the control group; the groups did not differ in the number of quality-adjusted life-years based on the proxy-rated EuroQol-5 Dimensions questionnaire. Work is needed to understand the impacts of assistive technology and telecare service configurations across public, voluntary and private sectors. Designers and service provider organisations should work with caregivers and people with dementia and their advocates to co-produce suitable technological interventions.

## Future work

Future work could examine whether or not improved assessment that is more personalised to each individual is beneficial.

## Trial registration

This trial is registered as ISRCTN86537017.

## Funding

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 25, No. 19. See the NIHR Journals Library website for further project information.





# Chapter 1 Introduction

Parts of this report are reproduced with permission from Leroi *et al.*<sup>1</sup> This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Parts of this report are reproduced with permission from Howard *et al.*<sup>2</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>. The text below includes minor additions and formatting changes to the original text.

## Scientific background

There are approximately 850,000 people with dementia in the UK<sup>3,4</sup> and an estimated 700,000 people who provide unpaid care for them. Many of these people with dementia will require accommodation in nursing or residential care homes when their illness has progressed to the point at which they can no longer live safely and independently in their own homes. It has been estimated that, over the next two decades, the number of people aged  $\geq 85$  years will increase by two-thirds.<sup>5</sup> Over half of all users of adult social care services are aged  $\geq 65$  years,<sup>6</sup> and a steep rise in the numbers of people living with dementia is expected over the next few decades. The financial cost of caring for people with dementia is considerable,<sup>3</sup> as is the social and psychological cost to unpaid caregivers (generally a relative or friend, subsequently referred to as 'caregivers'). Caregiver breakdown is a common reason for the unplanned admission of older people (many of whom will have dementia) to permanent nursing or residential care.<sup>7</sup>

Living Well with Dementia, the theme of the 2009 National Dementia Strategy for England,<sup>8</sup> involves helping people with dementia to retain their independence while living in their own homes, and to maintain their quality of their life. People living with dementia who move from their own homes into institutional care often experience a loss of independence and quality of life. To minimise this possibility, the NHS and councils with adult social services responsibilities (CASSRs) in England aim to support people with dementia to live safely in their own homes for as long as possible.

Assistive technology and telecare (ATT) offer relatively new means of delivering care and support to people with social care needs by helping to manage the risks facing older people with dementia who wish to remain living independently at home. It is claimed that sensors (e.g. to detect falls, floods or the presence of gas from an unlit appliance in someone's home), passive monitoring that uses sensors placed in a home environment to detect movement, and alerting devices to relay information from the person's home to a remote site such as a call centre support the independence of people with social care needs,<sup>9,10</sup> reduce the burden on caregivers<sup>11-15</sup> and save money for CASSRs.<sup>16</sup> By addressing risks associated with independent living for people with dementia, it is claimed that ATT help reduce the need for community care, prevent unnecessary hospital admissions and delay or prevent admission to residential or nursing care.<sup>12,17-19</sup> The evidence to support such claims is limited, and based largely on qualitative evidence or uncontrolled quantitative studies.<sup>20,21</sup> There is, therefore, an urgent need to provide evidence to inform decisions about whether or not to provide ATT in the homes of people with dementia.

The first use of electronic ATT in the UK, in the 1990s, was to provide support for people with dementia and their caregivers.<sup>17,22-25</sup> Within a decade, interest in ATT has developed from a fringe interest for a handful of enthusiasts to a multimillion-pound industry commanding government support, a Department of Health and Social Care (DHSC) strategy<sup>26</sup> and, increasingly, the use of ATT in CASSR settings as a mainstream service (see Woolham *et al.*<sup>25</sup>). However, as interest in ATT has increased, the specific focus on its application for those living with dementia has diminished.<sup>13</sup> The performance indicators that followed the Preventative Technology Grant (given to CASSRs in 2008 by the DHSC<sup>26</sup>) were intended to promote the widest possible use of telecare. The DHSC did not, however, offer a clear indication of what this grant was supposed to 'prevent'. Although Woolham<sup>12</sup> has drawn attention to the cost-effectiveness of telecare for people with dementia by closely matching ATT with assessed need, thereby preventing the need for more expensive forms of care, Poole<sup>27</sup> has argued that CASSRs should see ATT as a long-term investment, deploying it at an early stage without expecting immediate savings. This has contributed to a situation in which CASSRs have implemented ATT across several different care groups without always referring to the needs of the specific groups, such as people with dementia. The current economic situation, and a significant reduction in government CASSR funding, has led to increasing numbers of CASSRs developing an interest in ATT. Some have developed local strategies to use it, whereas others already have well-developed ATT services that can be deployed alongside, or instead of, non-institutional forms of support, often known as 'community care' in the UK.

Despite growing ATT use, the evidence to support its use is limited. The Whole System Demonstrator (WSD) study was funded by the DHSC in 2008 to investigate the impact and effectiveness of ATT in England.<sup>28-35</sup> However, individuals with dementia were not specifically included. This, together with the relative dearth of dementia-specific studies relating ATT, means that a significant gap in the evidence remains. Although there are relatively large numbers of qualitative studies, audits and service evaluations, there are few studies with sufficient rigour and appropriate design to offer any degree of generalisability<sup>21</sup> or agreement about how 'success' can be measured.<sup>36</sup> One study<sup>25</sup> has suggested that, when used appropriately, ATT are highly cost-effective, but limitations in design and methodology constrain the generalisability of this study's findings. A Cochrane review in 2017<sup>37</sup> found no research evaluating assistive technology for people via a randomised controlled trial (RCT), with the exception of this Assistive Technology and Telecare to maintain Independent Living At home for people with dementia (ATTILA) trial, which was in progress at the time of publication of the Cochrane review.<sup>37</sup> Evidence from a well-designed trial such as ATTILA is clearly needed to guide future policy direction.

The DHSC's 'Building Telecare' strategy in 2005<sup>13</sup> provided generic advice to CASSRs. As part of this strategy, a Preventative Technology Grant, which CASSRs were required to spend on developing local ATT services, was made available. England's 2009 National Dementia Strategy<sup>8</sup> recommended a 'watching brief' for emerging evidence of the impact of telecare, stating:

*However, with respect to more recent innovations, this is not an area where the strategy is able at this time to make specific recommendations. Instead, central, regional and local teams should keep in touch with initiatives in the areas of housing and telecare and make appropriate commissioning decisions as data become available, for example from the Department's large-scale field trials of telecare and assistive technology.*

*Reproduced from DHSC.<sup>8</sup> © Crown copyright 2009. Contains public sector information licensed under the Open Government Licence v3.0*

### **Aims and objectives of the trial**

The ATTILA trial was designed to answer questions about the efficacy and cost-effectiveness of ATT, with relevance for those who commission and provide care for people with dementia.

The aims of the ATTILA trial were to test the following hypotheses:

- that the application of ATT will significantly extend the time that people with dementia can continue to live independently and safely in their own homes
- that ATT interventions are cost-effective in the management of risk and maintenance of independence for people with dementia living in their own homes
- that provision of ATT interventions to people with dementia living at home will significantly reduce the number of incidents involving serious risks to safety and independent living, particularly those involving acute admissions to hospital
- that ATT interventions will reduce burden and stress in family and other caregivers and increase quality of life for people with dementia.

These hypotheses were tested by the following primary and secondary objectives:

- Primary objective – to establish whether or not ATT assessments and interventions extend the time that people with dementia can continue to live independently in their own homes and whether or not this is cost-effective.
- Secondary objectives –
  - to establish whether or not these technologies can significantly reduce the number of incidents involving serious risks to safety and independent living, including acute admissions to hospital
  - to reduce burden and stress in family and other caregivers, and increase quality of life for people with dementia and their caregivers
  - to collect qualitative and quantitative data from people living with dementia, their paid and unpaid caregivers, and members of the NHS and CASSR teams about their experience of using these technologies.

## Structure of the report

In *Chapter 2*, we provide a summary of the trial methods. In the chapters that follow, we set out the methods and results of the research, beginning with work carried out to describe the intervention (see *Chapter 3*). In subsequent chapters, we report on participant outcomes, cost-effectiveness, caregiver outcomes and ethnographic research with participants and caregivers. In *Chapter 8*, we summarise the findings, reflect on the strengths and weaknesses of the research and make recommendations for future research and practice.

## Deviations from the protocol

We did not conduct one proposed cost-effectiveness analysis. It was proposed that an analysis of the change in EuroQol-5 Dimensions, five-level version (EQ-5D-5L), score over 2 years would take into account the costs of permanent care home and hospital stays of those admitted to care homes over that period. This analysis was not conducted because no outcomes and costs data were collected from caregivers when participants were permanently admitted to care during the 2-year follow-up.



## Chapter 2 Methods

### Trial objectives

The ATTILA trial was a pragmatic RCT comparing outcomes for people with dementia who received a full ATT package with the outcomes for people with dementia who received equivalent community services but ATT were limited to a pendant alarm, non-monitored smoke and carbon monoxide detectors, and key safes. Assistive technology is defined as 'any item, piece of equipment, product or system, whether acquired commercially, off the shelf, modified or customised, that is used to increase, maintain, or improve functional capabilities of individuals with cognitive, physical or communication difficulties'.<sup>22</sup> Telecare can include many different interventions, including those aimed at delivering care and monitoring remotely.<sup>38</sup> For the purposes of this trial, these devices had to be provided to support challenges related to memory problems and recommended by a health or social care professional.

The primary objectives of the trial were to establish whether or not:

- ATT assessments and interventions can extend the time that people with dementia can continue to live independently and safely in the community
- ATT interventions are cost-effective in the management of risk and maintenance of independence in people with dementia living in their own homes.

The secondary objectives were to:

- establish whether or not these technologies can significantly reduce the number of incidents involving serious risks to safety and independent living, including acute admissions to hospital; reduce stress in family and other caregivers; and increase quality of life for those with dementia and their caregivers
- collect qualitative and quantitative data from people living with dementia and their formal caregivers about their experience of using these technologies.

### Trial design

The ATTILA trial was a multicentre, pragmatic RCT, conducted over 260 weeks, that took place in the homes of people living with dementia who were eligible to receive a package of care. The trial compared outcomes in two groups of participants randomised to one of the two trial arms: (1) receiving an assessment of needs followed by the installation of appropriate ATT devices and response services to be deployed by the CASSR or NHS (a full ATT package) or (2) receiving an assessment of needs followed by the installation of an ATT package restricted to smoke and carbon monoxide detectors, a key safe and a pendant alarm if indicated, also arranged by the CASSR (a basic ATT package). The co-primary outcomes were time to institutionalisation and cost-effectiveness of the intervention.

The trial was not funded to source, assess for, or deploy ATT. Our approach was to work alongside CASSRs who were charged by the Department of Health and Social Care with responsibility for establishing and developing local ATT services.

## Site identification and recruitment

Recruitment of local authority Adult Social Care Department (ASCD) sites to the trial was opportunistic because of anticipated difficulties in securing permissions. Sites known to have well-established telecare services were identified, as well as those located in geographical areas close to the place of employment of research team members. This also meant that participating ASCDs were geographically widely spread across England, and that all types of local authority were represented. Telephone contact was usually first made with a telecare manager in identified sites. In most cases, this person referred our request to the departmental senior management team or to the director. In some sites, repeated visits were needed to discuss the request. Several ASCDs declined to take part in the main trial, either because they did not feel that they had the resources to do so or because of lack of fit between the trial aims and the strategic priorities of the service.

## Participants

Participants were people with any dementia diagnosis, or suspected dementia, who were living in the community and were from one or more of three constituencies:

1. people who sought help or support from local authority social care services in the areas that had agreed to support the trial (Barnsley, Blackburn, Blackpool, Cambridgeshire, Croydon, Lambeth, Lancashire, Nottingham, Norfolk, Oxfordshire, Southwark and Suffolk) and who met local ASCD eligibility criteria for their support
2. people who were supported by the services of the NHS and were referred to an ASCD and met local ASCD eligibility criteria
3. people who were recruited from the caseload of NHS services for older adults and referred to local social services and met local ASCD eligibility criteria.

Those referred from the NHS usually had to meet eligibility criteria for social care because this often determined if ATT could be provided.

Most participants ( $n = 431$ , 87.1%) did have a dementia diagnosis, but some of those referred by LAs had not yet had a formal diagnosis. In these cases, clinical judgement was used by the research worker and health or social care staff involved to decide whether or not the cause of the potential participant's memory impairment was dementia. If necessary, the research worker could discuss further with the local principal investigator.

## Screening for eligibility and the preliminary information visit

All trial procedures, including the initial visit and consent visit, took place in participants' homes. At the first appointment, participants were assessed for eligibility based on the following inclusion and exclusion criteria.

### *Inclusion criteria*

- Had any dementia diagnosis, evidence of memory difficulties or possible dementia.
- Had a professionally assessed need for ATT from a health or social care professional.
- Was resident in a community.
- Lived in a dwelling suitable for the installation of ATT.

## Exclusion criteria

- Had already received an ATT intervention (excluding non-linked smoke detector or carbon monoxide detector, key safe or pendant alarm) or ATT had been previously provided but was not used.
- Was unlikely to comply with follow-up, for example owing to an unstable medical or psychiatric condition.
- Was participating in another clinical trial involving an intervention for dementia.
- Had an urgent need for a care package owing to immediate and severe risks to self or others.
- Did not have a suitable caregiver.
- Was living in accommodation unsuitable for the provision of ATT.

## Selection and recruitment

There were several routes for participant recruitment. Most participants were referred from local authority social services, but other referring services included not-for-profit organisations providing ATT; charitable organisations such as Age UK and the Alzheimer's Society; and NHS mental health, community care and primary care services. Those referred from the NHS had to meet eligibility criteria for social care provision.

After assessing eligibility of new referrals for both social care support and the ATTILA trial, participating services asked if a potential participant's contact details could be made available to a named individual in the local research team. Once identified, the research worker contacted this person and arranged to visit them and a caregiver who knew them well. Those meeting the eligibility criteria had the possible benefits and risks of participation in the trial explained to them. Following this, the participant was given a general outline of three possible options: (1) taking part in the ATTILA trial with the intervention (i.e. ATT package or regular support package without ATT) decided by randomisation, (2) declining to participate in the ATTILA trial and (3) taking more time to consider their decision about whether or not to participate. Those who were interested in taking part in the trial were provided with participant and caregiver information leaflets to find out more about the trial before deciding whether or not to participate. After a full explanation of the intervention options and the manner of treatment allocation, all suitable participants were invited to take part in the randomised component of the trial. If urgent provision of support services was required, then consent was sought at that visit so that they could be immediately randomised. Otherwise, information about the trial could be left with the prospective participant and, if they required more time to consider participation, the researcher would return at a later date to take consent and subsequently randomise the participant. Consent was also obtained from the caregiver using the caregiver consent form in the trial folder. If a participant lacked capacity, a professional or personal consultee was involved to ensure that participation in the trial was in the person's best interests (according to guidelines established in the *Mental Capacity Act 2005: Code of Practice*<sup>39</sup>). When appropriate, data-sharing agreements were agreed with the CASSRs and health services concerned to ensure that the transfer of personal data from the local authority to the research team was lawful. If consent was not given, the participant was not included and any personal data were removed from research team records and destroyed. Reasons why those who were potentially eligible did not consent to take part were recorded on a screening log in the ATTILA trial folder. After randomisation, assessment for ATT and provision of ATT services (within limits set by randomisation) were left entirely up to the local authority or health service operational teams concerned.

## Outcome measures

The co-primary trial outcomes were (1) time to institutionalisation and (2) the cost-effectiveness of the ATT intervention. *Table 1* shows the schedule of all assessment points and the measures used at each.

TABLE 1 Schedule of trial assessments

Assessment	Time point												
	Week -1	Eligibility and randomisation screening	Follow-up assessments										
			Face to face					Telephone					
		Week 0	Week 12	Week 24	Week 52	Week 104	Week 130	Week 156	Week 182	Week 208	Week 234	Week 260	
Participant information	X												
Inclusion criteria		X											
ATT needs assessment at home	X												
Capacity assessment	X	X (prior to consent)	X	X	X	X	X						
Informed consent		X											
Randomisation data		X											
Inform local authority of randomisation outcome		X											
Install intervention (ATT or alternatives) <sup>a</sup>			X										
SMMSE			X										
BADLS			X				X						
EQ-5D-5L			X	X	X	X	X						
EQ-5D-5L Proxy (carer)			X	X	X	X	X						
STAI-6 (carer)			X	X	X	X	X						
CES-D-10 (carer)			X	X	X	X	X						
ZBI (carer)			X	X	X	X	X						
SUTAQ (carer)				X	X	X	X						
CSRI (carer)			X	X	X	X	X						
Follow-up form				X	X	X	X	X	X	X	X	X	X
ATT checklist			X	X	X	X	X						
Adverse events			X	X	X	X	X	X	X	X	X	X	X

BADLS, Bristol Activities of Daily Living Scale; CES-D-10, 10-item Center for Epidemiological Studies Depression Scale; CSRI, Client Service Receipt Inventory; SMMSE, Standardised Mini-Mental State Examination; STAI-6, State-Trait Anxiety Inventory-6 items; SUTAQ, Service User Technology Acceptability Questionnaire; ZBI, Zarit Burden Interview.

a Ideally, this should have happened soon after randomisation and prior to the baseline visit, but, owing to the pragmatic nature of the trial, this was not always the case.



### ***Time in days from randomisation to institutionalisation***

This was defined as permanent transition of a participant from living in their own home to living in a nursing or residential care home or to admission to an acute care facility that results in permanent placement in a residential care or nursing home. Caregivers were asked to report the date of this transition; if necessary, health or social care results would also be consulted. Analyses were by intention to treat, with all randomised participants included in the comparison and analysed according to their randomised allocation, including those who discontinued the trial. The primary outcome of time to institutionalisation was compared between intervention and control arms using survival analysis methods. Kaplan–Meier survival curves were created for graphical representation of the time to event comparisons (see *Figures 4, 5 and 7*). Statistical significance was determined by the log-rank test. Analyses included all events, even those occurring after 2 years. Participants who died, withdrew from follow-up or were lost to follow-up were censored at the date of withdrawal from the trial.

### ***Cost-effectiveness***

Economic evaluation methods (see *Chapter 5*) included cost-effectiveness and cost-utility analyses. The evaluation considered three outcomes: days to institutionalisation, change in the EuroQol-5 Dimensions (EQ-5D) index<sup>40,41</sup> and quality-adjusted life-years (QALYs). Cost-effectiveness analyses were conducted from two perspectives: (1) health and social care and (2) societal. Costs were calculated by attaching nationally applicable unit cost measures to health and social service use.<sup>42,43</sup> These data focused on ATT, health-care and other service use patterns and caregiver inputs, and were collected at baseline and at 12, 24, 52 and 104 weeks for each participant using a modified version of the Client Service Receipt Inventory (CSRI).<sup>44</sup> Data on caregiver time and task inputs came from the CSRI and were valued using (and comparing, in sensitivity analyses) replacement wage and opportunity cost approaches. ATT intervention costs were calculated drawing on sources including key informant interviews about the production of ATT in ATTILA trial sites, and from price data drawn from procurement contract databases of the Northern Housing Consortium (NHC). Difference-in-difference analyses of EQ-5D change, with non-parametric bootstrapping, were performed; institutionalisation-free days and QALY outcome analyses employed a combination of population-averaged generalised gamma and survival models with non-parametric bootstrapping. Incremental cost-effectiveness ratios were computed and cost-effectiveness acceptability curves (CEACs) were plotted over a range of values of willingness to pay (WTP) for each outcome.

## **Secondary efficacy parameters**

### ***Caregiver burden***

We measured both burden associated with caregiving and levels of psychological distress among the principal caregivers of participants at baseline and at 12, 24, 52 and 104 weeks. The 22-item short version of the Zarit Burden Interview (ZBI) questions caregivers about their experiences in terms of emotional, physical and social strains or difficulties that result from their role as a caregiver. Items include topics such as feeling that one's own health has suffered, feeling that caregiving has affected relationships with family and friends and how burdened one feels. Caregivers respond by indicating how often they experience each item and responses are scored on a five-point scale ranging from 'never' to 'frequently'. Higher burden is indicated by a higher score and the combined 12 items have high reliability ( $\alpha = 0.86$ ).<sup>45</sup> We also assessed psychological distress with the 10-item Center for Epidemiological Studies Depression Scale (CES-D-10) and the State-Trait Anxiety Inventory (STAI).

### ***Number and severity of serious adverse events***

Serious adverse events (SAEs) were recorded and reported. Researchers systematically enquired about changes in participants' health, any compromises of participant safety or changes in living circumstances between assessments. Safety was assessed by the researcher at the 12-, 24-, 52- and 104-week assessments, and then at the 130-, 156-, 182-, 208-, 234- and 260-week telephone calls to participants' caregivers. The adverse event (AE) reporting arrangements that apply to investigational

medicinal products were not applicable, or appropriate, for the ATTILA trial. The focus was to capture as complete information as possible on compromises of participant safety that might have been preventable by the use of ATT. An adapted version of the AE reporting scheme was therefore used in the ATTILA trial.

A SAE was any compromise of participant safety that:

- resulted in death
- was life-threatening
- necessitated hospitalisation or prolongation of existing hospitalisation
- resulted in persistent or significant disability or incapacity
- necessitated the intervention of emergency services
- resulted in admission to permanent residential care.

### **Assessment of preventability**

The potential preventability of a SAE by the use of ATT was also assessed and categorised by the local researcher and principal investigator into one of the following five categories:

1. Not preventable with assistive technology – the event or its consequences would have been the same with or without ATT.
2. Unlikely to be preventable – the event or its consequences were unlikely to be altered by ATT.
3. Possibly preventable – it is possible that the event or its consequences might have been prevented or mitigated by ATT.
4. Likely to be preventable – it is reasonable to believe that the event or its consequences might have been prevented or mitigated by use of ATT.
5. Definitely preventable – the event or its consequences would have been prevented or mitigated by ATT.

In the analysis, ‘possibly’, ‘likely’ and ‘definitely’ preventable categories were considered as preventable. Throughout the trial, the local ASCD retained responsibility for the ATT and any other support provided, and retained full case responsibility. The trial team had a duty of care to report relevant issues if the ASCD involved were not already aware and would signpost when necessary, but it did not provide equipment, care or support to trial participants.

### ***Quantitative and qualitative data***

Data on the acceptability, applicability and reliability of ATT intervention packages were collected using the Service User Technology Acceptability Questionnaire. This questionnaire was validated using data from the WSD project.<sup>46</sup> We anticipated that unpaid caregivers’ experiences would provide examples of ways that their lives, well-being and caregiver roles had been enhanced and/or undermined by the use of these technologies. Longitudinal qualitative data were collected through an embedded ethnographic study with a subset of the ATTILA trial participants to observe how people with dementia and their caregivers actually used (or chose not to use) ATT in their everyday routines and built environments. This methodology allowed for the team to investigate changes in participants’ technologically enabled care practices over time, as the care needs of people with dementia became more acute.

### **Sample size**

The two primary outcome measures were time to transition to institutional care and cost-effectiveness. It was anticipated that 50% of participants with a Bristol Activities of Daily Living Scale (BADLS)<sup>47</sup> score of  $\geq 15$  would transition to institutional care after 24 months, based on observed institutionalisation rates in participants from the AD2000 (Alzheimer’s disease) cohort.<sup>48</sup> A reduction in the estimated 24-month transition to care home rate by 30% (i.e. 50% institutionalised at 2 years reduced to 35%)

would require the involvement of 500 participants, allowing for 10% attrition due to death while still community resident. This equated to an average of 55 days more of independent home life for each participant who received ATT. The trial would therefore be powered to detect a mean institutionalisation delay of just under 8 weeks. Expert opinion suggests that 8 weeks is close to the minimum clinically important difference in delaying institutionalisation.

## Trial interventions

As the trial design was pragmatic, all aspects of the intervention (ATT assessment, funding, choice of devices, or ordering and installation of devices) were determined by staff from participating LAs or telecare providers. We worked alongside these teams, which have been charged by the Department of Health and Social Care with responsibility for establishing and developing local ATT services. The trial was not funded to source, assess for or deploy ATT.

Each participant underwent an assessment with the ATT provider to determine the level of need and what services that they required. The intervention involved the installation of simple, battery-operated, standalone technologies and/or telecare (a range of devices and sensors that communicate and relay messages to an external call centre where an appropriate response is arranged). The installation and selection of the technology to be deployed was the responsibility of the LAs involved. Those in the control arm were limited to a pendant alarm, non-monitored smoke and carbon monoxide detectors, and a key safe, as recommended by the health or social care professional assessing their needs. Both arms could use additional support services, such as paid care, meals on wheels and day centres.

## Randomisation

Participants were randomised in a one-to-one ratio, using telephone-based randomisation and a computerised data entry portal provided by the Oxford Clinical Trial Service Unit. Treatment allocation was via a minimised randomisation procedure stratified by the following variables to reduce the risk of chance imbalances between arms. This information was obtained by the local trial team following consent and during the screening process. Variables were as follows:

- sex
- age (< 65, 65–80 or > 80 years)
- risk of wandering or leaving the home inappropriately (low, moderate or high risk)
- safety risk in the home (low, moderate or high risk)
- level of caregiver support available (live-in caregiver, caregiver visits at least once daily or caregiver visits less often than daily).

This stratification procedure was reviewed by the Trial Steering Committee after the first 100 randomisations.

## Blinding

Blinding was not undertaken for participants or trial staff collecting data as it was not practicable or ethical to conceal allocation of ATT. The staff who entered the data were unaware of which arm a participant had been allocated to.

## **Patient and public involvement**

The Alzheimer's Society was involved in devising the research question and in the production of the trial materials. Two service user representatives sat on the Trial Steering Committee.

## **Ethics approval**

The trial was conducted and designed in compliance with the principles of the Declaration of Helsinki<sup>49</sup> and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use – Good Clinical Practice (ICH-GCP).<sup>50</sup> All researchers working on the trial received training in ICH-GCP guidelines. The integrated form for both site-specific information and research and development approval at all participating NHS sites was approved prior to recruitment at each site. Annual progress and safety reports and a final report at conclusion of the trial were submitted to the Multicentre Research Ethics Committee and the Health Technology Assessment programme within the timelines agreed.

The trial was approved by the NHS Health Research Authority National Research Ethics Committee (reference number 12/LO/186) and is registered with the International Standard Randomised Controlled Trial Number registry (ISRCTN86537017).

## **Sponsorship**

The trial was sponsored by South London and Maudsley NHS Foundation Trust.

## Chapter 3 Describing the intervention

Parts of this chapter are reproduced with permission from Forsyth *et al.*<sup>51</sup> Reprinted from *Alzheimers & Dementia*, 5, Forsyth K, Henderson C, Davis L, Singh Roy A, Dunk B, Curnow E, *et al.*, Assessment of need and practice for assistive technology and telecare for people with dementia – The ATTILA (Assistive Technology and Telecare to maintain Independent Living At home for people with dementia) trial, 420–30, 2019, with permission from Elsevier.

### Introduction

A detailed exploration of the intervention under investigation is needed to give insight into the fidelity of the intervention and to allow for replication.<sup>52</sup> The aim, therefore, was to provide an overview of routine ATT practice and the systems in place to deliver ATT for people with dementia.

### Method

We adhered to the Template for Intervention Description and Replication (TIDieR)<sup>53</sup> checklist in describing the components of the ATTILA trial intervention, in terms of what happened; who was involved; how, where and when the intervention happened; how much ATT was provided; and whether or not it was tailored to participants.

#### *Assistive technology and telecare delivery systems*

To describe the delivery systems for ATT deployment, interviews were conducted by staff with key informants from local authority operational/commissioning teams and telecare monitoring centre managers in the seven sites from which the majority of trial participants were recruited ( $n = 484$ ). Invitations were sent to 21 potential key informants, resulting in 14 interviews covering six sites (no key informants were available for interview in one site) between June and September 2016. Interviews were not recorded but written notes were taken; interviewees were also asked for supporting documentation that might help in understanding the policies and procedures in relation to ATT deployment. Data were also collected on ATT assessment and delivery processes via pro formas completed by local researchers in 2015 and via a follow-up desk-based search in 2017. Data were examined using NVivo version 11 qualitative data analysis software (QSR International, Warrington, UK). Data were first structured into five production stages within a framework analysis:<sup>54</sup> assessment, equipment procurement/ordering, installation, call monitoring, and response to sensor activations. To identify commonalities in local systems for delivering ATT to trial participants, we took an approach based on value network role analysis.<sup>55,56</sup> Production inputs and processes observed in each site were mapped onto value network frameworks.

#### *Assistive technology and telecare*

The ATT intervention was defined for the purposes of the ATTILA trial as a two-stage process:

1. an ATT assessment, with subsequent ATT recommendation(s)
2. the installation of ATT devices alongside monitoring services, as appropriate.

### Framework analysis

We assumed that social services departments in each ATTILA trial site had distilled local and national guidelines on best practice in ATT assessment when constructing local assessment templates. To establish a practice standard for ATT assessments in the ATTILA trial sites, ATT assessment templates and guidance were sourced from each site between August 2013 and August 2016. Sites were asked to resend documentation if there were changes during the lifetime of the trial; as a result, two sets of

new documentation were submitted. Framework analysis<sup>54</sup> to identify common assessment themes across sites was applied to this documentation, using the Model of Human Occupation Screening Tool (MOHOST).<sup>57</sup> The MOHOST is designed to detail people’s values, insight, interests, routines, communication, cognitive and physical skills, and physical and social environment to gain a detailed picture of an individual’s life. The resultant ATT assessment standard consisted of a set of 14 ATT assessment areas (Table 2). A 4-point scale was developed for each assessment area in the ATT assessment standard, where 4 = no risk when doing daily activity, 3 = mostly risk free when doing daily activity, 2 = some risk when doing daily activity and 1 = significant multiple risks when doing daily activity. Specific definitions were developed for rating each assessment area (see Appendix 2). ATT needs were identified when an assessment area received a rating of 1 (significant multiple risks when doing daily activity) or 2 (some risk when doing daily activity).

TABLE 2 The ATT assessment standard: current practice<sup>a</sup> across sites

Key themes <sup>b</sup>	ATTILA trial site exemplar questions <sup>c</sup>
<p>Motivation</p> <ul style="list-style-type: none"> <li>The person’s motivation drives their choice to carry out or not carry out daily activity. They may not have insight into their ability to carry out daily activities safely or are motivated to do things that are of importance but not safe to do</li> </ul>	<p>1. Insight</p> <ul style="list-style-type: none"> <li>Does the person’s lack of insight into their difficulties put them at risk? For example, no insight into their lack of ability to safely do an everyday activity (may appear overconfident), lack confidence to do activities that may carry risks, lack insight to activate ATT if required, not able to be involved in ATT process</li> </ul>
	<p>2. Values</p> <ul style="list-style-type: none"> <li>Does what is important to the person put them at risk? For example, the person’s skills do not match what they think is really important to do; nothing is important to them, leading to passivity; support is not acceptable to them as they feel that it is important to be independent; not willing to explore options, that is they do not want ‘ugly’ equipment as they are house proud</li> </ul>
<p>Routines</p> <ul style="list-style-type: none"> <li>Maintaining particular routines and responsibilities for activities of daily living are pivotal aspects of life. These routines and activities provide meaning and structure to how people spend their time</li> </ul>	<p>3. Wandering/disorientation</p> <ul style="list-style-type: none"> <li>Does the person’s routine put them at risk? For example, wandering, disturbance in day/night activity levels, getting up at night and become disoriented, kitchen routines not effective, periods of restlessness, periods of agitation/aggression</li> </ul>
	<p>4. Daily activity</p> <ul style="list-style-type: none"> <li>Does the person’s responsibility for their daily activity put them at risk? For example, cannot manage medication, cannot safely do their cooking or make a hot drink/snack, cannot safely bathe/dress</li> </ul>
<p>Communication skills</p> <ul style="list-style-type: none"> <li>These skills enable people to describe their needs and to respond to the messages of others</li> </ul>	<p>5. Conversation</p> <ul style="list-style-type: none"> <li>Does the person’s ability to have a conversation put them at risk? For example, confabulation, unable to communicate their needs, unable to use a telephone or lifeline unit without becoming disoriented in conversation</li> </ul>
	<p>6. Express needs</p> <ul style="list-style-type: none"> <li>Does the person’s ability to express their needs put them at risk? For example, a speech impairment, an inability to express their needs, incomplete sentence structure, mute, speak another language only</li> </ul>

TABLE 2 The ATT assessment standard: current practice<sup>a</sup> across sites (continued)

Key themes <sup>b</sup>	ATTILA trial site exemplar questions <sup>c</sup>
Cognitive skills	7. Memory
<ul style="list-style-type: none"> <li>Impaired cognitive skill of a person can impact on their daily activities and on how ATT might be used to reduce risks and facilitate their engagement in meaningful activities</li> </ul>	<ul style="list-style-type: none"> <li>Does memory and having an understanding of how to do things put them at risk? For example, needing prompting, forgetting to take medication, forgetting to close doors/turn off taps, no awareness of how to use appliances, no awareness of how to respond to alarms</li> </ul>
Physical skills	8. Problem solving
<ul style="list-style-type: none"> <li>People use physical skills to move themselves or objects while doing everyday things. This includes posture, mobility, strength and effort</li> </ul>	<ul style="list-style-type: none"> <li>Does the ability to problem solve put the person at risk? For example, unable to anticipate and adapt to difficulties that arise and makes inappropriate decisions</li> </ul>
Physical environment	9. Mobility
<ul style="list-style-type: none"> <li>Each physical environment offers a different combination of opportunities and resources, demands and constraints</li> </ul>	<ul style="list-style-type: none"> <li>Does the person's mobility put them at risk? For example, poor posture and instability/poor balance when walking indoors; unsafe using stairs; unsafe walking outdoors; walks with a shuffle, putting them at risk of falls; very mobile (alongside disorientation)</li> </ul>
Social environment	10. Grip/dexterity
<ul style="list-style-type: none"> <li>The social environment consists of the people in the life of the person with dementia, for example caregivers, neighbours, home helps, friends, family. Daily activities are completed in particular ways that have been defined by society norms</li> </ul>	<ul style="list-style-type: none"> <li>Does the person's grip/dexterity put them at risk? For example, drops hot liquids/burn risk, cannot effectively use domestic appliances because of poor grip, cannot operate ATT because of poor grip and lack of strength</li> </ul>
	11. Space
	<ul style="list-style-type: none"> <li>Does the person's physical space put them at risks? For example, blocked access, rugs, cables, bolts/chains, poor state of repair, poor lighting, negotiating stairs, accessing rooms</li> </ul>
	12. Resources
	<ul style="list-style-type: none"> <li>Does the person's physical resources put them at risk? For example, appliances are in disrepair and are a fire risk, that is electric fire, cookers; no smoke alarms; excessively hot water/risk of scalding; only bath available, which is not safe for the person to use; no night light when needed</li> </ul>
	13. Social support
	<ul style="list-style-type: none"> <li>Does the person's social support put them at risk? For example, no family support; caregiver's needs not being met, no caregiver currently available when needed to prompt, provide emergency access or respond to an alert; no acceptance of a non-familiar person, no one to maintain ATT</li> </ul>
	14. The way an activity is completed
	<ul style="list-style-type: none"> <li>Does the way the person completes the activity put them at risk? For example, unsafely using an overhead gas grill instead of a toaster, unsafely (lack of light) going to the toilet at night, unsafely having a night-time bath when tired, using stairs repeatedly in the day when physically not able, not wearing shoes/coat outdoors in wet weather</li> </ul>

a As defined in the ATT assessment documentation across sites.

b Output from the framework analysis using the MOHOST.

c Each question was criterion-referenced and rated on a 4-point rating scale.



### **Fidelity of assistive technology and telecare assessment to assessment standard**

Locally completed ATT assessments for each participant were reviewed against the ATT assessment standard to assess whether or not locally completed ATT assessments across ATTILA trial sites addressed the ATT assessment areas identified by the templates. Fidelity to this standard was determined by two trial practitioners with experience in dementia care and ATT assessment, who independently classified the content of each locally completed ATT assessment against the ATT assessment standard and assigned risk ratings. They then reviewed ratings together and resolved discrepancies.

### **Assistive technology and telecare taxonomy/checklist**

There is no recognised taxonomy of ATT for people with dementia; therefore, a taxonomy was developed in collaboration with Trent Dementia Services Development Centre and the 'atdementia' initiative ([www.atdementia.org.uk](http://www.atdementia.org.uk); accessed 13 July 2018), an independent online ATT resource. This taxonomy was then developed into two identical technology checklist forms (one for recommended ATT and one for installed ATT), which covered the following ATT functions: (1) reminder or prompting devices, (2) devices to support safety, (3) safer walking technologies, (4) communication devices, (5) devices that support meaningful use of leisure time and (6) monitoring and response information. The form also recorded data about which type of assessor had assessed for ATT (ATT assessor, health or social care professional, other), the method of assessment (in person, at home; in person, not at home; telephone assessment; using case notes; other), whether or not ATT were monitored (yes/no) and who would respond to ATT alerts (direct to responder or via a call centre). Two trial practitioners with experience in dementia care and ATT assessment collaboratively classified each device recommended in the locally completed ATT needs assessment using the technology checklist (for recommended ATT).

### *Assistive technology and telecare installations*

#### **Assistive technology and telecare checklist**

Local trial researchers used the technology checklist (for installed ATT) during home visits at weeks 12, 24, 52 and 104.

#### **Statistical analysis**

Categorical data were summarised in percentages and numbers of observations. Correlations between count variables were tested using non-parametric methods (Kendall rank correlation coefficient,  $\tau$ ). The Kruskal–Wallis test was used to assess if there were statistically significant differences between multiple groups for outcomes. Freidman's test was used to determine the significance of change over time in the count variables. In the case of categorical variables, differences between observed and expected frequencies were tested using Pearson's chi-squared test for independence, or, alternatively, Fisher's exact test, when the assumption of minimum expected cell count in contingency tables was not met.<sup>58</sup> Standardised Mini-Mental State Examination (SMMSE) scores were categorised into stages of dementia<sup>59</sup> for the purposes of analysis (30 = no dementia, 26–29 = questionable dementia, 21–25 = mild dementia, 11–20 = moderate dementia and 0–10 = severe dementia). Effective tailoring of the intervention was described through the strength of the correlation<sup>60</sup> between ATT needs and ATT recommendations at baseline and between ATT recommendations and ATT installation by 24 weeks. We also compared the ATT that were recommended in the needs assessment with subsequent installations for each participant in the intervention arm up to 24 weeks. Any installation after 24 weeks was considered unrelated to the baseline ATT assessment.

## **Results**

### *Participants*

A total of 495 participants were randomised to the ATTILA trial (intervention group,  $n = 248$ ; control group,  $n = 247$ ). Of these, 451 had a documented needs assessment. A total of 209 intervention group participants had documented ATT installations.



## Assessment

Of the 451 documented ATT needs assessments available, 413 contained an ATT recommendation. Of the 248 participants recruited to the intervention arm, data from 209 participants were available for analysis of ATT installations.

In total, 60% of assessment responses identified an ATT need, with 4.4 ATT needs (range 0–12) identified per participant (Tables 3 and 4). The mean number of ATT needs identified varied, ranging from two to six per site ( $p < 0.001$ ). The areas of concern most frequently identified as triggering the need for ATT were daily activities (93%), memory (89%) and problem-solving (83%). Health and social care professionals identified more ATT needs than ATT assessors ( $p = 0.047$ ). More ATT needs were identified through in-person, at-home assessments than through telephone assessment methods ( $p < 0.001$ ). There was no significant difference between ATT needs in men and women ( $p = 0.337$ ). The number of ATT needs identified for each participant differed depending on the risk of wandering ( $p = 0.005$ ): a medium risk of wandering was associated with more ATT needs than a low risk of wandering ( $p = 0.016$ ). ATT needs varied by category of SMMSE score ( $p < 0.001$ ): participants with severe dementia had more ATT needs than those with mild ( $p < 0.001$ ), those with moderate ( $p = 0.002$ ) or those with questionable dementia ( $p < 0.001$ ).

## Fidelity of assessment

The local ATT assessment fidelity with the ATT assessment standard was 52% (7.2 assessment areas were addressed per assessment) (see Tables 3 and 4). Of 451 ATT assessments reviewed, 99 (22%) addressed 0–2 areas of assessment. There was higher fidelity to assessment areas relating to ‘mobility’ (74%), ‘social support’ (72%), ‘daily activity’ (71%) and ‘memory’ (71%). Fidelity varied across sites: the mean number of assessment areas addressed ranged from two to 13 per site ( $p < 0.001$ ), with public

TABLE 3 Fidelity with ATT assessment standard and identified ATT needs, by assessment areas

Site ATT assessment areas/standard	Fidelity with ATT assessments standard		ATT needs (i.e. responses rated as ‘at risk’)	
	n/N	%	n/N	%
1. Insight	241/451	53	151/241	63
2. Values	245/451	54	100/245	41
3. Wandering/disorientation	284/451	63	219/284	77
4. Daily activity	321/451	71	298/321	93
5. Conversation	226/451	50	100/226	44
6. Express needs	175/451	39	24/175	14
7. Memory	320/451	71	284/320	89
8. Problem-solving	218/451	48	181/218	83
9. Mobility	335/451	74	224/335	67
10. Grip/dexterity	147/451	33	18/147	12
11. Space	140/451	31	47/140	34
12. Resources	128/451	28	26/128	20
13. Social support	325/451	72	183/325	56
14. The way the activity is completed	162/451	36	118/162	73
Total responses	3267/6314	52	1973/3267	60

TABLE 4 Fidelity with ATT assessment standard and identified ATT needs, by participant and assessment characteristics

Characteristic	Fidelity with ATT assessments standard			Number of ATT needs		
	Median	Mean	%	Median	Mean	%
<b>Participant characteristic</b>						
Gender						
Female	8	7.67	62	4	4.46	60
Male	5	6.65	38	3	4.25	40
	$p = 0.027$			$p = 0.337$		
Risk of wandering						
Low	7	6.93	70	4	4.10	68
Medium	9	8.37	23	5	5.04	23
High	6	7.24	7	4	5.24	9
	$p = 0.038$			$p = 0.005$		
SMMSE score of 18 points						
Questionable dementia (26–29)	7	7.22	13	3	3.38	10
Mild dementia (21–25)	7	6.6	27	4	3.9	27
Moderate dementia (11–20)	7	7.38	45	4	4.27	44
Severe dementia (0–10)	8.5	7.96	15	5.5	5.79	19
	$p = 0.309$			$p < 0.000$		
<b>Assessment characteristic</b>						
Assessors						
Health and social care professionals	8	7.85	68	4	4.66	67
ATT assessor	5.5	6.51	29	3	3.86	29
	$p = 0.051$			$p = 0.028$		
Assessment method						
In person, at home	10	9.14	85	5	5.06	82
In person, not at home	5	6.43	8	3	3.38	8
Telephone	2	3.42	6	2	2.71	9
Case notes	3	3.33	1	2.5	3	1
	$p < 0.000$			$p < 0.000$		
Service structure						
Public telecare provider	7	7.59	73	4	4.41	70
Not-for-profit telecare provider	6	6.41	25	4	4.31	28
	$p = 0.026$			$p = 1.00$		
	Mean fidelity with ATT assessment standard per participant: 7.2 assessment areas addressed (range 0–13)			Mean number of responses per participant rated as an ATT need: 4.4 ATT needs (range 0–12)		

telecare providers addressing more assessment areas than not-for-profit telecare providers ( $p = 0.026$ ). Health and social care professionals addressed more assessment areas than ATT assessors ( $p = 0.046$ ). Fidelity varied across assessment methods ( $p < 0.001$ ), with the in-person, at-home assessment method addressing more assessment areas than in-person, not-at-home ( $p = 0.003$ ), telephone ( $p < 0.001$ ) and case notes assessment methods ( $p = 0.003$ ). Women had more assessment areas addressed than men ( $p = 0.027$ ). More assessment areas were addressed for participants at medium risk of wandering than for participants at low risk of wandering ( $p = 0.028$ ).

## Assistive technology and telecare delivery system

### Value networks

Networks delivering services (offering value) to participants in ATTILA trial sites were classified into two types (Figures 1 and 2). First were 'public telecare provider networks' ( $n = 4$ ), for which two assessor roles were identified: the ATT assessor and the authorised (or trusted) assessor (health or social care professional). ATT assessors were employed by public agencies (NHS or CASSRs); their primary role was to assess for a full range of ATT devices ['networked' (monitored by a telecare call centre or caregiver) or 'standalone']. Authorised assessors could offer first-generation telecare (pendant-only systems) or straightforward ATT (e.g. adding on an additional sensor or providing a memo minder), depending on their level of experience and local permissions; they performed ATT assessment as a secondary role. In these networks, most or all of the ATT infrastructure for procurement, installation, stock control and maintenance of ATT devices fell to units in the CASSR. The second type of networks were 'not-for-profit provider networks' ( $n = 3$ ). Three assessor roles were identified across these 'not-for-profit telecare networks'. Telecare assessors working for not-for-profit telecare providers assessed for AT that was networked to providers' call-monitoring centres. Assessment for standalone assistive technology fell to assessors in the CASSR. A 'social care ATT assessor' role was also identified; these assessors could assess for ATT (networked or standalone) and work with a choice of suppliers to procure and arrange the installation of ATT devices. Private companies offered combinations of procurement and stock control, installation, and maintenance services to the not-for-profit telecare providers.

### Assistive technology and telecare recommendations

A documented ATT recommendation was given for 413 participants, with 1090 ATT devices recommended at baseline [mean three devices (range 1–14 devices)]. For 57% ( $n = 235$ ) of participants, just one or two ATT devices were recommended. The correlation between the ATT needs and the ATT recommendations identified in local ATT assessments was weak ( $\tau = 0.242$ ;  $p < 0.001$ ). Most recommendations were for safety-related devices (59%, 644/1090), followed by reminder/prompting devices (25%, 269/1090). ATT devices required monitoring in 62% (673/1090) of recommendations, and 67% (353/526) of monitored devices with an identified responder required a formal (call centre) response.

### Assistive technology and telecare installations

#### Frequency of assistive technology and telecare categories

By 24 weeks, a mean of 3.5 devices had been recommended for participants in the intervention arm. Of the ATT devices recommended, 53% (306/572) were not installed.

#### Relationship of assistive technology and telecare installations to assistive technology and telecare recommendations

A total of 62% (438/704) of the ATT devices that were installed had not been recommended in the needs assessment (Table 5). There was a moderate negative correlation between number of recommendations and number of installations per participant per ATT category ( $\tau = -0.470$ ; both  $p < 0.001$ ).




FIGURE 1 Public assessor value networks. a, Featured in some but not all networks.




FIGURE 2 Not-for-profit value networks. a, Featured in some but not all networks.

## DESCRIBING THE INTERVENTION

TABLE 5 Recommended ATT devices matched to ATT devices installed at 24 weeks (intervention arm only)

ATT technology checklist	ATT devices, n/N (%)				
	Recommended	Recommended and installed by 24 weeks	Recommended but not installed	Installed by 24 weeks	Not recommended but installed
<b>Control group technology</b>					
Pendant alarm	44/572 (8)	22/44 (50)	22/44 (50)	89/704 (13)	67/89 (75)
Non-monitored smoke detector	0/572 (0)	0 (0)	0 (0)	68/704 (10)	68/68 (100)
Non-monitored carbon monoxide detector	1/572 (0)	0/1 (0)	1 (100)	36/704 (5)	36/36 (100)
Key safe	18/572 (3)	9/18 (50)	9/18 (50)	89/704 (13)	80/89 (90)
Activity monitors assessment only	8/572 (1)	4/8 (50)	4/8 (50)	5/704 (1)	1/5 (20)
Other devices	1/572 (0)	0/1 (0)	1/1 (100)	6/704 (1)	6/6 (100)
<b>Intervention group technology</b>					
<i>Reminder or prompting devices</i>					
Date and time reminders	31/572 (5)	13/31 (42)	18/31 (58)	46/704 (7)	33/46 (72)
Item-locator devices	9/572 (2)	8/9 (89)	1/9 (11)	11/704 (2)	3/11 (27)
Medication reminders/dispensers	56/572 (10)	25/56 (45)	31/56 (55)	33/704 (5)	8/33 (24)
Voice recorders and memo minders	46/572 (8)	27/46 (59)	19/46 (41)	38/704 (5)	11/38 (29)
Other reminder/prompting devices	1/572 (0)	0/1 (0)	1/1 (100)	6/704 (1)	6/6 (100)
<i>Devices to promote safety</i>					
Activity monitors – ongoing monitoring	5/572 (1)	1/5 (20)	4/5 (80)	6/704 (1)	5/6 (83)
Fall detectors	75/572 (13)	31/75 (41)	44/75 (59)	53/704 (8)	22/53 (42)
Continence management devices	1/572 (0)	1/1 (100)	0/1 (0)	1/704 (0)	0/1 (0)
Alarm and pager units	5/572 (1)	2/5 (40)	3/5 (60)	5/704 (1)	3/5 (60)
Flood detectors and water temperature monitor	14/572 (2)	9/14 (64)	5/14 (36)	11/704 (2)	2/11 (18)
Gas detectors	21/572 (4)	8/21 (38)	13/21 (62)	19/704 (3)	11/19 (58)
Monitored carbon monoxide detectors	25/572 (4)	8/25 (32)	17/25 (68)	22/704 (3)	14/22 (64)
Monitored smoke detectors	59/572 (10)	39/59 (66)	20/59 (34)	47/704 (7)	8/47 (17)
Monitored extreme temperature sensors	26/572 (5)	18/26 (42)	15/26 (58)	19/704 (3)	8/19 (42)
Lighting devices	2/572 (0)	1/2 (50)	1/2 (50)	8/704 (1)	7/8 (88)
Other safety and security devices	15/572 (3)	2/15 (13)	13/15 (87)	9/704 (1)	7/9 (78)

TABLE 5 Recommended ATT devices matched to ATT devices installed at 24 weeks (intervention arm only) (continued)

ATT technology checklist	ATT devices, n/N (%)				
	Recommended	Recommended and installed by 24 weeks	Recommended but not installed	Installed by 24 weeks	Not recommended but installed
<i>Safer walking technologies</i>					
To locate the user	43/572 (8)	20/43 (47)	23/43 (53)	28/704 (4)	8/28 (29)
To alert the responder to movement	59/572 (10)	25/59 (42)	34/59 (58)	37/704 (5)	12/37 (32)
<i>Communication devices</i>					
Intercoms	2/572 (0)	0/2 (0)	2/2 (100)	1/704 (0)	1/1 (100)
Telephones	3/572 (1)	0/3 (0)	3/3 (100)	7/704 (1)	7/7 (100)
Communication aids	0/572 (0)	0/0 (0)	0/0 (0)	1/704 (0)	1/1 (100)
Other communication devices	1/572 (0)	0/1 (0)	1/1 (100)	0/704 (0)	0/0 (0)
<i>Devices that support meaningful use of leisure time</i>					
Computer aids	0/572 (0)	0/0 (0)	0/0 (0)	0 (0)	0 (0)
Dementia-friendly television/radio/music players	0/572 (0)	0/0 (0)	0/0 (0)	0 (0)	0 (0)
Electronic photograph albums/electronic reminiscence aids	0/572 (0)	0/0 (0)	0/0 (0)	0 (0)	0 (0)
Electronic games	0/5572 (0)	0/0 (0)	0/0 (0)	1/551 (0)	1/1 (100)
Other devices	1/572 (0)	0/1 (0)	1/1 (100)	2/551 (0)	2/2 (100)
Total	572	266/572 (47)	306/572 (53)	704	438/704 (62)

### Week 12–104, assistive technology and telecare devices installed (intervention arm only)

From week 12 to week 104, 888 ATT devices were installed for 209 participants in the intervention arm, which is a mean of 4.2 devices per participant (range 1–15 devices). Of the devices installed for intervention participants (Table 6), 42% (374/888) involved the types of technology provided to control arm participants (e.g. non-monitored smoke detectors). Installations decreased over time ( $p = 0.031$ ), with 79% (704/888) of ATT installed by week 24. Intervention participants' ATT devices were most frequently installed for safety reasons (38%) or for reminder/prompting (18%). ATT assessors were most frequently identified as having assessed for the installed devices (32%), followed by health and social care professionals (20%), but 40% of assessors' backgrounds were unknown. A total of 41% of installations followed an in-person home visit (41%), but in 42% of cases participants could not report the method of assessment. Nearly half (47%) of the ATT devices installed required monitoring; 38% of monitored devices were networked to a call centre (so that any alerts would receive an initial response from paid services).

## DESCRIBING THE INTERVENTION

TABLE 6 The ATT installations, 12–104 weeks (intervention arm only)

	Week, n (%)				Total (weeks 12–104), n (%)
	12	24	52	104	
<b>Control group technology installed</b>					
Basic ATT	235 (41)	58 (47)	45 (52)	36 (37)	374 (42)
<b>Intervention technology installed</b>					
Reminder/prompting	116 (20)	18 (15)	9 (10)	17 (18)	160 (18)
Safety	220 (38)	45 (36)	30 (35)	43 (44)	338 (38)
Communication	8 (1)	1 (0)	2 (2)	1 (1)	12 (2)
Support leisure time	1 (0)	2 (2)	1 (1)	0 (0)	4 (0)
Any other devices	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Total installed	580 (100)	124 (100)	87 (100)	97 (100)	888 (100)
<b>Assessor</b>					
Health or social care professional	126 (22)	20 (16)	13 (15)	17 (18)	176 (20)
ATT assessor	152 (26)	58 (47)	23 (26)	45 (46)	278 (32)
Other	68 (12)	0 (0)	3 (4)	4 (4)	75 (8)
Unknown	234 (40)	46 (37)	48 (55)	31 (32)	359 (40)
Total installed	580 (100)	124 (100)	87 (100)	97 (100)	888 (100)
<b>Assessment method</b>					
In person, at home	216 (37)	70 (57)	30 (34)	55 (57)	371 (41)
In person, not at home	7 (1)	3 (2)	1 (1)	4 (4)	15 (2)
Telephone	50 (9)	4 (3)	1 (1)	4 (4)	59 (7)
Using case notes	7 (1)	0 (0)	0 (0)	2 (2)	9 (1)
Other	56 (10)	1 (1)	2 (2)	0 (0)	59 (7)
Unknown	244 (42)	46 (37)	53 (61)	32 (33)	375 (42)
Total installed	580 (100)	124 (100)	87 (100)	97 (100)	888 (100)
<b>Monitoring</b>					
Yes	292 (51)	56 (45)	32 (37)	42 (43)	422 (47)
No	147 (25)	45 (36)	25 (29)	40 (41)	257 (29)
Unknown	141 (24)	23 (19)	30 (34)	15 (16)	209 (24)
Total installed	580 (100)	124 (100)	87 (100)	97 (100)	888 (100)
<b>Response</b>					
Formal services	104 (36)	29 (52)	15 (47)	14 (33)	1622 (38)
Informal services	79 (27)	11 (20)	8 (25)	16 (38)	1142 (27)
Mixed services	106 (36)	14 (25)	8 (25)	12 (29)	1402 (33)
Unknown	3 (1)	2 (3)	1 (3)	0 (0)	62 (2)
Total installed	292 (100)	56 (100)	32 (100)	42 (100)	422 (100)



## Summary

The findings are the first to describe assistive technology for people with dementia. The components of the ATTILA trial intervention have been described, in terms of what happened, who was involved, how, where and when the intervention happened, how many devices was provided and whether or not the intervention was tailored to participants. Value networks operating in ATTILA trial sites were characterised as either public or not-for-profit telecare provider network types. The ATTILA trial intervention is summarised in *Table 7*, using the TIDieR format.

TABLE 7 Current ATT practice with people with dementia, using the TIDieR format

TIDieR format	Current ATT practice for people with dementia
<b>When?</b>	
When did assessments, recommendation and installations happen?	Baseline (week 0): assessment and recommendations Weeks 12, 24, 52 and 104: assessment and installation
<b>What?</b>	
What areas of assessment, in local ATT assessments, had higher fidelity to the ATT assessment standard?	Daily activity, memory, mobility and social support
What areas of assessment more frequently triggered the need for ATT?	Daily activities, memory and problem-solving
What ATT devices were recommended more frequently in local ATT assessments?	Devices for safety issues and to remind/prompt with monitoring/formal response
What ATT devices were installed more frequently?	Devices for safety issues and to remind/prompt with monitoring/formal response and control arm devices (e.g. non-monitored smoke detectors)
<b>How much?</b>	
How much of the ATT assessment was completed?	52% of the ATT assessment areas were completed 7.2 ATT assessment areas were addressed, on average (range 0–13)
How many ATT needs were present?	4.4 ATT needs, on average (range 0–12 needs)
How many ATT recommendations were identified?	3 ATT devices, on average (range 1–14 devices) 57% of participants had one or two ATT devices recommended
How many installations were conducted?	4.2 ATT devices were installed, on average (range 1–15 devices) (including control arm devices) 79% were installed by week 24, with a reduction in installation over time
How much monitoring and response happened?	47% of installed ATT devices required monitoring, of which 38% required a formal response
<b>Who?</b>	
Who were the participants?	> 80 years of age, female, widowed, white British, not living alone and had moderate dementia

continued

TABLE 7 Current ATT practice with people with dementia, using the TiDieR format (continued)

TiDieR format	Current ATT practice for people with dementia
Who were the assessors of the installed devices?	Baseline: <ul style="list-style-type: none"> <li>• 57% – health and social care professionals</li> <li>• 33% – ATT assessors</li> <li>• 10% – not known</li> </ul> Weeks 12–104: <ul style="list-style-type: none"> <li>• 32% – ATT assessors</li> <li>• 20% – health and social care professionals</li> <li>• 40% – not known</li> <li>• 8% – other</li> </ul>
<b>Where?</b>	
Where did the ATT assessment take place?	41% of assessments were in-person, at home
Where did the installations take place?	Participant's homes
<b>Tailoring</b>	
Were the devices tailored to the participants?	There was an expectation that ATT installations would be tailored to participants by the baseline ATT assessment; however, there was weak to moderate tailoring between (1) baseline ATT needs and ATT recommendations ( $\tau = 0.242$ ; $p < 0.000$ ) and (2) ATT recommendations and the ATT installed ( $\tau = -0.470$ ; $p < 0.000$ ); 62% of devices were installed for ATT needs that had not been identified in the assessment process, and 53% of the devices recommended as a result of assessment were not installed by week 24

## Chapter 4 Primary outcome results

### Recruitment

Eleven sites in England were opened for recruitment to the ATTILA trial. The first participant was randomised on 14 August 2013; recruitment ended on 26 October 2016. The ATTILA trial randomised over a period of 38 months, with an average recruitment rate of 13 participants per month. Yearly recruitment per site is shown in *Table 8*.

A total of 1411 people were assessed for trial eligibility; of these, 495 were randomised across the 11 sites: 248 were randomised to receive ATT and 247 were randomised to the control arm. The Consolidated Standards of Reporting Trials flow diagram of participants through the ATTILA trial is shown in *Figure 3*, and *Table 9* shows the participant status at the end of the trial.

Those people who declined to consent did so because they wanted ATT ( $n = 53$ ), because they did not want ATT ( $n = 83$ ) or because they did not want to participate in research ( $n = 162$ ). Other reasons for being excluded were, primarily, that the researcher was unable to contact the potential participant ( $n = 131$ ) or because participation was deemed inappropriate ( $n = 48$ ).

During the follow-up of the ATTILA trial, in total, 200 participants were admitted to care, 89 participants died, 42 withdrew from further follow-up and 18 were lost to follow-up. This resulted in 146 participants finishing the trial living independently in the community: 85 in the intervention arm and 61 in the control arm. Relatively few participants (3.6%) were lost to follow-up, as, once randomised, every effort was made to follow up participants throughout the trial to obtain all follow-up forms and outcome assessments. Of the 18 lost to follow-up, 10 were in the intervention arm and eight were in the control arm.

TABLE 8 Yearly recruitment per site

Site	Year (number of participants recruited)				Total number of participants recruited
	2013	2014	2015	2016	
Croydon	4	21	13	10	48
Lambeth	5	13	28	17	63
Southwark	3	21	21	26	71
Cambridge	2	49	37	51	139
Oxford	0	18	8	4	30
Suffolk	3	23	24	11	61
Lancashire	1	14	35	22	72
Blackpool	0	1	3	0	4
Nottingham	0	2	0	0	2
Barnsley	0	0	0	3	3
Blackburn	0	0	2	0	2
Yearly total	18	162	171	144	495

PRIMARY OUTCOME RESULTS




FIGURE 3 The Consolidated Standards of Reporting Trials flow diagram.

TABLE 9 Participant status at the end of the ATTILA trial

Status	Trial arm, n (%)		Total (N = 495), n (%)
	Intervention (N = 248)	Control (N = 247)	
Admitted to care	93 (37.5)	107 (43.3)	200 (40.4)
Death while a community resident	41 (16.5)	48 (19.4)	89 (18.0)
Withdrew from further follow-up	19 (7.7)	23 (9.3)	42 (8.5)
Lost to follow-up (unable to contact)	10 (4.0)	8 (3.2)	18 (3.6)
Finished trial living in the community	85 (34.3)	61 (24.8)	146 (29.5)

Once a participant was admitted to care, the follow-up was terminated and no outcome assessments were collected. *Table 10* displays a comparison of the key participant characteristics of the 495 participants randomised.

All characteristics appear to be reasonably well balanced across the two randomised arms. The average age was 80.9 years, 59% (290/495) were female and 48% (240/495) had a live-in caregiver. The majority of participants, 72% (358/495), were classified as being at low risk of wandering or leaving their home inappropriately. Half of the participants (249/495) were deemed to have low safety risks identified within the home. The average SMMSE score was 18.7 points in the intervention arm and 16.9 points in the control arm, so participants in the intervention arm had a slightly higher baseline SMMSE score than those in the control arm. The average BADLS score was 19.5 in the intervention arm and 20.4 in the control arm. The missingness of these data was similar between the two arms.

TABLE 10 Participant baseline characteristics

Characteristic	Trial arm	
	Intervention (N = 248)	Control (N = 247)
<b>Age (years)</b>		
< 65, n (%)	11 (4)	4 (2)
65–80, n (%)	89 (36)	93 (38)
> 80, n (%)	148 (60)	150 (61)
Mean (SD)	81.0 (8.2)	80.8 (7.4)
<b>Gender, n (%)</b>		
Male	102 (41)	103 (42)
Female	146 (59)	144 (58)
<b>Risk of wandering/leaving home inappropriately, n (%)</b>		
Low	178 (72)	180 (73)
Medium	52 (21)	48 (19)
High	18 (7)	19 (8)
<b>Safety risks within home identified, n (%)</b>		
Low	125 (50)	124 (50)
Medium	104 (42)	101 (41)
High	19 (8)	22 (9)

continued

TABLE 10 Participant baseline characteristics (continued)

Characteristic	Trial arm	
	Intervention (N = 248)	Control (N = 247)
<b>Level of caregiver support, n (%)</b>		
Live in	119 (48)	121 (49)
Once daily	60 (24)	61 (25)
Less than once daily	69 (28)	65 (26)
<b>SMMSE score<sup>a</sup></b>		
0–9, n (%)	23 (10)	34 (15)
10–19, n (%)	79 (36)	96 (43)
20–25, n (%)	87 (39)	74 (33)
26–30, n (%)	32 (14)	19 (9)
Mean (SD)	18.7 (6.6)	16.9 (6.9)
<b>BADLS score<sup>b</sup></b>		
0–4, n (%)	17 (7)	10 (4)
5–14, n (%)	72 (31)	64 (28)
15–29, n (%)	95 (41)	102 (45)
30–60, n (%)	46 (20)	49 (22)
Mean (SD)	19.5 (11.3)	20.4 (10.9)

a Scores range from 0 to 30; higher scores indicate better cognitive function.  
b Scores range from 0 to 60; higher scores indicate greater impairment.

## Primary outcomes

### Time to institutionalisation

The primary analysis of admission to care was defined as a permanent transition from living in a participant's own home to living in nursing or residential care, or admission to an acute care facility that resulted in permanent placement. The end point was compared between the intervention and control arms using survival analysis. Kaplan–Meier curves are for graphical representation of time to an event. Statistical significance was determined through log-rank test. The primary analysis was conducted according to intention to treat, and participants who have died, withdrawn from follow-up or who were lost to follow-up were censored at the date of withdrawal. The time to admission to care, split by randomised arm, is shown in *Figure 4*.

The intervention and control arms showed a similar pattern of time to admission to care over the 3-year period plotted. Comparing the ATT arm with the control arm, the hazard ratio is 0.76 [95% confidence interval (CI) 0.58 to 1.01;  $p = 0.054$ ]. This unadjusted analysis showed a borderline significant difference in slowing the time to admission to care with ATT use when compared with the control. At 2 years, the admission to care rate for the ATT arm was 65.6% (95% CI 58.8% to 71.5%), compared with 63.4% (95% CI 56.3% to 69.7%) for the control arm.

The rates of admission to care can be affected by participants' functional ability. This was measured using the BADLS. BADLS scores range from 0–60, with higher scores indicating greater impairment. *Figure 5* shows the time to admission to care split by BADLS scores 0–4, 5–14, 15–29 and 30–60.




FIGURE 4 Kaplan-Meier survival curve: time to admission to care by randomised arm, unadjusted analysis.




FIGURE 5 Kaplan-Meier survival curve: time to admission to care by baseline BADLS score.

There was a highly significant difference in the time to admission to care when comparing baseline BADLS scores. Participants with a higher baseline BADLS score were more likely to be admitted to care ( $p < 0.0001$ ). Baseline BADLS scores are presented in *Table 10* and shows an imbalance in baseline scores. More participants in the intervention arm than in the control arm had a lower baseline BADLS score. As *Figure 5* showed that participants with a higher baseline BADLS score are more likely to be admitted to care; this difference at baseline was adjusted for in the primary analysis. A forest plot split by baseline BADLS score is shown in *Figure 6*.

When adjusting for baseline BADLS scores, there is no significant difference in the time to admission to care between those in the intervention group and those in the control group (hazard ratio 0.84, 95% CI 0.63 to 1.12;  $p = 0.20$ ).

The reasons for admission to care are usually multifactorial. To determine whether or not ATT might have helped prevent admissions to care, the reasons given for institutionalisation have been categorised as having any mention of safety, then any mention of wandering and then falls, with others classified as inability to perform activities of daily living (ADL), behaviour, other medical condition, deterioration (unspecified), caregiver health, other and unknown. This can give only an approximate classification, given the complexity of Alzheimer's symptoms, but the breakdown of the most likely causes is given in *Table 11*.

## PRIMARY OUTCOME RESULTS




FIGURE 6 Forest plot: admission to care by randomised arm, adjusted for baseline BADLS score. NS, not significant; O/E, observed over expected; Var., variance.

TABLE 11 Reasons for admission to care categorised

Categorised reason	Trial arm (number of participants)		Total number of participants (N = 495)	p-value <sup>a</sup>
	Intervention (N = 248)	Control (N = 247)		
Safety concern	12	4	16	0.043
Wandering	5	13	18	0.054
Falls	13	13	26	0.990
Loss of ADL	14	29	43	0.016
Behaviour	8	10	18	0.630
Other medical condition	7	6	13	0.790
Deterioration (unspecified)	14	11	25	0.540
Caregiver health	9	3	12	0.081
Other	6	8	14	0.580
Unknown	5	10	15	0.190
Any cause	93	107	200	

<sup>a</sup> p-value from Mantel-Haenszel test (ignoring time to event).

The most common reason for admission to care is the inability to perform ADL. Institutionalisation for safety concerns, which might have been expected to be reduced by ATT, is actually more common in the intervention group (12 vs. 4 participants;  $p = 0.043$ ). By contrast, the risk of wandering, which might, again, be mitigated by appropriate ATT, was reduced in the intervention group (5 vs. 13 participants;  $p = 0.054$ ). There was also a significant reduction in the number of participants moving into residential care because of the inability to perform ADL (14 vs. 29 participants;  $p = 0.016$ ). A total of 15 admissions to care were classified as being for an unknown reason.



## Subgroup analysis

To investigate whether or not ATT use varied by baseline characteristics, we did subgroup analyses of admission to care in the ATT group compared with admission to care in the control group by gender, age, risk of wandering from home and safety risk within the home (Figure 7). As there were no significant differences seen, there is no indication of any benefit from ATT use in any of these subgroups.

## Deaths while in the community

Eighty-nine participants died while in the community. Figure 8 is the Kaplan–Meier graph of time to death while community resident and Table 12 shows the categorised reasons for cause of death. In the Kaplan–Meier analysis, participants who had been admitted to care, withdrawn from follow-up or lost to follow-up were censored at the date of withdrawal.

There were no significant differences seen overall ( $p = 0.14$ ) or in the grouped categories for cause of death (see Figure 8 and Table 12).




FIGURE 7 Subgroup analyses of admission to care for the ATT group vs. the control group, by baseline characteristics. O/E, observed over expected; Var., variance.

## PRIMARY OUTCOME RESULTS




FIGURE 8 Kaplan–Meier survival curve: time to death while community resident, by randomised arm.

TABLE 12 Causes of death categorised

Cause of death	Trial arm (number of participants)		Total number of participants (N = 495)	p-value <sup>a</sup>
	Intervention (N = 248)	Control (N = 247)		
Health/dementia deterioration	8	4	12	0.25
Pneumonia/respiratory failure	4	10	14	0.10
Heart attack/heart failure	3	8	11	0.13
Stroke	7	5	12	0.56
Cancer	7	4	11	0.36
Infection	6	4	10	0.53
Other	2	4	6	0.41
Unknown	4	9	13	0.16
Total	41	48	89	

a p-value from Mantel–Haenszel test (ignoring time to event).

### Serious adverse events

Serious adverse events have been grouped into broad categories and are summarised in *Tables 13* and *14*. The categories were decided on by members of the ATTILA trial team with clinical expertise and were categorised separately by two members of the team, then assessed for consistency. Any differences were discussed, and input sought from a clinical expert in the team. Raters were unaware of treatment allocation of the participants involved. *Table 13* presents the counts of SAEs recorded and *Table 14* presents the number of participants reporting the SAEs, as participants can report multiple SAEs. Similarly to the reasons for admissions to care, SAEs could be multifactorial. The categories are any mention of safety concerns, wandering, falls, dementia progression, behaviour, other medical condition, caregiver related, accidents, health deterioration, other and unknown.

TABLE 13 Counts of categorised SAEs

Categorised SAE	SAE count (n)		
	Intervention arm	Control arm	Total
Safety concerns	15	5	20
Wandering	36	71	107
Falls	182	187	369
Dementia progression	37	46	83
Behaviour	5	21	26
Other medical condition	214	220	434
Caregiver related	11	10	21
Environmental/accident	14	21	35
Health deterioration	6	3	9
Other	2	1	6
Unknown	10	18	28
Total count of SAEs	532	603	1135

TABLE 14 Number of participants reporting categorised SAEs

Categorised SAE	Number of participants			p-value
	Intervention arm	Control arm	Total	
Safety concerns	13	5	18	0.06
Wandering	25	36	61	0.13
Falls	86	88	174	0.83
Dementia progression	37	43	80	0.45
Behaviour	5	16	21	0.01
Other medical condition	107	109	216	0.83
Caregiver related	11	10	21	0.83
Environmental/accident	13	15	28	0.69
Health deterioration	5	2	7	0.26
Other	2	1	3	0.57
Unknown	10	16	26	0.22
Total	195	201	396	0.45

Participants reported multiple SAEs. Overall, 1135 SAEs were reported from 396 participants. The most common SAE was 'other medical condition', which was reported by 216 participants. The second most-reported SAE was related to falls (369 falls were reported by 174 participants). *Figure 9* plots the number of participants experiencing each SAE type, ordered by hierarchy of classification, with a test of significance between intervention and control participants.

PRIMARY OUTCOME RESULTS




FIGURE 9 Forest plot of the incidence of SAEs. p-values from Mantel-Haenszel tests (ignoring time to event). OR, odds ratio.

Figure 9 shows that there was a significant reduction in the number of participants experiencing behavioural-related SAEs in the intervention group, compared with the control group ( $p = 0.01$ ). More participants in the intervention group than in the control group reported SAEs related to safety concerns ( $p = 0.06$ ).

## Chapter 5 Economic evaluation

The economic evaluation addressed the question ‘are ATT interventions cost-effective in the management of risk and maintenance of independence in people with dementia living in their own homes?’.

### Methods

The economic evaluation included cost-effectiveness and cost-utility analyses.

### Outcomes

The economic evaluation examined three outcomes for participants with dementia:

1. the incremental cost of community-based support per institutional day avoided (days to institutionalisation)
2. the incremental cost of change in the EQ-5D-5L index over 24, 52 and 104 weeks
3. the incremental cost per QALY over 24, 52 and 104 weeks.

Participant-rated and proxy-rated utilities were calculated from the EQ-5D-5L, valued by ‘crosswalking’ EQ-5D-5L health-state profiles to the UK value set for EuroQol-5 Dimensions, three-level version,<sup>61,62</sup> as currently recommended by the National Institute for Health and Care Excellence (NICE).<sup>63</sup>

### Perspective

Analyses were conducted from a health and social care perspective (cost to the NHS and to CASSRs) and from a societal perspective (costs to the participant and caregiver). We assumed service costs (e.g. of community, primary and hospital health care) were borne by public payers, except in the case of home adaptations and ADL equipment, for which only items reported to have been paid for by the NHS or council were included. Societal costs included lost production, costs of providing unpaid care and out-of-pocket payments for home adaptations and ADL equipment and travel costs (restricted to dementia-related treatment and day care).

### Time horizon

The participant- and caregiver-reported EQ-5D-5L and the caregiver-reported CSRI were administered alongside other measures at each assessment point (see *Table 1*). The CSRI covered service receipt over the previous 3 months. An annual discount rate of 3.5%<sup>64</sup> was applied to costs and days in the community in the second year, as the time horizon was 2 years.

### Costs

The analysis considered comprehensive costs of care and support to the person with dementia. Health-care, social care and societal costs (excluding direct costs of the ATT intervention) were calculated by drawing on data from the CSRI. Direct costs of the ATT intervention were calculated from the ATT technology checklist and from interview data (see *Intervention costs, Valuing assessment time and Valuing the assistive technology and telecare package*). Costs of health and social care service use were calculated from service use data by applying the relevant published unit costs.<sup>42,43</sup> Caregiver inputs were valued by taking an opportunity-costs approach in the main analyses, following methods described in Wimo *et al.*,<sup>65</sup> by valuing the lost working time of working caregivers at the national average wage<sup>66</sup> and lost leisure time of non-working caregivers at 35% of that figure. In the case of care from others (e.g. other relatives), caregivers were assumed to be working and their time was valued at national average wage. A replacement-costs valuation (using the hourly cost of a domiciliary care worker) was applied in a sensitivity analysis.<sup>43,67</sup> Unit costs used in valuing resource use are reported in *Appendix 3*.

The costs of individual services were first aggregated to category level (hospital; primary and community health; mental health; overnight respite; community, social and day care; equipment and adaptations; mental health medications; telecare intervention; and caregiver), and then to health and social care and societal totals. Costs at category level were calculated so that if > 2% of component costs in the category were not available, the total of the category was considered missing. Total costs across categories were considered missing if any category of cost was missing.

The CSRI data did not cover the entirety of the 2-year follow-up, as caregivers were always asked to report service use over the previous 3 months. The costs of the intervening periods were estimated by carrying forward cost categories of the previous period to the interval between the 24-week point and the retrospectively recalled 3-month period ending at week 52, and then between week 52 and the retrospectively recalled 3-month period ending at week 104. The carrying-forward process for the 9-month interval in year 2 created three additional intervals running up to the 3 months prior to the 104-week assessment point. The one exception in the process of carrying forward costs was for hospital admissions and emergency department visits: data drawn from SAE reporting were used to estimate these costs. Therefore, the costs of routinely used services were assumed to be constant over the intervening periods, but emergency department and hospital admissions reflected the observed use in those periods. The costs were not carried forward to intervals when the person had been admitted to care, died, was lost to follow-up or no longer wished to participate.

### *Intervention costs*

Proposed methods of costing the ATT intervention are described in detail in *Appendix 1*. We planned to describe the production of the full ATT package and to assess the feasibility of collecting data from sites to calculate the costs of the ATT intervention. Data on the delivery system for ATT were collected from local researchers via pro formas and from key informants via interviews with local authority operational/middle managers in adult services, local authority commissioners of telecare and managers in telecare provider organisations. Interviews in seven sites took place in 2016 (only sites with more than five participants were approached). We had planned to request data on ATT equipment from providers, but it proved difficult to draw up the necessary data-sharing agreements covering electronic data extraction in every site. The scope and level of detail of information on total costs and unit costs of ATT gathered to date varied considerably between sites, depending on the size of the local authority and the complexity of the local ATT market. Information from this process was used to describe, in some detail, the local actors involved in delivering ATT and the process of ATT production in each site. Based on these descriptions, the production of ATT across all sites involves the following components: assessment, procurement/purchasing, installation, call-handling (monitoring) and response. The data collected were not consistent enough to enable calculation of the costs of ATT for use in the economic evaluation. Instead, the costs of the ATT production process were built up from several sources; some components will reflect costs at a more granular level of detail than others, as described in *Valuing assessment time* and *Valuing the assistive technology and telecare package*.

### *Valuing assessment time*

The time taken to carry out ATT assessments could vary substantially depending on the level of need and the specific devices required. Feedback from pro formas and interviews yielded a range of estimates of assessment time. The assumption based on information from interviews was that an ATT assessment took 1 hour.

The personnel conducting assessments varied depending on the site and the nature of the ATT need. Data from the ATT technology checklist were available: the checklist distinguishes between health and social care assessors and specialist ATT assessors, but researchers were not always able to determine an assessor's qualifications. There was considerable variation in assessment personnel, depending on the local area and the sector of the assessor's employer (see *Chapter 3*). The assumption made in costing assessor time was that health and social care assessors were non-specialist NHS professionals paid at (NHS) Agenda for Change band 5 and that specialist ATT assessors were specialist community

occupational therapists paid at (NHS) Agenda for Change band 6.<sup>43</sup> Assessor costs (including on-costs, overheads and capital costs; see *Appendix 3*) were calculated from the relevant costs per working hour given in the *Unit Costs of Health and Social Care 2017*.<sup>43</sup>

When the assessor type was unknown, the proportions of health and social care assessors and specialist ATT assessors (disregarding other/unknown assessor types) conducting assessments at the needs assessment point (see *Tables 3 and 4 and Appendix 3*) were used to calculate a weighted hourly rate. Only the pre-baseline ATT needs assessment was costed into the package, in line with the protocol's definition of the intervention. ATT device data were taken from the ATT checklist data. All device types noted by the researchers at each time point were considered to be relevant costs.

### **Valuing the assistive technology and telecare package**

Data to estimate ATT package costs were taken from several sources. Data from the NHC<sup>68</sup> were obtained to enable valuation of components of the ATT production process. The NHC offers consortium procurement services to the UK public sector organisations that make up its membership. Members include local authorities, not-for-profit providers, housing associations and industry partners. Each consortium procurement framework remains in place for 4 years, recording contract prices paid by members for any service or product covered by the framework to supply partners in relevant industries. Two consortium frameworks that were relevant to ATT products and services were in operation during the trial period. The Assisted Living framework, and the Technology Enabled Care Services (TECS) framework that superseded it, covered telecare products and related installation and services. The TECS framework covered a broader range of ATT devices than the Assisted Living framework (not only telecare, but also telemedicine and telehealth). The TECS framework covered services such as installation and maintenance of devices, call monitoring and mobile response. The NHC supplied data from consortium framework databases on actual contract prices paid during contracts that had expired by 2017. Data were available from Assisted Living framework contracts in place in 2015 and from TECS contracts in place in 2016. The frameworks covered key elements of ATT provision relevant to purchasers in local authorities and not-for-profit agencies. The activities covered by the contracts corresponded well with three ATT production stages (as previously outlined): installation, call-handling/monitoring and response. A per-person annual cost of the installation, maintenance, call-monitoring and mobile response elements of ATT was calculated from contract prices derived from NHC framework data (see *Appendix 3*).

### **Assistive technology and telecare devices**

The Consortium provided information on 2016 device prices from the TECS framework suppliers' catalogue. Prices for some categories of devices were available as mean and median prices across that category, weighted (by volume) and including NHC discounts available to members. In other cases, only the lowest and highest prices per item were available, and it was not possible to calculate a weighted mean. In such cases, the lowest and highest costs were summarised by category and the mid-point of the range between these was used. Device costs were annuitised over 5 years at a discount rate of 3.5%. Data on the types of ATT devices installed at each assessment point (see *Chapter 3*) were taken from the ATT checklist; valuation of these devices was drawn from information obtained from the NHC price data, as described in the preceding section.

### **Missing data**

A sizeable number of participants and caregivers declined to complete at least one of the follow-up assessments while continuing to participate in status checks. Missingness in the CSRI data available from people who had participated in complete assessments was very low for most variables (typically around 1%). Data on certain variables were missing at baseline because of subsequent version changes in the ATT and CSRI measures. The first version of the CSRI (subsequently revised in September 2014) did not include questions on caregivers' time spent providing care (for this reason, 8% of baseline data on this variable were missing) and thus missing for reasons unrelated to participants' health status.



Missing data reduction strategies were employed in certain cases. When ADL equipment/adaptations provider data were missing (fewer than 10 instances), the provider was assumed to be the local authority. For medication costs, if the dates of first use were missing, when there was information on first use and ongoing use of particular medications, dosages, units and frequencies, these dates were assigned to preceding and succeeding periods when the same medication, unit dosage and frequency were reported, as long as the dates preceded the assessment date. As a further step, the average duration over which medications were taken in contiguous periods from baseline to 24 weeks (per medication, per participant) was calculated from available duration data and applied to missing durations over these periods. The average duration of medications taken in these periods was 84 days, and < 5% had durations of  $\leq 36$  days, indicating long-term use. For the remaining missing durations, it was assumed that the medication had been taken over the whole of the prior period. For future evaluations, the medication question could be improved by asking whether or not the participant had been taking the medication for > 3 months, rather than asking the date of first use. No assumptions could reasonably be made on caregiver time spent providing care when this was missing because of version changes.

Compared with the expected number of responses (given the number of assessments administered), approximately 10% of EQ-5D participant-reported index scores were missing at baseline. At 12 weeks, 13% of intervention participants' and 20% of control participants' responses were missing; at 24 weeks, 15% of intervention and 21% of control group participants' responses were missing; at 52 weeks, 25% intervention and 31% of control group participants' responses were missing. At 104 weeks, 22% of intervention and 34% of control group participants' responses were missing. The proportion of missing responses did not differ between groups at the 5% level on chi-squared tests at any time point. Of expected responses (given the number of assessments administered), proxy-completed EQ-5D index scores featured lower levels of missingness than seen in the participant-reported measure (baseline missingness: 9% intervention, 12% control; missingness at 12 weeks: 10% intervention, 9% control; missingness at 24 weeks: 8% intervention, 8% control; missingness at 52 weeks: 5% intervention, 9% control; and missingness at 104 weeks: 4% intervention, 7% control).

When EQ-5D index scores were missing, index score values were interpolated between adjacent time points. Compared with the expected number of responses (given the number of assessments administered) for the EQ-5D participant-reported index scores, after interpolation, at 12 weeks, 7% of the intervention and 14% of control group participants' responses were missing; at 24 weeks, 12% of the intervention and 15% of control group participants' responses were missing; and at 52 weeks, 20% of intervention and 25% of control group participants' responses were missing. Of expected responses (given the number of assessments administered) for the proxy-completed EQ-5D index scores, after interpolation, at 12 weeks, 6% of intervention and 5% of control group participants' responses were missing; at 24 weeks, 3% of the intervention and 6% of control group participants' responses were missing; and at 52 weeks, 4% of the intervention and 7% of control group participants' responses were missing.

Apart from these measures, missing costs and outcome data were not imputed. Data required for the cost-effectiveness analyses were 'missing' for several reasons. When the trial end point of care home admission was met, no further assessments were administered. Some participants died, there was loss to trial follow-up and some dyads decided to cease participation in the trial completely. Some dyads did not complete assessments (no measures were administered), although the dyad continued to participate in the trial status checks; this could have been for several reasons, including disagreement with allocation, burden of assessments and delays in assessments being completed. Missingness was handled in different ways, depending on the analysis. The difference-in-difference analyses were estimated by maximum likelihood (see *Analyses*). Cases were excluded from the analyses when the dyad had participated in no assessments over the trial and when the baseline BADLS score was missing (there were no missing data in other baseline covariates, which were stratifying variables used in the randomisation procedure). The analyses of institutionalisation-free days and QALYs employed models to explicitly manage data-censoring due to withdrawal, loss to follow-up and death.



## Analyses

Descriptive analyses were produced for service and other resource use items available at each time point, presented in terms of the proportions of each treatment group using the service and the mean use of the service in each group. Group means and standard errors (SEs) were calculated for categories and totals of costs and for outcomes at each time point, as were mean differences and SEs of the difference between groups.

For the outcome days in the community until admission to a care home, the number of days was estimated in a survival analysis accelerated failure time model using the Weibull distribution, adjusting for baseline BADLS score. A further step was involved in the QALY outcome: to quality-adjust the days lived in the community, taking a population (or group-based) approach to produce a quality-adjusted survival curve, using the EQ-5D index scores at each assessment point to estimate the average utility per treatment group.<sup>69,70</sup> Costs were partitioned and estimated in a generalised gamma accelerated failure time model with a square root link; the probability of not being censored in each time interval was estimated by accelerated failure time models (generalised gamma model at 104 weeks and a Weibull model at 52 and 104 weeks, as the generalised gamma model did not converge), generating inverse probability weights for costs at each interval.<sup>70-72</sup> Cost regressions were adjusted for the treatment allocation, BADLS score and stratifying variables. Cases without a baseline BADLS score and cases for whom the dyad had never participated in assessments were excluded from the analyses. Bias-corrected bootstrapped CIs of regression estimates of cost and outcome differences were produced (25,000 resamples).

For the change in EQ-5D-5L index outcome, multilevel linear difference-in-difference models were fitted to costs and EQ-5D index scores data. The models estimated the difference in the change in scores from baseline to follow-up in the intervention group, less the difference in the change in scores from baseline to follow-up in the control group (i.e. the difference between groups in the difference between baseline and follow-up costs/outcomes in each group). Models were adjusted for stratifying variables and the three-category BADLS variable for dependency (see *Chapter 4*). Multilevel mixed-effects linear models were estimated by maximum likelihood, assuming that data were missing at random on the response variable. In other words, missingness was assumed to be dependent on model covariates or on previous or following responses, had they been observed, but not on the missing responses.<sup>73,74</sup> Cases at 52 and 104 weeks were considered available for analysis if baseline outcome/cost data and at least two follow-up data points were available; at 24 weeks, cases were considered available if baseline outcome/cost data and at least one follow-up data point were available. Bias-corrected bootstrapped CIs of the model estimates of cost and outcome differences were obtained (5000 resamples).

## Cost-effectiveness analyses

Incremental cost-effectiveness ratios (ICERs) were calculated for each outcome. ICERs were calculated separately for the difference in the EQ-5D outcome at the 24-, 52- and 104-week follow-ups, and for QALY-adjusted institutionalisation-free days. The ICER was defined as the difference in mean costs incurred by the intervention and control groups ( $\Delta C$ ), divided by the difference in mean outcome ( $\Delta E$ ) between the treatment groups. The ATT intervention can be interpreted as representing value for money if the ICER is below some threshold of WTP for a unit of additional effectiveness,  $\lambda$ :<sup>75</sup>

$$\Delta C / \Delta E < \lambda. \quad (1)$$

A full package of ATT can be considered cost-effective if (1) the package is significantly more effective and less expensive than a basic package of ATT or (2) ATT is significantly more effective and more expensive, but the payer is willing to pay the additional cost (up to  $\lambda$ ) to achieve the additional

effectiveness or, possibly, (3) ATT is significantly less effective and less expensive, but the payer considers the sacrifice of some effectiveness worth making because of the savings that could be achieved. ATT can be considered, unambiguously, to be not cost-effective if it is both significantly less effective and more expensive.

Incremental net monetary benefit<sup>75</sup> can be expressed as a rearrangement of the decision rule in (1):

$$\lambda \times \Delta E - \Delta C > 0. \quad (2)$$

This is the monetary value of gains in outcomes associated with the treatment at a given WTP threshold, net of (less) the additional cost of providing the treatment.<sup>76</sup>

Cost-effectiveness acceptability curves (CEACs) were produced when the intervention strategy was more effective and costs were lower. Estimates of cost and outcome differences were obtained by non-parametric bootstrapping of regression estimates, producing 25,000 replicates in the case of the institutionalisation-free days and QALY outcomes and 5000 replicates in the case of the change in EQ-5D index outcome. The proportion of replicates for which the net monetary benefit was positive was graphed over a series of WTP values from £0 to £50,000 to produce CEACs. The current NICE WTP threshold for the adoption of new technologies is between £20,000 and £30,000 per QALY.<sup>77</sup>

A sensitivity analysis explored the impact on societal costs of valuing time spent by caregivers in providing care to the person with dementia at replacement cost (the hourly cost of a home care worker) at 104 weeks.

## Results

### Sample numbers

The flow of dyads who completed assessments is given in *Figure 10*. As can be seen, some dyads declined to participate in full assessments involving the completion of participant-/proxy-/caregiver-reported measures, but agreed to remain in the study and provide more limited information on community residence and SAEs or AEs (by telephone follow-up). There were 412 dyads who participated in the baseline and at least one follow-up assessment. A small number (intervention,  $n = 11$ ; control,  $n = 14$ ) did not participate in an assessment at any point and 45 (intervention,  $n = 19$ ; control,  $n = 26$ ) participated only at baseline. A substantial proportion of the 12-week follow-up assessments were not conducted: 20% in the intervention group and 17% in the control group. The numbers of dyads contributing data to the cost-effectiveness analyses varied depending on the measures and the analysis; valid numbers of observations associated with each measure are presented with the results of the analyses (see *Cost-effectiveness analyses*). Demographic characteristics of the sample participating in full assessments at baseline are given in *Appendix 4*.

### Use of care and support services

#### Baseline

The participant use of community health and social care services at baseline was very high (see *Appendix 4*): 69% of intervention and 65% of control participants had seen a general practitioner (GP) in the previous 3 months. Practice nurses were seen by 38% of participants in both groups. Thirteen per cent of intervention and 17% of control group participants had used emergency department services. In terms of inpatient stays, 10% of intervention and 16% of control group participants had had a spell in hospital prior to baseline; the mean number of inpatient days among control group participants was twice that among intervention group participants [2.39 days (SD 0.57 days) vs. 1.24 days (SD 0.35 days), respectively]. In terms of outpatient attendances, 43% of intervention and 41% of control group participants had had at least one outpatient attendance. Use of community




FIGURE 10 The ATTILA trial flow of dyads. Delayed: researcher noted that the assessment had been delayed enough that the date of the assessment was closer to that of the next scheduled assessment than to that of the previous assessment or randomisation screening visit.

rehabilitation professionals, particularly occupational therapists, was noticeably higher at baseline than at the other time points. This suggests that some initial ATT assessment-related visits were being reported as being community rehabilitation-related visits or that involvement in the trial in some other way stimulated referrals to these services. One-third of participants had seen a social worker or care manager over the previous 3 months and 40% of participants received home care (an average of 57 and 60 visits were received among intervention and control group participants, respectively). Day centre use was reported by approximately one-sixth of participants. Almost all caregivers reported providing care to participants over the previous 3 months. A mean of 564 hours of unpaid care was provided to participants in the intervention group, and a mean of 661 hours of unpaid care was provided to participants in the control group.

In terms of ATT devices (of any type, including those defined as 'basic', and rounding to whole numbers), intervention participants had three ATT devices whereas control participants had two ATT devices.

### Follow-up time points

Over the follow-up assessments, the proportion reporting GP visits declined slightly, then increased to around baseline levels at 104 weeks (71% and 65% for the intervention and control groups, respectively). Practice nurses were seen by 30% of both groups at 104 weeks. About one-sixth of participants used emergency department services across all follow-ups. The numbers of home care visits and the total duration (in hours) of visits rose steadily in each group over the follow-up period. At 104 weeks, 49% of intervention participants and 56% of control participants remaining in the community received home care; these users received very substantial numbers of visits (98 and 110 visits in the intervention and control groups, respectively), indicating the receipt of multiple visits per day. Few received any other community social services, such as meals on wheels. Day centres were used by between one-quarter and one-fifth of participants at the 52- and 104-week follow-ups. As at baseline, most caregivers reported providing care to participants over the previous 3 months. At 104 weeks, caregivers had provided 656 hours of care to intervention group participants, and 777 hours of care to control group participants, over the previous 3 months. Control group participants had received somewhat more care hours than intervention group participants at all follow-ups.

In terms of ATT devices of any type, intervention group participants had three ATT devices at 12 and 24 weeks and four devices at 52 and 104 weeks; control group participants had two devices at 12 and 24 weeks and three devices at 52 and 104 weeks.

## Outcomes

The mean EQ-5D participant-reported index scores (*Table 15*) were higher than the proxy-reported scores at all time points. The mean participant-reported baseline and week 12 scores were similar between groups, but at 24, 52 and 104 weeks, the mean scores for the intervention group were significantly lower than the scores for the control group ( $p < 0.05$  in each case). The mean scores of the proxy-reported measures did not differ between groups.

### Costs of care and support services

#### Baseline

Baseline costs (unadjusted for covariates) over the previous 3 months (*Table 16*) were similar between the groups except for hospital costs, which were significantly higher for the control group (−£518, 95% CI −£1025 to −£12;  $p = 0.045$ ). The costs of ATT were £85 (SE £2) and £75 (SE £2) for the intervention and control groups, respectively. Average health and social care costs (including the intervention) were £2276 for the intervention group and £3400 for the control group. Societal costs were more than double those of health and social care in both arms.

TABLE 15 Mean EQ-5D index scores and SEs, at baseline and at the 12-, 24-, 52- and 104-week assessment points

Outcome measure	Trial arm				Intervention – control, mean difference (95% CI) in score	p-value
	Intervention		Control			
	Responses received (n)	Mean (SE) score	Responses received (n)	Mean (SE) score		
<b>Baseline</b>	<b>Expected = 229</b>		<b>Expected = 224</b>			
EQ-5D – participant	208	0.748 (0.016)	199	0.774 (0.016)	-0.026 (-0.070 to 0.018)	0.2452
EQ-5D – proxy	208	0.539 (0.015)	197	0.526 (0.018)	0.014 (-0.032 to 0.060)	0.5616
<b>Week 12</b>	<b>Expected = 189</b>		<b>Expected = 188</b>			
EQ-5D – participant	175	0.734 (0.019)	161	0.767 (0.017)	-0.033 (-0.084 to 0.018)	0.2031
EQ-5D – proxy	178	0.551 (0.017)	178	0.512 (0.019)	0.039 (-0.011 to 0.088)	0.1248
<b>Week 24</b>	<b>Expected = 178</b>		<b>Expected = 168</b>			
EQ-5D – participant	157	0.731 (0.02)	143	0.785 (0.019)	-0.054 (-0.108 to 0.001)	0.055
EQ-5D – proxy	172	0.512 (0.019)	158	0.517 (0.019)	-0.006 (-0.059 to 0.048)	0.8371
<b>Week 52</b>	<b>Expected = 150</b>		<b>Expected = 139</b>			
EQ-5D – participant	120	0.709 (0.023)	104	0.787 (0.02)	-0.079 (-0.139 to -0.018)	0.0112
EQ-5D – proxy	144	0.482 (0.023)	129	0.48 (0.022)	0.001 (-0.062 to 0.065)	0.9643
<b>Week 104</b>	<b>Expected = 96</b>		<b>Expected = 90</b>			
EQ-5D – participant	75	0.73 (0.03)	59	0.818 (0.026)	-0.088 (-0.169 to -0.008)	0.0321
EQ-5D – proxy	92	0.462 (0.029)	84	0.429 (0.029)	0.032 (-0.048 to 0.113)	0.4305

TABLE 16 Mean costs (SEs): health and social care services for participant, caregiver costs, out-of-pocket costs, total health and social care and societal costs over the previous 3 months, at baseline and at the 12-, 24-, 52- and 104-week assessments (2016–17 Great British pounds)

Cost	Trial arm				Intervention – control, mean difference (95% CI)
	Intervention		Control		
	Responses received (n)	Mean (SE) cost	Responses received (n)	Mean (SE) cost	
<b>Baseline</b>	<b>Expected = 229</b>		<b>Expected = 224</b>		
Hospital	229	619 (130)	223	1138 (225)	-518* (-1025 to -12)
Primary and community health	229	253 (18)	223	227 (18)	26 (-25 to 77)
Community mental health	227	62 (7)	223	51 (7)	11 (-8 to 30)
Respite residential/nursing	228	35 (19)	223	83 (40)	-48 (-135 to 39)
Community care	224	1433 (299)	220	1813 (405)	-380 (-1367 to 608)

continued

**TABLE 16** Mean costs (SEs): health and social care services for participant, caregiver costs, out-of-pocket costs, total health and social care and societal costs over the previous 3 months, at baseline and at the 12-, 24-, 52- and 104-week assessments (2016–17 Great British pounds) (continued)

Cost	Trial arm				Intervention – control, mean difference (95% CI)
	Intervention		Control		
	Responses received (n)	Mean (SE) cost	Responses received (n)	Mean (SE) cost	
Day care (any provider)	229	153 (36)	223	127 (23)	27 (-58 to 111)
Equipment and adaptations <sup>a</sup>	218	4 (1)	203	6 (1)	-2 (-5 to 2)
Medications	226	23 (5)	222	23 (5)	-1 (-14 to 12)
Unpaid care <sup>b</sup>	217	5928 (488)	202	6553 (473)	-625 (-1965 to 715)
Equipment and adaptations – self <sup>c</sup>	218	2 (1)	203	2 (1)	0 (-3 to 3)
Out of pocket <sup>d</sup>	219	8 (2)	202	4 (1)	3 (-0 to 7)
Health and social care	210	2231 (228)	201	3281 (521)	-1050 (-2152 to 52)
Intervention	223	85 (2)	203	75 (2)	11*** (5 to 16)
Intervention + health and social care	205	2276 (228)	189	3400 (550)	-1124 (-2262 to 14)
Societal <sup>e</sup>	208	8162 (540)	200	9836 (680)	-1674 (-3374 to 26)
Intervention + societal <sup>e</sup>	203	8262 (546)	188	9963 (715)	-1701 (-3454 to 52)
<b>Week 12</b>	<b>Expected = 189</b>		<b>Expected = 188</b>		
Hospital	189	467 (121)	186	623 (148)	-156 (-532 to 220)
Primary and community health	188	223 (21)	185	231 (23)	-8 (-70 to 54)
Community mental health	186	36 (8)	186	38 (8)	-1 (-24 to 21)
Respite residential/nursing	188	45 (26)	185	82 (31)	-38 (-117 to 41)
Community care	188	1857 (377)	185	2060 (508)	-203 (-1445 to 1038)
Day care	189	229 (45)	186	185 (39)	44 (-72 to 160)
Equipment and adaptations <sup>a</sup>	186	4 (1)	184	5 (2)	-1 (-6 to 3)
Medications	189	34 (9)	186	26 (5)	8 (-12 to 28)
Unpaid care <sup>b</sup>	186	6214 (470)	183	6928 (547)	-714 (-2129 to 702)
Equipment and adaptations – self <sup>c</sup>	186	2 (1)	184	4 (2)	-2 (-6 to 2)
Out of pocket <sup>d</sup>	188	7 (2)	184	6 (2)	1 (-5 to 7)
Health and social care	182	2930 (416)	181	2986 (457)	-57 (-1271 to 1158)
Intervention	188	61 (3)	166	39 (3)	21*** (13 to 29)
Intervention + health and social care	181	2978 (418)	161	3005 (501)	-27 (-1301 to 1247)
Societal <sup>e</sup>	182	9202 (620)	180	10,010 (679)	-807 (-2616 to 1001)
Intervention + societal <sup>e</sup>	181	9283 (624)	160	10,017 (734)	-734 (-2616 to 1148)

**TABLE 16** Mean costs (SEs): health and social care services for participant, caregiver costs, out-of-pocket costs, total health and social care and societal costs over the previous 3 months, at baseline and at the 12-, 24-, 52- and 104-week assessments (2016–17 Great British pounds) (continued)

Cost	Trial arm				
	Intervention		Control		Intervention – control, mean difference (95% CI)
	Responses received (n)	Mean (SE) cost	Responses received (n)	Mean (SE) cost	
<b>Week 24</b>	<b>Expected = 178</b>		<b>Expected = 168</b>		
Hospital	177	296 (73)	168	848 (274)	-552* (-1098 to -7)
Primary and community health	177	193 (20)	168	215 (31)	-22 (-94 to 50)
Community mental health	177	21 (4)	168	25 (5)	-4 (-16 to 9)
Respite residential/nursing	175	35 (21)	166	37 (26)	-2 (-67 to 64)
Community care	176	2475 (537)	165	2005 (439)	469 (-906 to 1844)
Day care	177	230 (48)	167	181 (36)	49 (-70 to 168)
Equipment and adaptations <sup>a</sup>	176	7 (2)	168	5 (2)	1 (-4 to 7)
Medications	177	26 (5)	168	22 (5)	3 (-10 to 17)
Unpaid care <sup>b</sup>	175	6843 (575)	168	7352 (592)	-510 (-2133 to 1113)
Equipment and adaptations – self <sup>c</sup>	176	3 (2)	168	1 (1)	2 (-1 to 6)
Out of pocket <sup>d</sup>	177	6 (2)	168	7 (3)	-2 (-8 to 5)
Health and social care	173	3298 (560)	162	3289 (531)	9 (-1513 to 1532)
Intervention	176	55 (3)	157	43 (3)	13** (5 to 20)
Intervention + health and social care	171	3382 (566)	151	3358 (554)	24 (-1542 to 1591)
Societal <sup>e</sup>	172	9954 (769)	162	10637 (766)	-683 (-2820 to 1454)
Intervention + societal <sup>e</sup>	170	10,032 (778)	151	10,567 (797)	-535 (-2731 to 1660)
<b>Week 52</b>	<b>Expected = 150</b>		<b>Expected = 139</b>		
Hospital	148	470 (149)	137	786 (177)	-316 (-769 to 137)
Primary and community health	148	195 (18)	137	266 (32)	-71 (-143 to 0)
Community mental health	148	28 (18)	137	17 (5)	10 (-28 to 48)
Respite residential/nursing	148	60 (37)	137	94 (45)	-34 (-148 to 80)
Community care	148	3377 (747)	137	2206 (462)	1171 (-590 to 2933)
Day care	148	361 (72)	137	212 (44)	149 (-21 to 318)
Equipment and adaptations <sup>a</sup>	148	8 (2)	137	5 (2)	3 (-3 to 9)
Medications	147	25 (5)	137	22 (6)	2 (-13 to 17)
Unpaid care <sup>b</sup>	147	6851 (560)	136	9002 (793)	-2151* (-4040 to -262)

continued



**TABLE 16** Mean costs (SEs): health and social care services for participant, caregiver costs, out-of-pocket costs, total health and social care and societal costs over the previous 3 months, at baseline and at the 12-, 24-, 52- and 104-week assessments (2016–17 Great British pounds) (continued)

Cost	Trial arm				Intervention – control, mean difference (95% CI)
	Intervention		Control		
	Responses received (n)	Mean (SE) cost	Responses received (n)	Mean (SE) cost	
Equipment and adaptations – self <sup>c</sup>	148	6 (2)	137	3 (2)	3 (-3 to 9)
Out of pocket <sup>d</sup>	147	6 (2)	136	7 (3)	-2 (-8 to 5)
Health and social care	147	4510 (777)	137	3608 (523)	901 (-970 to 2773)
Intervention	146	64 (3)	129	50 (3)	15*** (6 to 23)
Intervention + health and social care	143	4613 (797)	129	3615 (548)	998 (-947 to 2942)
Societal <sup>e</sup>	146	11,442 (927)	136	12,629 (972)	-1187 (-3830 to 1457)
Intervention + societal <sup>e</sup>	143	11,492 (947)	128	12,526 (1010)	-1033 (-3757 to 1690)
<b>Week 104</b>	<b>Expected = 96</b>		<b>Expected = 90</b>		
Hospital	93	430 (186)	89	767 (202)	-337 (-877 to 203)
Primary and community health	93	227 (26)	89	283 (44)	-56 (-155 to 43)
Community mental health	93	4 (2)	89	10 (3)	-6 (-14 to 2)
Respite residential/nursing	93	3 (3)	89	69 (33)	-66* (-130 to -3)
Community care	93	4537 (1264)	87	3062 (754)	1475 (-1478 to 4427)
Day care	93	365 (98)	89	285 (70)	80 (-159 to 319)
Equipment and adaptations <sup>a</sup>	93	9 (3)	89	3 (1)	7* (0 to 13)
Medications	93	21 (6)	89	18 (5)	4 (-11 to 19)
Unpaid care <sup>b</sup>	93	7308 (781)	89	7672 (753)	-364 (-2508 to 1779)
Equipment and adaptations – self <sup>c</sup>	93	3 (2)	89	2 (1)	1 (-4 to 6)
Out of pocket <sup>d</sup>	93	6 (3)	89	9 (4)	-3 (-12 to 6)
Health and social care	93	5693 (1300)	87	4599 (811)	1094 (-1978 to 4166)
Intervention	93	63 (4)	87	51 (4)	12* (2 to 23)
Intervention + health and social care	92	5808 (1314)	84	4728 (838)	1080 (-2060 to 4220)
Societal <sup>e</sup>	93	12,961 (1599)	87	12,347 (1013)	614 (-3178 to 4406)
Intervention + societal <sup>e</sup>	92	13,117 (1614)	84	12,535 (1045)	582 (-3291 to 4455)

\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .

a Funded by the NHS or Personal Social Services.

b Unpaid caregivers' time in care and support to participant.

c Expenditure by self or family on equipment purchases.

d Expenditure by self or family on travel to appointments.

e Societal costs: participant's health and social care costs; unpaid caregivers' time in care and support to participant; and expenditure by self or family on travel to appointments, equipment purchases.



## Follow-up time points

The 3-month hospital costs were higher in the control group than in the intervention group at the 24-week follow-up (−£552, 95% CI −£1098 to −£7;  $p = 0.047$ ). Average health and social care costs (including the intervention) were similar to those prior to baseline at the first two follow-ups. Costs in the intervention sample remaining in the community were 36% higher at 52 weeks than at the 24-week point and 72% higher at 104 weeks than at the 24-week point; costs of controls were 8% higher at 52 weeks than at the 24-week point and 41% higher at 104 weeks than at 24 weeks. The 3-month costs of unpaid care were higher in the control group than in the intervention group at 52 weeks (−£2151, 95% CI −£4040 to −£262;  $p = 0.026$ ). Societal costs at 12 weeks were approximately 13% higher than baseline in the intervention group, but had changed little in the control group. Societal costs at 52 weeks were 15% higher than at 24 weeks in the intervention group, and 18% higher than at 24 weeks in the control group. At 104 weeks, the societal costs of intervention group participants were 14% higher than at 52 weeks, whereas the societal costs of control group participants were similar to those at 52 weeks.

The costs of ATT devices varied little among the groups over the follow-ups. Unsurprisingly, the 3-month costs of the full ATT package were significantly higher than those of the basic package at each time point; however, the additional cost was low in absolute terms (ranging between £11 at baseline and £21 at week 12).

Estimated costs for intervals not covered by the CSRI are given in *Appendix 5*. The raw mean cumulative costs (see *Appendix 6*) of ATT over the 2-year follow-up were estimated to be £322 (SE £18) in the intervention group and £214 (SE £16) in the control group. The raw mean cumulative costs of ATT over the baseline and follow-up period were estimated at £408 (SE £18) in the intervention group and £288 (SE £16) in the control group (a difference of £119, 95% CI £71 to £168;  $p = 0.000$ ). Cumulative costs were estimated at £19,649 (SE £3206) and £15,186 (SE £2102) in the intervention and control groups, respectively.

## Cost-effectiveness analyses

### Model results: outcomes and costs

#### Institutionalisation-free days

The regression estimate of the between-group difference in days lived in the community to 104 weeks was 7.9 days (95% CI −26.2 to 42.2 days) (*Table 17*). Adjusted mean days in the intervention group were 597 and 589 in the control group (approximately 85 weeks and 84 weeks, respectively). Total health and social

TABLE 17 Institutionalisation-free days and costs at 104 weeks (450 participants)

	Trial arm, mean (95% CI) <sup>a</sup>		Intervention – control, mean difference (95% CI) <sup>a</sup>	Cost (£) per institutionalisation-free day <sup>a</sup>
	Intervention	Control		
Institutionalisation-free days (n)	597.075 (572.464 to 620.939)	589.177 (563.373 to 614.062)	7.898 (−26.438 to 42.425)	–
Health and social care costs (£)	20,616 (16,229 to 26,708)	21,525 (17,134 to 28,435)	−909 (−5336 to 3345)	−909/7.898 = −115
Societal costs (£)	56,770 (50,175 to 64,584)	60,316 (52,647 to 69,843)	−3545 (−13,914 to 6581)	−3545/7.898 = −449

a Bias-corrected bootstrapped 95% CIs, bootstrapped estimates (25,000 replications). Difference in QALY rounded to the third decimal place.

#### Note

Costs are in 2016–17 Great British pounds.

care costs over 104 weeks were £909 lower in the intervention group, but with very wide CIs that crossed zero (95% CI -£5336 to £3345), indicating that the costs did not differ between the intervention and control groups. Adjusted mean health and social care costs per participant over 2 years were £20,616 (95% CI £16,229 to £26,708) in the intervention group and £21,252 (95% CI £17,134 to £28,435) in the control group.

### EuroQol-5 Dimensions

#### Participant reported

Difference-in-difference coefficients and bootstrapped CIs are presented in *Table 18*. Model estimates of group means, within-group differences from baseline to follow-up and model-based SEs are presented in *Table 17* and in *Appendix 7, Tables 30–35*.

**TABLE 18** Difference-in-difference estimates: differences in between-group differences on participant and proxy-rated EQ-5D scores and 3-month costs. Sample: available cases

Time point	Difference	95% CI <sup>a</sup>	ICER <sup>b</sup> (difference in costs/MCID)
<b>24 weeks</b>			
Participant reported (n = 287)			
EQ-5D <sup>c</sup> score	-0.011	-0.052 to 0.028	367/-0.148 = -2475
Health and social care <sup>d</sup> costs (£)	367	-850 to 1474	
Participant reported (n = 284)			
EQ-5D <sup>c</sup> score	-0.015	-0.056 to 0.024	251/-0.204 = -1231
Societal <sup>d</sup> costs (£)	251	-1164 to 2005	
Proxy reported (n = 309)			
EQ-5D <sup>c</sup> score	0.034	-0.007 to 0.074	313/0.463 = 677
Health and social care <sup>d</sup> costs (£)	313	-949 to 1313	
Proxy reported (n = 308)			
EQ-5D <sup>c</sup> score	0.033	-0.008 to 0.073	110/0.448 = 246
Societal <sup>d</sup> costs (£)	110	-1569 to 1630	
<b>52 weeks</b>			
Participant reported (n = 229)			
EQ-5D <sup>c</sup> score	-0.056	-0.617 to 0.5	534/-0.004 = -9595
Health and social care <sup>d</sup> costs (£)	534	-748 to 2082	
Participant reported (n = 227)			
EQ-5D <sup>c</sup> score	-0.105	-0.675 to 0.441	116/-0.008 = -1103
Societal <sup>d</sup> costs (£)	116	-1765 to 2185	
Proxy reported (n = 257)			
EQ-5D <sup>c</sup> score	0.027	-0.015 to 0.068	442/0.360 = 1226
Health and social care <sup>d</sup> costs (£)	442	-926 to 1502	
Proxy reported (n = 257)			
EQ-5D <sup>c</sup> score	0.027	-0.015 to 0.068	-220/0.360 = -611
Societal <sup>d</sup> costs (£)	-220	-2175 to 1443	

TABLE 18 Difference-in-difference estimates: differences in between-group differences on participant and proxy-rated EQ-5D scores and 3-month costs. Sample: available cases (*continued*)

Time point	Difference	95% CI <sup>a</sup>	ICER <sup>b</sup> (difference in costs/MCID)
<b>104 weeks</b>			
Participant reported (n = 243)			
EQ-5D <sup>c</sup> score	-0.016	-0.056 to 0.021	698/-0.217 = -3221
Health and social care <sup>d</sup> costs (£)	698	-919 to 2309	
Participant reported (n = 243)			
EQ-5D <sup>c</sup> score	-0.019	-0.06 to 0.017	153/-0.262 = -584
Societal <sup>d</sup> costs (£)	153	-1969 to 2248	
Proxy reported (n = 266)			
EQ-5D <sup>c</sup> score	0.021	-0.022 to 0.06	478/0.281 = 1699
Health and social care <sup>d</sup> costs (£)	478	-938 to 1946	
Proxy reported (n = 266)			
EQ-5D <sup>c</sup> score	0.021	-0.022 to 0.06	-32/0.281 = -113
Societal <sup>d</sup> costs (£)	-32	-1956 to 1908	

MCID, minimal clinically important difference.

a Bias-corrected bootstrapped 95% CIs, bootstrapped estimates (5000 replications). EQ-5D scaled by MCID rounded to three decimal points.

b Cost per gain of 0.074 in EQ-5D.<sup>78,79</sup>

c Estimates from outcome equation: covariates are allocation to ATT, BADLS categories and stratifiers.

d Estimates from costs equation: covariates are allocation to ATT, BADLS categories and stratifiers.

#### Note

Available cases at 24 weeks = cost and outcome data available from baseline and at least one follow-up point; available cases at 52 and 104 weeks = cost and outcome data available from baseline and at least two follow-up points.

At the 24-week follow-up, the between-group difference in change from baseline EQ-5D scores was positive in both groups, but the change was larger in the control group than in the intervention group. At the 52-week follow-up, the between-group difference in change from baseline to follow-up EQ-5D scores was negative because, although changes were negative in both groups, the change was larger in the intervention than in the control group. At the 104-week follow-up, the between-group difference in change from baseline to follow-up EQ-5D scores was negative because the change was negative in the intervention group and positive in the control group. However, at each time point, the bootstrapped CIs of the difference-in-difference coefficient crossed zero, indicating no significant difference in between-group change in outcome. The difference between groups in the change in 3-month costs from baseline to follow-up was positive at each of these time points, but bootstrapped CIs of the difference-in-difference coefficient again crossed zero. Health and social care costs and societal 3-month costs were (non-significantly) higher in the intervention group than in the control group.

#### Proxy reported

At the 24-, 52- and 104-week follow-ups, the between-group difference in change from baseline scores (see Table 18) was positive, but CIs of the difference crossed zero, indicating no difference between groups in this outcome. At all time points, proxy-rated EQ-5D scores were lower than participant-rated scores.

The difference in average follow-up health and social care 3-month costs from baseline were (non-significantly) higher in the intervention group than in the control group. The difference in average follow-up societal 3-month costs from baseline were slightly (non-significantly) lower in the intervention group than in the control group (reflecting the larger size of the sample with proxy-reported outcomes available than on the participant-reported measure).

**Quality-adjusted life-years**

Results are given in *Tables 19* and *20*.

**Derived from the participant-rated EuroQol-5 Dimensions**

At 24 weeks, in terms of QALYs derived from the participant-rated EQ-5D, the intervention group had 0.016 fewer QALYs than the control group; the CIs of the difference crossed zero, indicating that the groups did not differ on this outcome. At 52 weeks, in terms of QALYs derived from the participant-rated EQ-5D, the intervention group had 0.044 fewer QALYs than the control group; the CIs did not cross zero, although the upper confidence limit was very close to it ( $p = 0.0498$ ). At 104 weeks, in terms of QALYs derived from the participant-rated EQ-5D, the intervention group had 0.105 fewer QALYs than the control group, and the CIs did not cross zero. Thus, at 52 and 104 weeks, the intervention group participants had a worse outcome on this measure than the control group participants.

**Derived from the proxy-rated EuroQol-5 Dimensions**

There were small gains in QALYs in the intervention group at 24, 52 and 104 weeks (of 0.01, 0.016 and 0.03, respectively), but the CIs of the differences crossed zero in each case, indicating that the groups did not differ on this outcome.

TABLE 19 Quality-adjusted life-years and costs at 24, 52 and 104 weeks (450 participants)

Time point	Trial arm, mean (95% CI) <sup>a</sup>		Intervention – control, mean difference (95% CI) <sup>a</sup>
	Intervention	Control	
<b>24 weeks</b>			
<i>Costs (£)</i>			
Health and social care	4455 (3428 to 5883)	4964 (3672 to 6975)	-509 (-1883 to 579)
Societal	14,109 (12,251 to 15,738)	15,368 (13,083 to 18,233)	-1258 (-4680 to 1461)
<i>QALY (EQ-5D-5L)</i>			
Participant reported	0.334 (0.319 to 0.348)	0.350 (0.336 to 0.364)	-0.016 (-0.036 to 0.003)
Proxy reported	0.245 (0.231 to 0.258)	0.234 (0.220 to 0.248)	0.010 (-0.009 to 0.029)
<b>52 weeks</b>			
<i>Costs (£)</i>			
Health and social care	9363 (7296 to 11,999)	10,122 (7843 to 13,332)	-759 (-3109 to 1430)
Societal	28,180 (24,733 to 31,839)	29,293 (25,648 to 33,414)	-1114 (-6186 to 3701)
<i>QALY (EQ-5D-5L)</i>			
Participant reported	0.680 (0.646 to 0.712)	0.724 (0.692 to 0.754)	-0.044 (-0.088 to -0.000)
Proxy reported	0.485 (0.453 to 0.516)	0.470 (0.439 to 0.499)	0.016 (-0.026 to 0.057)
<b>104 weeks</b>			
<i>Costs (£)</i>			
Health and social care	20,524 (16,109 to 26,413)	21,602 (17,234 to 28,395)	-1078 (-5648 to 3062)
Societal	56,745 (50,085 to 64,530)	60,399 (52,804 to 69,823)	-3654 (-13,884 to 6316)
<i>QALY (EQ-5D-5L)</i>			
Participant reported	1.201 (1.127 to 1.271)	1.306 (1.234 to 1.376)	-0.105 (-0.204 to -0.007)
Proxy reported	0.828 (0.762 to 0.894)	0.798 (0.733 to 0.861)	0.030 (-0.058 to 0.117)
<sup>a</sup> Bias-corrected bootstrapped 95% CIs, bootstrapped estimates (25,000 replications).			
<b>Note</b>			
Costs are in 2016–17 Great British pounds.			

TABLE 20 Incremental cost-effectiveness ratio: 24-, 52- and 104-week QALYs (EQ-5D)

Time point and costs	ICER (£) intervention over control <sup>a</sup>	
	QALYs derived from participant-reported EQ-5D	QALYs derived from proxy-reported EQ-5D
<b>24 weeks</b>		
Health and social care	$-509/-0.016 = 31,561$	$-509/0.010 = -49,656$
Societal	$-1258/-0.016 = 77,994$	$-1258/0.010 = -122,711$
<b>52 weeks</b>		
Health and social care	$-759/-0.044 = 17,279$	$-759/0.016 = -48,861$
Societal	$-1114/-0.044 = 25,339$	$-1114/0.016 = -71,654$
<b>104 weeks</b>		
Health and social care	$-1078/-0.105 = 10,237$	$-1078/0.030 = -35,432$
Societal	$-3654/-0.105 = 34,706$	$-3654/0.030 = -120,125$
<p><b>a</b> Cost of achieving a QALY gain over the follow-up period; difference in QALY is rounded to the third decimal place.  <b>Note</b>  Point ICER for intervention over control, from health and social care and societal perspectives (<math>n = 450</math>).</p>		

### Incremental cost-effectiveness ratios and probability of cost-effectiveness

#### Institutionalisation-free days

At 104 weeks, the cost per institutionalisation-free day from either health and social care or societal perspectives was negative (see *Table 17*) because the point estimate for cost difference (from either perspective) was negative and the point estimate for institutionalisation was positive. The CEAC indicates that there is no WTP value in the range of WTP values of between £0 and £50,000 at which we could be certain that either the basic or full ATT package was better value for money (see *Appendix 7, Figure 13*), as the probability of cost-effectiveness did not exceed 72% (health and social care) and 80% (societal perspective) over that range.

#### Proxy-reported EuroQol-5 Dimensions

At the 24-week point, on the proxy-reported EQ-5D (see *Table 18*), the ICERs for health and social care costs and societal costs were positive because the estimates of both costs and outcomes differences were positive. The CEAC (see *Appendix 7, Figure 14*) indicates that the probability of cost-effectiveness on achieving a minimal clinically important difference from either perspective is approximately 90% at a WTP of £5200 and just under 95% across WTP values of between £25,700 and £50,000. We cannot, however, be confident from either perspective at the 95% level that the full ATT package strategy is more cost-effective than the basic ATT package over the range.<sup>80</sup> At the later time points, the ICERs from the health and social care perspective were positive (small positive differences in outcomes and costs), and from the societal perspective they were negative (small positive differences in outcomes and small negative differences in costs). At 52 weeks, the probability of cost-effectiveness (see *Appendix 7, Figure 15*) did not exceed 90% from either perspective over a range of WTP of between £15,000 and £50,000; at 104 weeks, the probability of cost-effectiveness did not exceed 84% from either perspective over this range (see *Appendix 7, Figure 16*). As with the 24-week results, we cannot be confident from either perspective at the 95% level that the full ATT package strategy is more cost-effective than the basic ATT package over this range. The probability of cost-effectiveness at WTP values of £20,000 was highest in the short term (24 weeks) and lowest in the long term (104 weeks), from both perspectives.

**Participant-reported EuroQol-5 Dimensions**

In the case of ICERs produced for participant-reported EQ-5D (see *Table 18*) the outcome was (non-significantly) worse in the intervention group and costs were (non-significantly) higher or lower in the intervention group, depending on perspective and time horizon. The CEACs have not been presented for this reason.

**Quality-adjusted life-years****Derived from the proxy-rated EuroQol-5 Dimensions**

At the 24-, 52- and 104-week time points, in terms of the QALYs generated from the proxy-reported EQ-5D (see *Table 19*), the ICERs for health and social care costs and societal costs were negative because of negative cost difference estimates and positive QALY difference estimates. The CEAC (see *Appendix 7, Figure 17*) indicates that the probability of cost-effectiveness was highest at the 24-week point from the health and social care perspective, but this did not exceed 90% across a range of WTP values of £0–50,000. Curves for the later time points were lower than those at 24 weeks, with the 104-week probabilities being the lowest (not exceeding 82%, from the societal perspective, over the £0–50,000 range).

**Derived from the participant-rated EuroQol-5 Dimensions**

The ICERs for QALYs based on the participant-reported EQ-5D were positive, but this was because the costs were slightly lower and the outcomes somewhat worse in the intervention group than in the control group. The CEAC is not presented for this reason.

**Sensitivity analysis: replacement cost of unpaid care**

The impact on societal costs and the ICER of valuing unpaid care at replacement cost at 104 weeks was explored in a sensitivity analysis. The costs of unpaid care and societal and intervention costs using replacement costs are presented in *Appendix 7, Table 36*. Cost-effectiveness analysis results are presented in *Appendix 7, Tables 37–39*.

**Institutionalisation-free days**

Valuation of caregiver time at replacement cost resulted in a smaller difference between groups in total societal costs over 104 weeks, but, as with the main results, the 95% CIs of the difference crossed zero. The ICER remained negative, in line with the main results.

**EuroQol-5 Dimensions**

Valuation of caregiver time at replacement cost yielded larger estimates of the difference-in-difference between groups in societal costs. For the participant-reported EQ-5D, this yielded a larger negative ICER (because the difference-in-difference in cost was non-significantly positive and the outcome was non-significantly worse in the intervention group than in the control group); for the proxy-completed EQ-5D, this also yielded a larger negative ICER (because the difference-in-difference in cost was non-significantly negative and because the outcome was non-significantly better in the intervention group than in the control group). The results were in line with the main results valuing caregiver time at opportunity cost.

**Quality-adjusted life-years**

As with the main results, the ICER for QALYs based on the participant-reported EQ-5D remained positive (with non-significantly lower total costs and with fewer QALYs for the intervention group than the control group), but was lower (approximately half). The ICER for QALYs based on the proxy-reported EQ-5D remained negative (with non-significantly lower total costs and with non-significantly more QALYs for the intervention group than the control group) and was lower (approximately half).



## Discussion

The additional 3-month cost of a full ATT package over a basic package at each time point was modest (ranging from £11 at baseline to £21 at week 12). Although the cumulative cost estimated for the full package was significantly greater than that of the basic package (an additional £119), the average costs of ATT were modest in both the intervention and control groups (£408 and £288, respectively). Mean (unadjusted) societal costs were in the order of three times that of health and social care costs. Total health and social care and societal costs over 104 weeks, taking censoring into account, did not differ between groups. Average 3-month costs estimated in difference-in-difference analyses did not differ between groups at 24, 52 or 104 weeks. Change in proxy-rated and participant-rated EQ-5D index scores estimated in difference-in-difference analyses also did not differ between groups at those time points. For the institutionalisation-free days outcome, there was no statistical difference between the intervention and control groups in days spent in the community. Groups did not differ on proxy-reported QALYs. The mean participant-reported QALY was lower in the intervention group than in the control group at the 52- and 104-week time points. The probability of cost-effectiveness on a measure of change in proxy-rated health-related quality of life was greater in the short term than in the long term from the health and social care and societal perspectives, at a WTP of £20,000. A similar pattern was seen in proxy-rated QALYs from the health and social care perspective, but the probability of cost-effectiveness was higher in the long term from the societal perspective.

Some limitations must be acknowledged. Costs were measured by asking caregivers to retrospectively report service use, so the results could be subject to recall bias. The costs accrued during the intervals between periods with CSRI data available were estimated by carrying forward most costs, although the costs of inpatient and emergency department use were estimated from the SAE data available over these times. Costs of regularly used services were thus assumed to be constant over these intervening periods. Participant-reported EQ-5D data were missing for one-quarter of intervention group participants and for one-third of control group participants who had participated in assessments at 104 weeks. Although difference-in-difference analyses controlled for baseline covariates (stratification variables and dependency, as measured by the BADLS) that might have accounted for differences in data availability between groups on this measure, QALY analyses drew on group mean utilities at each time point and did not adjust for baseline characteristics. Therefore, the finding that the intervention group had fewer QALYs derived from participant-reported EQ-5D must be interpreted with some caution as substantial rates of missingness in that measure could be a concern. Generalisability of these findings may also be limited because all assessment data were missing from some participating dyads at the baseline and follow-up points (8% of the sample at baseline and between 16% and 19% of the community-dwelling sample still participating in the study over the follow-ups did not participate in an interview).

The study sample size was powered to detect a delay to entry to permanent care home residence of 55 days over 24 months. As can be seen from the measures of uncertainty around all point estimates of cost differences, there was substantial variability in the cost data (as might be expected). It is possible that, because the variance around the mean difference in costs was of a greater magnitude than the variance around the survival outcome, a larger sample size would have been required to detect a between-group difference in costs than in days.

The mean EQ-5D proxy-rated index scores were consistently lower than index scores derived from the participant-rated version of the measure. This pattern is in line with that reported in other studies involving people with dementia and caregiver proxy raters.<sup>81</sup> The EQ-5D has been reported to be more reliable than some dementia-specific quality-of-life measures in terms of agreement between caregiver proxy-rated and self-rated total scores, in a population with mild and moderate dementia participating in a psychosocial intervention.<sup>82</sup> The divergence we observed between proxy and participant raters' EQ-5D and QALY outcomes may relate to selection effects, validity of the instrument when used for people with more advanced dementia and genuine differences in perspectives between raters.<sup>81</sup>

The participant-proxy inter-rater reliability of the EQ-5D index scores from this study merits further investigation, as does the response rate of participants at different stages of dementia.

### **Conclusions**

The results suggest that the health and social care and societal costs of a full package of ATT were not greater than those of a basic package of ATT for people with dementia. There was little evidence that the intervention influenced the length of time lived in the community over 104 weeks, improved health-related quality of life as rated by participants and proxies or increased participants' QALYs based on quality of life as rated by proxies. The results suggest that the intervention reduced participants' QALYs based on quality of life rated by people with dementia themselves. Generalisability of findings based on the dyad-reported outcomes data is limited by the extent of missing data at the individual outcome measure and at the assessment level.



## Chapter 6 Impact of assistive technology for people with dementia on burden and psychological well-being in unpaid caregivers

People living with dementia increasingly depend on informal caregivers who assist with ADL, ensure safety, manage challenging behaviours and provide company to the cared-for person. The majority of caregivers for people with dementia are family members, and approximately 60–70% of them are women.<sup>83</sup> It is estimated that 11% of all caregivers in the UK provide care to someone with dementia in a home setting.<sup>84</sup> As caregivers are frequently middle-aged or older children of the person with dementia, many may be in part- or full-time employment, which results in difficulties in balancing work and care commitments that are likely to diminish their ability to provide care.<sup>85</sup> Moreover, a large number of people providing unpaid care have a long-standing illness or disability themselves.<sup>86</sup>

These caregivers are normally untrained to deliver care and the performance of the caring role is a potential source of substantial psychosocial stress. There is some evidence showing that this stress is manifested in some measures of immunity and may also affect cognition.<sup>87</sup> Caregivers report worsening of their mental health and physical health due to their caring role.<sup>88</sup> Importantly, caregivers of people with dementia show higher levels of anxiety and depression than caregivers of other conditions.<sup>89,90</sup> Caring for a person with dementia has been found to adversely affect a caregiver's financial resources through early retirement, reduced paid working hours or reliance on benefits.<sup>91,92</sup> The physical health of these caregivers is also adversely affected.<sup>93–95</sup>

As this care is provided informally and is generally unfunded, the savings to the public purse are extensive. The annual cost of unpaid care in the UK has been estimated to be £11.6B.<sup>96</sup> One study estimated that the total societal worldwide costs of unpaid care for dementia at US\$329B per year.<sup>97</sup> This is a rough estimate and assumes informal care time of 3.7 hours per day. It is cheaper to care for people with mild dementia at home (£26,000 per annum) than in residential care (£31,000 per year).<sup>96</sup>

'Carer burden' refers to 'the degree to which a carer's emotional or physical health, social life or financial status had suffered as a result of caring for their relative';<sup>98</sup> it is often used to describe the impact of providing unpaid care. Both patient and caregiver characteristics have been found to contribute to caregiver burden, for example the type of dementia, the extent of personality change, cognitive changes and the presence of behavioural and psychiatric symptoms due to the dementia. Importantly, a systematic review<sup>99</sup> confirmed that a person with dementia's functional status, prevalence of behavioural disturbances and level of neuropsychiatric symptoms, such as wandering and delusions, were found to be the most burdensome characteristics for caregivers. Factors that influence the impact of caregivers include gender; age; cultural values; the nature of the relationship with the person with dementia; the amount of unpaid and paid care available; the caregiver's physical and mental status, personality and coping strategies; and the duties of caregiving.<sup>99</sup>

Nonetheless, it should be acknowledged that providing unpaid care may also benefit these caregivers. For example, there are some reports of caregivers gaining satisfaction by performing the caregiver role and developing a close relationship with the recipient.<sup>100–102</sup> To this end, interventions to support caregivers that aim to minimise the negative impacts and enhance the benefits of the caregiving relationship, both for the cared-for person and the caregiver, have been developed.

A number of psychosocial interventions are specifically directed to caregivers of people with dementia. The bulk of these involve face-to-face delivery. Some other interventions involve telephone delivery.<sup>103</sup> An early systematic review of 40 studies found that the content of these interventions varied a lot.<sup>104</sup>

Approximately two-thirds of the interventions did not result in improvements in any outcome measure, but, of those that were successful, the inclusion of a social component, with or without a cognitive component, proved to be important. The small numbers in the studies as well as a number of methodological issues were noted as limitations of the review.<sup>104</sup> It has been reported that, in the 30 years up to 2015, > 200 interventions for caregivers have been tested in randomised trials and found to have some efficacy on caregivers' outcomes.<sup>105</sup>

Some of these have used information and communications technology (ICT) to facilitate collecting, capturing, storing, processing, transmitting, exchanging and presenting information and/or communication.<sup>106,107</sup> A 2019 systematic review<sup>108</sup> examined the impact of ICT interventions on dementia caregivers' outcomes. Of the six studies that used telephone interventions, three resulted in significant effects on a range of caregiver outcomes, including reducing caregivers' depressive symptoms. Three of the four studies evaluating video interventions had an effect on a range of caregiver outcomes, as did the two computer-based interventions. The authors<sup>108</sup> conclude that interventions that use the telephone show the most evidence to support their use. Similarly to interventions directed at the person with dementia, interventions for caregivers can be delivered to the individual, in a group setting, online or to the caregiver–cared-for person dyad. However, the evidence is as yet unclear about which is the most effective delivery method for caregiver outcomes.

An alternative to interventions that are specifically directed to caregivers are interventions that aim to remotely monitor and manage the care recipient. Commonly termed telecare, these interventions involve installing ATT devices to remotely monitor the care recipient. The devices are generally employed to continuously, automatically and remotely monitor for real-time emergencies and lifestyle changes to manage risks of living at home. Although directed at the care recipient, these may also affect caregiver outcomes by improving sleep and reducing worry and stress by preventing serious incidents such as falls, cooking accidents, or wandering. A systematic review<sup>109</sup> explored the evidence for the use of these devices on caregiver well-being across several types of care recipient and identified seven studies, all of which were rated as having weak methodological quality. The most common types of equipment were passive sensors such as bed and door sensors, and sensors to monitor home emergencies such as flood and gas alarms. However, a tentative conclusion was that the evidence indicated that telecare exerts a positive effect on caregiver stress and strain. Only one study evaluated the impact of telecare on quality of life<sup>110</sup> and one study investigated caregiver burden;<sup>111</sup> neither study found evidence for a positive impact of their interventions. Two<sup>112,113</sup> of the seven studies in the systematic review<sup>109</sup> examined caregivers of people with dementia. Holthe<sup>112</sup> reported on 25 caregivers of people with dementia, of whom slightly more than 50% lived with a person being cared for; Woolham<sup>113</sup> reported on 123 caregivers. Although limitations of the studies' methodologies were identified, they reported a positive impact on caregiver stress, suggesting a potential benefit of telecare for caregivers as well as care recipients that is deserving of further investigation.

### **Aims**

We aimed to assess and compare the use of ATT with usual care for people with dementia on caregiver psychosocial and health outcomes, namely caregiver burden, depression and anxiety.

### **Methods**

#### ***Design and participants***

Participants were caregivers of participants recruited to the main ATTILA RCT, and, as such, were recruited and allocated to their study group according to their care recipient's randomisation allocation.

Eligibility criteria for the recruited care recipient participants are discussed in detail in *Chapter 2*. They were adults, and were spouses, partners or children of the care recipient. Caregivers could be resident or non-resident with the trial participant. Caregivers remained in the trial until their care recipient left owing to death or a move to residential care.

### **Intervention and control conditions**

Caregivers were not the direct recipient of the ATT assessment and interventions. The related care recipient received the intervention ATT assessment and installation or control package, randomly allocated as described in *Chapter 2*.

### **Recruitment**

The recruitment of participants is described in *Chapter 2*.

### **Sample size**

The sample size was estimated on the expected effect size of the intervention on the primary outcome for the ATT recipients. No required number of participants was identified for the caregiver sample.

### **Procedure**

Outcome rating scales were completed by caregivers at the same time points as data collections for their care recipient: baseline (0 weeks) and 12, 24, 52 and 104 weeks. Participants completed the baseline paper outcome rating scales at home, with or without the assistance of the data collection assistants. Further assessments were mailed to participants or completed at the care recipients' follow-up appointments.

### **Data collection**

Outcome rating scales relevant to the assessment of caregiver outcomes are reported here.

### **Descriptive data and covariates**

Data about the caregiver, their caring responsibilities, and their relationship to the participant were collected: (1) caregiver age; (2) frequency of caring responsibility – lives with the care recipient, visits once per day or visits fewer times than once per day; and (3) who lived with the care recipient – spouse or partner, care recipient lives alone or other. Data about the severity of the care recipient's dementia symptoms were captured using the SMMSE.<sup>114</sup>

### **Caregiver outcome data**

Data were collected about carer outcomes on three scales:

1. Caregiver burden – the ZBI<sup>115</sup> is a 22-item scale assessing the burden of caregiving. Participants respond on a five-point Likert scale ranging from 0 (never) to 4 (always). A single score is calculated by summing the responses to the 22 items. A higher score indicates greater burden, with 0–20 indicating little or no burden, 21–40 indicating mild to moderate burden, 41–60 indicating moderate to severe burden and 61–88 indicating severe burden.
2. Depression – CES-D-10: a 10-item scale. Participants respond on a four-point Likert scale ranging from 0 (rarely/none of the time) to 3 (all of the time). A single score is calculated by reverse-scoring two items and summing the 10 item scores. A score of  $\geq 10$  indicates depression.
3. STAI-6 – short form of the state scale of the STAI:<sup>116</sup> a six-item scale on which participants rate anxiety symptoms on a four-point Likert scale ranging from 1 (not at all) to 4 (very much). Three items are reverse-scored, followed by a sum of items multiplied by 20/6. A single score is calculated ranging from 20–80. A 'normal' score is 34–36; higher scores indicate greater anxiety.

It was also planned to use the Short Form questionnaire-12 items to assess quality of life, but there were some difficulties in registering the use of this instrument; therefore, it was not deployed.

## Analyses

### Data analysis

We analysed the data with IBM SPSS Statistics version 25 (IBM Corporation, Armonk, NY, USA) (alpha level = 0.05). Preliminary analyses provided descriptive details for all the measures at the item or scale level, as appropriate. We explored normality of the data by visually inspecting histograms and conducting the Shapiro–Wilk test of normality. We also conducted a principal component analysis with an oblimin rotation on the ZBI. We used the Kaiser–Meyer–Olkin measure to check the suitability of the data for principal component analysis. We then used a scree plot to determine the number of factors to retain and decided to extract three components (see *Appendix 7, Table 40*).

### Selection of cases for inclusion in analyses

There were several sources of attrition across time points, including loss to follow-up, death and institutionalisation of the care recipient. Because the attrition rate was substantially higher at the last two time points (i.e. weeks 52 and 104), reaching approximately 50% by week 104, than at the first three time points (i.e. baseline and weeks 12 and 24), we excluded the last two time points from the analyses. We conducted our analyses according to the intention-to-treat principle.

### Imputation

To account for missing data across demographic variables and outcomes, we conducted multiple imputation for baseline only by including all predictors to fill the missing data. We used data from all time points (baseline, week 12 and week 24) within the same multiple imputation model. We produced 10 imputed data sets; each of the multiply imputed data sets was analysed as usual, after which the 10 sets of results produced for each analysis were combined using Rubin's rules.<sup>117–119</sup>

### Descriptive data, randomisation and loss to follow-up analyses

Means and standard deviations (SDs) were calculated for continuous data, and frequencies and percentages were calculated for categorical data. We conducted linear mixed modelling (LMM) to analyse between-group differences, change over time (baseline, week 12, week 24) as well as interaction effects of group and time. An initial set of analyses was conducted to examine the assumption that within-participant scores are highly correlated by calculating the intraclass correlation. The second set of models included covariates. Time was entered as a fixed effect for each linear mixed model, with participants' identification numbers as a random effect with the default variance components structure.

In addition to the main effects of group and time, the effects of the time–group interaction were examined and interpreted where a significant interaction term indicating differential treatment effectiveness was found. The decomposition of interaction effects for (1) group differences at each time point and (2) changes over time within each group individually were examined. Significant effects were investigated using pairwise comparison with the estimated marginal means. The 95% CI around the estimated marginal means on each outcome for each group were also calculated.

## Results

The findings reported here consist of the first three waves of data collection in the ATTILA trial: at baseline and at 12 and 24 weeks. All LMM analyses in each section were adjusted for each of the demographic variables presented in *Tables 21 and 22*. The tables below (see *Tables 23–26*) provide the adjusted means of both groups on each outcome variable. We conducted a whole-sample analysis and two secondary subgroup analyses. The results are broken up into three sections:

- section 1 – all caregivers in the study
- section 2 – caregivers who were living with the person with dementia (co-resident)
- section 3 – caregivers who were partners of the person with dementia (spousal care partners).

TABLE 21 Caregiver and care recipient demographics (whole sample, N = 495)

Variable	Mean	SEM	95% CI	p-value
Caregiver age	62.5	0.60	61.3 to 63.7	
Control	62.1	0.85	60.4 to 63.7	0.455
Intervention	63.0	0.85	61.3 to 64.6	
Care recipient SMMSE score	17.8	0.30	17.2 to 18.4	
Control	17.0	0.43	16.2 to 17.8	0.006
Intervention	18.6	0.41	17.8 to 19.4	

SEM, standard error of the mean.

**Note**

Alpha level was set at 0.05.

TABLE 22 Caregiver relationship to care recipient and residential status

Variable	Caregiver visits	
	Frequency	%
<b>Living status</b>		
Living alone	229	46.3
Living with spouse/partner	195	39.4
Other	71	14.3
Total	495	100
<b>Caregiver status</b>		
Caregiver visits at least once per day	121	24.4
Caregiver visits less than once per day	134	27.1
Live-in caregiver	240	48.5
Total	495	100

**Caregiver participants**

Of the 495 caregivers in the trial, 354 provided data on age (control group,  $n = 182$ ; intervention group,  $n = 172$ ). Therefore, we imputed the remaining 141 missing data for age; SMMSE scores were also imputed. Details of caregivers' ages, the SMMSE scores of the people with dementia and the living status and frequency of caregiver visits to the person with dementia are provided in *Tables 21* and *22*.

**Section 1: findings for all caregivers****Caregiver burden**

The ZBI was analysed as a total score, and into its three component factors following a principal component analysis. The three components were defined as:

- component 1 – negative appraisal of the care partner role
- component 2 – adequacy as a care partner
- component 3 – caregiver burden and strain.

Total scores for the ZBI were not significantly different between the control and intervention groups at week 24. Furthermore, there were no significant within-group or interaction effects across all time points. Similarly, we found no significant between-group differences at week 24 for component 1, 2 or 3. There were no significant within-group or interaction effects for any of the components. Parameter estimates and adjusted mean scores for each group at each time point are presented in *Tables 23 and 24*.

**Caregiver mood**

Total scores for the CES-D-10 (depressed mood) were not significantly different between the control and intervention groups at week 24. There were no significant group or interaction effects across all time points. Similarly, total scores for the STAI-6 (anxiety) were also not significantly different between the control and intervention group at week 24. Group and interaction effects across all time points for the STAI-6 were also not statistically significant. Parameter estimates and adjusted mean scores for each group at each time point are presented in *Tables 25 and 26*.

**Section 2: spousal caregivers who were living with the person with dementia (co-resident)**

The sample of caregivers in the ATTILA trial were diverse in their living arrangements with the person with dementia. Some lived in the same home as the person with dementia. Others were resident in proximity, but living separately, and some were located some distance from the person with dementia. As there is some evidence that co-location of the caregivers with the person in receipt of care implies a more involved role in caring for the person with dementia,<sup>120</sup> this group was selected for secondary analysis, whereby effects of the telecare intervention on caregivers’ outcomes were examined only for those who were living in the same household. Details of the group in this substudy are presented in *Table 27*.

TABLE 23 The ZBI: burden for all caregivers for total score and for three principal components

Time, group and interaction effects	F-value	df		p-value
		1	2	
<b>Total score</b>				
Time	0.472	2	1438503	0.623
Group	0.036	1	161355	0.849
Interaction	0.172	2	2228089	0.842
<b>Component 1: negative appraisal of caring</b>				
Time	0.127	2	645845	0.881
Group	0.042	1	654751	0.838
Interaction	0.200	2	4649804	0.819
<b>Component 2: adequacy as a caregiver</b>				
Time	1.259	2	318819	0.284
Group	0.144	1	37476	0.704
Interaction	0.653	2	50769	0.520
<b>Component 3: caregiver burden and strain</b>				
Time	1.696	2	250490	0.183
Group	0.030	1	272088	0.863
Interaction	1.657	2	578798	0.191

df, degrees of freedom.

TABLE 24 Zarit Burden Interview mean and component scores, SEs and 95% CIs for each group at each time point

Time point	Trial arm	Mean	SE	95% CI
<b>Total score</b>				
Baseline	Control	29.6	1.36	26.9 to 32.3
	Intervention	29.3	1.44	26.4 to 32.1
Week 12	Control	29.7	1.41	27.0 to 32.5
	Intervention	30.0	1.48	27.1 to 32.9
Week 24	Control	30.0	1.43	27.2 to 32.7
	Intervention	29.7	1.48	26.7 to 32.6
<b>Component 1: negative appraisal of caring</b>				
Baseline	Control	13.8	0.67	12.5 to 15.1
	Intervention	14.0	0.70	12.6 to 15.4
Week 12	Control	14.3	0.70	13.0 to 15.7
	Intervention	14.2	0.73	12.8 to 15.6
Week 24	Control	14.3	0.70	13.0 to 15.7
	Intervention	14.2	0.73	12.8 to 15.6
<b>Component 2: adequacy as a caregiver</b>				
Baseline	Control	3.8	0.25	3.3 to 4.3
	Intervention	3.9	0.26	3.4 to 4.4
Week 12	Control	3.9	0.27	3.3 to 4.4
	Intervention	4.1	0.27	3.5 to 4.6
Week 24	Control	3.9	0.27	3.3 to 4.4
	Intervention	3.7	0.28	3.2 to 4.3
<b>Component 3: caregiver burden and strain</b>				
Baseline	Control	7.8	0.503	6.8 to 8.8
	Intervention	7.4	0.527	6.4 to 8.5
Week 12	Control	7.5	0.526	6.5 to 8.6
	Intervention	8.0	0.544	6.9 to 9.1
Week 24	Control	7.7	0.532	6.6 to 8.7
	Intervention	7.8	0.547	6.7 to 8.8

TABLE 25 The CES-D-10 and STAI-6 scores according to group and time point for all caregivers

Time, group and interaction effects	F-value	df		p-value
		1	2	
<b>CES-D-10</b>				
Time	1.726	2	935042	0.178
Group	0.282	1	341074	0.596
Interaction	0.595	2	830859	0.551
<b>STAI-6</b>				
Time	1.110	2	4613788	0.329
Group	0.539	1	2187757	0.463
Interaction	0.713	2	896778.4	0.490

df, degrees of freedom.



TABLE 26 Anxiety and Depression mean scores, SEs and 95% CIs for each group at each time point

Time point	Trial arm	Mean	SE	95% CI
<b>CES-D-10</b>				
Baseline	Control	9.6	0.56	8.5 to 10.7
	Intervention	8.7	0.59	7.5 to 9.8
Week 12	Control	9.8	0.59	8.6 to 10.9
	Intervention	9.1	0.61	7.9 to 10.3
Week 24	Control	9.7	0.59	8.5 to 10.8
	Intervention	9.3	0.61	8.1 to 10.5
<b>STAI-6</b>				
Baseline	Control	40.3	1.22	37.9 to 42.7
	Intervention	39.7	1.28	37.2 to 42.2
Week 12	Control	39.9	1.30	37.4 to 42.5
	Intervention	40.2	1.34	37.6 to 42.8
Week 24	Control	40.1	1.33	37.5 to 42.7
	Intervention	41.2	1.36	38.5 to 43.9

TABLE 27 Demographic characteristics of participants with dementia in the subgroup analysis including only caregivers who lived with the cared-for person (n = 195)

Variable	Mean	SEM	95% CI	p-value
Age (years)	71.8	0.80	70.2 to 73.4	
Control	71.9	1.12	69.7 to 74.1	0.901
Intervention	71.7	1.14	69.5 to 73.9	
SMMSE score <sup>a</sup>	17.4	0.49	16.5 to 18.4	
Control	17.0	0.68	15.6 to 18.3	0.344
Intervention	17.9	0.71	16.5 to 19.3	

SEM, standard error of the mean.

a Score of the person with dementia.

**Note**

Alpha level was set at 0.05.

The analyses presented in the following sections mirror those conducted for all caregivers in the previous sections.

**Caregiver burden**

Total scores for the ZBI were not significantly different between the control and intervention groups at week 24. There were no significant group or interaction effects across all time points. Similarly, we found no significant between-group differences at week 24 for any of the three subcomponents of the ZBI. There were no significant group, time or interaction effects for any of the components. Parameter estimates and adjusted mean scores for each group at each time point are presented in *Appendix 7, Tables 41 and 42.*



### Caregiver mood

Total scores for the CES-D-10 (depressed mood) were not significantly different between the control and intervention groups at week 24. Furthermore, there were no significant within-group or interaction effects across all time points. Similarly, total scores for the STAI-6 were also not significantly different between the control and intervention groups at week 24. Within-group and interaction effects across all time points for the STAI-6 were also not statistically significant. Parameter estimates and adjusted mean scores for each group at each time point are presented in *Appendix 7, Tables 43 and 44*.

## Section 3: caregivers who were the spouse or partner of the person with dementia

Much of the literature on caregivers has selected spousal care partners for special attention, and there is evidence that spouses are particularly vulnerable to burden and poor psychological well-being.<sup>121-123</sup> Spousal caregivers of people with dementia have to live with an altered relationship with the person they elected to partner and live with as the mental faculties of the person with dementia alter. Furthermore, spousal carers may be of similar age to the care recipient and, therefore, may be experiencing physical or cognitive difficulties themselves. A secondary analysis was conducted on spousal caregivers of the person with dementia in the sample, so as to keep the relationship between the caregivers and the person with dementia constant. Details of their age and the SMMSE score of the person with dementia are provided in *Table 28*.

### Caregiver burden

In this subgroup analysis, total scores for the ZBI were not significantly different between the control and intervention groups at week 24. Furthermore, there were no significant within-group or interaction effects across all time points. Similarly, we found no significant between-group differences at week 24 for components 1, 2 or 3. There were no significant within-group or interaction effects for any of the components. Parameter estimates and adjusted mean scores for each group at each time point are presented in *Appendix 7, Tables 45 and 46*.

### Caregiver mood

Total scores for the CES-D-10 (depressive mood) were not significantly different between the control and intervention groups at week 24. Furthermore, there were no significant within-group or interaction effects across all time points. Similarly, total scores for the STAI-6 (state anxiety) were not significantly different between the control and intervention groups at week 24. Within-group and

TABLE 28 Demographic characteristics of participants with dementia in the subgroup analysis including only caregivers who were the spouse or partner of the care recipient ( $n = 240$ )

Variable	Mean	SEM	95% CI	p-value
Age	68.6	0.83	66.9 to 70.2	
Control	68.7	1.14	66.5 to 70.9	0.863
Intervention	68.4	1.23	66 to 70.8	
SMMSE score <sup>a</sup>	17.3	0.45	16.4 to 18.2	
Control	16.8	0.62	15.6 to 18	0.255
Intervention	17.8	0.65	16.5 to 19.1	

SEM, standard error of the mean.

a Score of the person with dementia.

#### Note

Alpha level was set at 0.05.

interaction effects across all time points for the STAI-6 were also not statistically significant. Parameter estimates and adjusted mean scores for each group at each time point are presented in *Appendix 7, Tables 47 and 48*.

## Discussion

The impact on caregivers' health and well-being of caring for someone with dementia has led to the development of interventions to reduce the burden they face. It has also been recognised that these interventions may have a broader impact, as the alleviation of caregiver burden may reduce the likelihood of the cared-for person being institutionalised, thereby reducing social and health-care costs. In this study within the ATTILA trial, we investigated the effects of using ATT for people with dementia on the outcomes of the participants' caregivers, namely caregiver burden and psychological well-being in the first 24 weeks following installation of the ATT intervention.

No effects of the installation of ATT compared with usual care were found on caregiver burden and its subcomponents, or depression and state anxiety. We also conducted post hoc subgroup analyses among live-in caregivers, and among caregivers who were the spouse or partner of the cared-for person, in whom we might expect poorer psychological well-being and levels of burden. Neither of these subgroup analyses revealed differences between the two groups in any of these outcomes. It is notable that the levels of caregiver burden, depression and anxiety remained stable during the course of the trial. Although this is not a non-inferiority trial, the data suggest no negative impact of receiving the ATT interventions.

One explanation for the lack of impact on these outcomes is the relatively low levels of burden, depression and state anxiety reported in the sample at baseline.<sup>124</sup> The mean levels of burden across both the intervention and control groups for the overall sample and the examined subgroups were in the mild to moderate range. Similarly, mean levels of depression in this sample were below the clinically relevant threshold on the CES-D-10 scale, for which a score of > 10 indicates depression. Mean scores on the STAI-6 at baseline were 9.6 and 8.7 for control and intervention group participants, respectively. These data suggest that there may have been limited scope to reduce burden, depression and anxiety among the sampled caregivers. A previous study<sup>125</sup> indicated higher levels of depression and anxiety at baseline in its study population, and a 2016 study,<sup>126</sup> using the same instrument for assessing depression as used in this study, found higher scores, above the clinically relevant threshold, in its sample.

Alternatively, it is possible that the effects of ATT interventions may be limited in effecting change in these outcomes, and that interventions specifically targeting caregivers' well-being may be more effective than those aiming to support the cared-for person. Meta-analyses indicate that caregiver-directed interventions have demonstrated effectiveness in reducing burden, depression and anxiety in this population. Effective interventions include cognitive-behavioural therapy, cognitive reframing and educational interventions.<sup>127-130</sup> Therefore, to optimise the benefits of the installation of ATT for both the care recipient and the caregiver, it may be important to provide additional caregiver-directed support. Effective and potentially low-burden and low-cost interventions include the use of telephone- and internet-based interventions to improve caregiver outcomes.<sup>131,132</sup>

In the current sample, the mean scores on the SMMSE indicated moderate levels of cognitive impairment in the cared-for participant sample (mean 10-19). There is some evidence indicating that the severity of the dementia is related to levels of depression and anxiety, with only severe dementia leading to caregivers having high levels of depression and anxiety,<sup>133</sup> although this relationship has not always been supported.<sup>134</sup> It is possible that the level of dementia in the current study was not sufficiently severe to produce high scores at baseline in the caregivers such that they may have been reduced by the intervention.

## Strengths, limitations and suggestions for future research

This study provides the first insight into the potential impact of up-to-date technological interventions for people with dementia on outcomes for their informal caregivers within 6 months of deployment. A large data set to assess impact of ATT is available; however, the extent of missing data at follow-up precluded investigation of longer-term effects of the technology on caregiver outcomes. Furthermore, loss to follow-up in the caregiver data set was non-random, introducing some degree of bias. This is because dropout among some caregivers was partly due to the care recipient moving into residential care or dying. Furthermore, power analysis was conducted on the study primary outcome (time to institutionalisation), rather than on caregivers' outcomes. Therefore, it is possible that our analyses were statistically underpowered.

A general limitation of the trial should also be recognised, as we have reported elsewhere<sup>51</sup> that there was limited fidelity of technology deployment in relation to the recommendations arising out of the needs assessment. This mismatch may have also contributed to the lack of any impact on caregiver burden and mood.

Future work will need to determine the minimum sample size required to detect an effect of the ATT intervention based on expected effect size for caregiver outcomes. It may well be that longer follow-up times with additional caregiver support are necessary to produce any intervention effects for caregivers' outcomes.

## Conclusions and implications for practice

This study provides a first insight into the potential impact of ATT on caregiver burden, psychological well-being and quality of life. No impact of ATT on caregiver burden, depression and anxiety was identified. As key drivers of transfer to long-term residential care, interventions aiming to specifically target these aspects of caregiver psychosocial well-being along with the deployment of ATT may be important for delaying institutionalisation and preventing the costs associated with this, both for social care services and for the individual and their family members. Evidence-based effective interventions to prevent negative impact of caregiving may include care partner-directed psychological and educational techniques, as well as ensuring that caregivers have an appropriate understanding of the role of ATT.



## Chapter 7 Practices of people with dementia and caregivers using assistive technologies and telecare at home: a community-based ethnographic study

Industry, government and care service providers see ATT services as likely to enable people with dementia to continue living independently and safely in their communities. There is relatively little research to examine how people with dementia and their caregivers actually use these technologies in their everyday lives and how such experiences may affect their well-being and ability to sustain their community-based care arrangements. The little research that exists is limited in scale and quality. The ethnographic ATTILA substudy described here [referred to elsewhere as ACCOMMODATE (A Collaborative COMMunity-based ethnography Of people with Dementia using Assistive technology and Telecare at home in England)] aimed to address this empirical research gap from a subsample of ATTILA trial participants and to complement the ATTILA trial findings on the effects of participants' technology use in their everyday routines. In-depth participant cases presented here are pseudonymised to ensure anonymity and confidentiality.

### Aims and research questions

The study aimed to exemplify and examine how and why people with dementia and their caregivers used or chose not to use ATT in their lives and the ways in which ATT use affected their environments and relationships.

To address this research aim, the study team sought to answer three research questions:

1. How and why do people with dementia and their caregivers use ATT at home?
2. How does ATT fit into people's lives and care in their homes?
3. How does ATT affect people's lives and care in their homes?

### Methods

This study used a qualitative ethnographic observational, longitudinal design to investigate how and why people with dementia in the intervention arm of the ATTILA trial used or did not use the ATT offered to them. This section describes the study design, sampling strategy, data collection and analysis methods.

### Design

Ethnographic approaches have commonly relied on sustained fieldwork, whereby a researcher takes part in a group's practices while observing them, so as to rigorously interpret how people make sense of their everyday lives and social systems.<sup>135</sup> The ethnographic approach used in this study, however, drew on recent multidisciplinary research in trials to design a study 'embedded' in the ATTILA trial<sup>136,137</sup> to collect focused<sup>138,139</sup> observational data on situated practices of people with dementia and their caregivers when using ATT in their everyday lives. We used these data to construct in-depth extended cases<sup>140,141</sup> of how people with dementia and caregivers used (or chose not to use) these technologies, to help explain how and to what extent specific technologies for supporting people with dementia may be relevant in the context of their everyday places and interactions in home and community settings.

This study demonstrates how technology-enabled dementia care systems work with and for people, how they attempted to fit ATT into their lives and homes and how ATT-related processes affected their activities and care relationships.

To provide 'trustworthy'<sup>142,143</sup> findings and interpretations, we formulated credible, transferable, dependable, and confirmable processes for data collection and analysis through:

- Extensive and intensive data collection from participants (see *Participant observation and Analysis*) and critically discussing anonymised data (credibility) findings within the study teams (credibility, dependability).
- Noting in contextualised detail participants' situated practices and how noting these may affect interpretation of findings to other contexts (transferability).
- Reflecting on researcher role in the process and how this could affect interpretations. Detailed fieldnotes and accounts of the research context to allow future research to confirm, challenge or otherwise build on findings from this study (confirmability).

Ethics approval for the study was granted by the National Research Ethics Services Committee East of England, Norfolk (reference number 15/EE/0015) on 3 February 2015.

### Sample

A purposive sampling strategy was used to select potential participants from the wider ATTILA trial population who were able to provide data relevant to examining care practices and specific reasons for, and ways of, their uptake (or not) of diverse technological interventions.

This strategy, therefore, had to incorporate the ATTILA trial inclusion and exclusion criteria (see *Chapter 2*), but also ethnographic-specific purposive sampling criteria that would provide contextually relevant and diverse types of participants' experiences from three characteristics:

1. severity of the person's dementia, as recorded by ATTILA trial research workers
2. type of family relationship between the caregiver and person with dementia
3. types of ATT equipment provided to the person with dementia.

### Settings

To recruit participants, we collaborated with local ATTILA trial research workers, who collected data across three distinct authorities in east and south-east England: 'Shire', 'Metropolitan' and 'Coast'. They included a mix of urban and rural populations in areas of economic wealth and areas of economic deprivation.<sup>144</sup> These are pseudonymised to ensure anonymity and confidentiality:

- 'Shire' – participants from this area lived in large villages or small market towns with independent vendors and occasional high-street shops.
- 'Metropolitan' – a major city divided into different districts. Trial participants lived in two adjoining districts with historical reputations of poverty. More recent gentrification is transforming these areas.
- 'Coast' – two counties with a seaside border, sharing service responsibilities for adult services. Participants from this area lived predominantly in large market towns or in villages near major regional city hubs.

These brief setting descriptions highlighted distinct features of the wider areas where people with dementia lived to contextualise wider relations with their environment.

## Recruitment

The ethnographic team recruited prospective participants alongside three ATTILA trial research workers responsible for recruiting and collecting data from ATTILA trial participants in Metropolitan, Shire or Coast. This process to embed ethnographic recruitment in the ATTILA trial involved four steps:

1. The fieldworker (ML) collaborated with an ATTILA trial research worker to identify prospective ACCOMMODATE participants from the existing ATTILA trial sample. The fieldworker selected people based on how they aligned with the purposive sampling criteria for ACCOMMODATE. He selected participants to ensure a maximum variation across all three purposive sampling criteria.
2. The fieldworker attended the pre-arranged ATTILA trial follow-up visit with the area's local research worker to meet with prospective participants to discuss participation in the ethnographic substudy.
3. The fieldworker sought substudy informed consent from people with dementia and their caregiver to take part in the ethnography substudy, or a consultee declaration from the caregiver for the person with dementia to participate.
4. The fieldworker continually renegotiated informed consent or consultee declaration for each subsequent monthly visit during independent fieldwork.

## Participant observation

The study included nine ethnographic cases, each consisting of at least one person with dementia ( $n = 10$ ) and their caregiver ( $n = 10$ ). Two cases included more than one caregiver (the Campbells included two caregivers) or more than one person with dementia (the Stewarts included two people with dementia). Data collection involved up to six visits over 6 months (one per month) to the home of each person with dementia. These monthly visits lasted between 1 and 5 hours (mean 3.5 hours). A total of 208 hours of observation took place over 60 visits. Each visit involved Matthew Lariviere observing the practices of people with dementia and their caregivers, focusing particularly on whether or not and how they were using ATT and unstructured ethnographic interviews with participants to elicit their reasons for using or not using ATT.

## Analysis

Initial notes from observations were written in a journal during or immediately after the visit and maps were drawn to illustrate objects and people's places in settings. The initial notes were later transcribed and developed into field notes with any accompanying audio-recordings from conversations. Additional researcher memos identified where participants were interacting with or discussing the technologies.

We analysed each case using situational analysis of longitudinally extended cases.<sup>8,11</sup> The main themes identified from early memos highlighted how people with dementia and caregivers attempted to fit ATT into their everyday practices, leading to placing, replacing and displacing care and uses of spaces inside and outside the home. Focused coding was used to identify instances of these themes during different visits for each ethnographic case, which informed comparisons within and across cases and contextualised specific instances of these analytical themes. The findings are presented in the following section as extended cases that highlight everyday features seen as common to several cases. These are depicted further through indicative maps.

## Findings

Each of these ethnographic cases provides in-depth representations of how participants enacted their practices with ATT in their homes. *Table 29* provides descriptions of the nine ethnographic cases to highlight the diversity of the nine cases based on their case name, location, the severity of the person's dementia, the nature of participant's family or care relationship, and the types of assistive technologies and/or telecare devices in place. Ethnographic cases were evenly distributed across different levels of dementia severity (i.e. three mild, three moderate and three severe cases). Participants in the ethnographic substudy most commonly received a falls detector ( $n = 6$ ) and door sensors ( $n = 4$ ).

TABLE 29 Description of ethnographic cases

Case names and location	Dementia severity	Nature of relationship with caregiver(s)	ATT devices
Clydes – Coast	Moderate	Father (person with dementia) lived in his own house. Son and daughter-in-law (caregivers) lived in separate house, but they worked from an office in the front room of the father's house	Automatic falls detector (wristband model), keysafe
Drapers – Coast	Mild	Mother (person with dementia) lived in her own home. Son (caregiver) lived in his own separate home, but visited her for up to 6 hours every day	Calendar-clock, bed sensors, automatic falls detector, falls alarm (wrist version; replaced pendant after first visit), keysafe
Stewarts – Coast	Moderate (both parents)	Mother and father (people with dementia) lived in an annex of the daughter's house (caregiver)	Door sensors
Betty and Rose – Shire	Severe	Betty (caregiver) is Rose's (person with dementia) neighbour. They each lived in their own house	Automatic falls detector (pendant), keysafe
Anthony and Mrs Archer – Metropolitan	Severe	Mrs Archer (person with dementia) lived in a sheltered housing flat. Anthony (caregiver; friend of family) lived his own flat in the same neighbourhood as Mrs Archer. He visited her a few days each week	GPS tracking device, calendar-clock, automatic falls sensor (pendant), cooker-timer
Campbells – Metropolitan	Severe	Son (caregiver) lived in mother's (person with dementia) home	Bed sensor, door sensor/alarm, pendant alarm
Browns – Shire	Mild/MCI	Wife (caregiver) shared house with husband (person with dementia); daughter (caregiver) and son-in-law lived in annex	Door sensors, object finder
Anansis – Metropolitan	Moderate	Father (person with dementia) lived alone in a flat; daughter (caregiver) visited him regularly from her home across the city	Automatic falls detector (pendant), GPS 'watch' and pendant (Buddi; Buddi, Rickmansworth, UK)
Smiths – Shire	Mild	Father lived alone in his own house. Daughter (caregiver) lived with her family in village in another county and tended to arrange her visits to coincide with other activities, such as doctor visits. Her visits appeared more ad hoc than those in the other cases in which caregivers all lived closer to the people under their care	Wrist alarm, automatic falls detector (waist), calendar-clock (self-purchased), door sensors, networked smoke alarm, activity monitoring sensors and software (Just Checking Ltd, Lapworth, UK)

GPS, Global Positioning System; MCI, mild cognitive impairment.



Keysafes ( $n = 3$ ) and calendar-clocks ( $n = 3$ ) were also relatively common. In most cases, an adult child was caring for an older parent with dementia ( $n = 6$ ). Caregivers rarely co-resided with the person with dementia under their care ( $n = 3$ ).

This diverse range of characteristics across all cases supported robust interpretation of how this diversity shaped differences and similarities across the nine ethnographic cases. Three key themes were identified as relevant to understanding the ATT-relevant and care-relevant everyday practices, routines and relationships of study participants:

1. Placing technology in care.
2. Replacing care with technology.
3. Technology displacing care and everyday life. Displacing everyday life refers to how people's everyday routines and built environments become disrupted and altered.

### Placing technology in care

The theme 'placing technology in care' refers to instances when people with dementia and/or caregivers fit ATT products into their existing care arrangements. It addresses participants' processes and practices in incorporating and adapting technologies into their everyday lives with varying degrees of success.

The Drapers showed initial troubles in how they placed a falls detector within their pre-existing everyday practices. The person with dementia, Violet Draper, received a neck-worn falls detector pendant, after experiencing several falls. Around the when time research visits began, she had another fall, but the alarm did not trigger. She decided not to trigger the alarm manually as she 'did not want to be a bother' to her son and caregiver, Thomas, or to the emergency response services. Thomas also commented that his mother frequently forgot to wear the pendant or took it off in the evening with her bed having been moved down to the sitting room (*Figure 11* shows a map). After this fall, Thomas changed two elements of his mother's care. First, he asked the local ATT provider to swap the pendant-style detector for one worn around the wrist. Second, he reminded Violet every day to 'press the button' if she ever fell again. A couple of months later, Violet had another much more serious fall in which she broke her leg; this time, the falls detector did not detect the fall automatically, but Violet did remember to press the falls detector button to contact first responders and Thomas.




FIGURE 11 Map of sitting room in Violet Draper's home.

This case highlights that both Thomas and Violet acted to make the falls detector fit into their lives. Their case illustrates the work of caregivers to instruct and to reinforce any such instruction to ensure 'successful' implementation of ATT that would otherwise be invisible to care workers and designers of the technology. Such work was even more important here because the falls detector did not activate automatically. This raises further questions about the different types of technologies designed to enhance the safety of people with dementia. The key distinction here is between 'passive' devices that automatically trigger, not requiring the user to perform any actions, and devices that require an action to be performed to activate them. It seems important to consider what use of passive devices is appropriate in the case of people with dementia, especially where they are either reluctant to trigger alarms or have memory difficulties that lead them to fail to remember to trigger a device. This case demonstrated how social connections and support were important even for enacting 'technology-enabled' care systems.

In contrast, the Stewarts' case illustrates how people with dementia or caregivers may appropriately place assistive technology, yet find that other objects in the home may suitably address problems when they arise. Mary and Michael are a married couple, both of whom have dementia. Their daughter, Sally, moved them into an annex of her home to support them full time. During one fieldwork visit, Sally asked her parents for the date. Neither Michael nor Mary knew the date. They also did not appear to notice the nearby calendar-clock that had been provided to display this information but did perceive wooden calendar blocks across the room, which helped orientate them. Michael told Sally the correct date.

This case highlights the importance of appropriately placing ATT in a person's home. Here, a wooden calendar may be seen to serve as more 'assistive' than the 'formally provided' calendar-clock. Although the calendar-clock did not disrupt or disorientate Michael or Mary, the technology did not actively facilitate them to be orientated to date and time. Someone still had to interact with the regular calendar to make it work by changing the date each day, but its familiar location and design may have more easily supported their orientation because it relied in part on older memory and was perhaps more readily recognisable than more recent digital counterparts.

The Browns' case raises further questions about how researcher and practitioners come to define 'use' of ATT. Sam Brown, a person with mild cognitive impairment, had a memo minder in his house entrance. A recording of his daughter's voice reminded him to lock the front door whenever anyone walked in front of the infrared motion sensor. Sam told the researcher that he always remembered to lock the door because of it. Sam also shared his home with his wife and with his adult daughter and son-in-law, who lived in a converted garage annex. The other household residents became annoyed with the memo minder repeatedly going off whenever they went to put on or remove their shoes and outerwear. Sam decided to turn off the recording but leave the memo minder in its place next to the front door. He insisted, and the researcher observed and confirmed, multiple times, that seeing the now-silent memo minder, still beside the door, reminded him to close and lock it when he left the house to go back home.

Such practices blur 'use' of ATT and its 'non-use'. Although the person with dementia switched off this device, its co-location with him in its 'appropriate' place provided the prompt he needed to remember to lock up. This case, alongside others, illustrates both the importance of 'place' in sustaining appropriate technology-enabled care for people with cognitive impairments, and how people are able to actively accommodate technology to work in their shared spaces and their relationships with others, including their caregivers.

### ***Technology replacing care***

This theme, 'technology replacing care', particularly addresses how caregivers, through ATT, replaced or reconfigured their practices of caring for people with dementia.

The Clydes' case involved Arthur Clyde, an older person with dementia, who received a falls detector from his local authority. His son and daughter-in-law, Mark and Cathy, visited his home every weekday to work from the front room of his house, which they had converted into an office for Mark's business. Mark also used to visit his father at least 1 day over the weekend to see whether or not he remembered to heat up and eat his pre-prepared meals. However, after Arthur started to wear the falls detector around his wrist, Mark visited his father less frequently. Mark told the researcher that he had 'peace of mind' that the call centre would notify him if his father had a fall. Mark decided instead to telephone Arthur on Saturdays and Sundays to ask him whether or not he had eaten his meals instead of visiting to confirm this.

This case illustrates how caregivers may change their care practices for a person with dementia after they introduce ATT into their arrangements. Here, the caregiver visited his father less frequently and relied on the falls detector and telephone to monitor his father with dementia. Falls detectors and telephones reconfigure monitoring practices to be mediated through technologies rather than face-to-face interactions. Caregivers' sense of security, often articulated as their 'peace of mind', was a common response across cases, including the case that follows.

In the Smiths' case, Lauren had the local service provider install an activity monitoring system in the living room of her father's bungalow. Lauren thought her father, Christopher Smith, frequently got up from his favourite chair to walk around the house based on activity reported on the monitoring system's accompanying application for her tablet. Lauren told the researcher that she had 'peace of mind' that her father remained active even when home alone, especially as she lived in another county, distant from her father. However, the researcher rarely saw Christopher move from his chair during his visits (*Figure 12* shows a map). During one visit, Lauren and the researcher noticed the dog jumping on the couch. The activity monitoring system's motion sensors happened to be at the same height as the dog. The researcher asked Lauren whether or not she possibly monitored the dog instead of her father. She looked at the application and noticed recent activity when no one else appeared to have moved in the room except for the dog. She wondered aloud how frequently her father really left his chair.




FIGURE 12 Map of Christopher Smith's bungalow.

The Smiths' case highlights how people use the devices for reassurance and peace of mind. In this case, the poorly placed product led to inaccurate information and misguided reassurance. Once this was established, the caregiver's 'peace of mind' became replaced by concern as she could no longer be certain whether the activity monitoring system monitored only her father's movement or also that of other people or animals.

In contrast to the other two cases exemplifying this theme, the case of the Campbells demonstrates how people can independently adopt 'other technologies', and how this will also shape their care practices. Kenneth Campbell shared his home with Lillian, his mother living with dementia. They were offered door and bed sensors, but Lillian tore out the cable of the bed sensor from under the mattress. They did not have a telephone line for the door sensor to connect with. Instead, Kenneth independently purchased and used a closed-circuit television (CCTV) system to monitor the downstairs rooms of the house, where his mother lived, through monitors in his living room upstairs.

The Campbells' case displays marked changes in how caregivers may provide care with the addition of technologies. Notably, here, the ATT did not appear to fit into the lives of Kenneth or Lillian. Rather than reconfigure their practices or home, Kenneth adapted security equipment, namely CCTV, as a means to monitor his mother in their home. This case raises further questions about how we characterise means to monitor people with dementia in their home as appropriate yet still ensure dignity and safeguard them against harm. It also calls into question, as noted in *Chapter 6*, whether or not carers' work here may have changed rather than diminished.

### ***Technology displacing care and everyday life***

The final theme, 'technology displacing care and everyday life', refers to cases in which people with dementia experienced their care arrangements and everyday practices as being displaced from their usual routines by ATT.

In the Rose and Betty case, Rose previously visited the local chapel in her village every Sunday for her church service. She received a lift from another neighbour to attend this service. Rose became increasingly frail, which affected her ability to move safely around in, and leave, the house. To support her living safely, she received a falls detector. However, the neighbouring family decided to stop attending the same service. Rose did not have the physical capacity to walk to the chapel herself, so she had to stop going to the local service.

Here the technology she received, a falls detector, could not facilitate her social participation in activities centrally important to her. The ATT here was not necessarily designed to facilitate these connections, but it shows how, as people with dementia encounter increased challenges in their participation in everyday activities, technology cannot facilitate and support every connection and activity in a person's life. Other interventions from friends and family may support such inclusion for a person with dementia, but they may not sustain support for social participation indefinitely. Other participants with dementia became increasingly isolated as their dementia progressed and they experienced more acute care needs that were met in only limited ways by home monitoring.

In some cases, technology played a greater role in displacing people's activities and care. In the Anansi case, for example, technology seemed to constrain how William Anansi could engage as he wanted with his wider community. William received a Global Positioning System (GPS) tracking system from his local council. Claire, his daughter and primary caregiver, told the researcher that she hoped this device would allow both her father to leave the house when he wished but also for her to locate him if he became lost. During one research visit, William left his flat without telling Claire. She called the call centre for the GPS tracking device, which located him in a nearby market that he frequented for his favourite Caribbean cuisine. Claire called her father on his mobile phone to tell him to return home. She also told the call centre operator to contact him through the speaker on the GPS tracking device.

William initially did not answer any calls. After 10 minutes of her calling him, he answered his mobile phone and told Claire that he had had lunch. Claire again told him to return home. The call centre operator confirmed that William appeared to be on a bus on his way back to his flat.

This case illustrates how caregivers can use technologies to affect how people with dementia interact with spaces outside their home and engage with their wider community. Here, Claire tracks her father's location through the GPS system worn on his person, with the assistance of a call centre operator to confirm his movement and changes to his location. Such practices with ATT illustrate how people can attempt to control the movements and behaviour of people with dementia, even when this may contest how they want to live their lives. Again, as noted in *Chapter 6*, new challenges and concerns for caregivers may be raised, rather than removed, by ATT.

## Discussion

These findings illustrate how technological mediation through ATT with associated applications and screens could replace, displace and disrupt co-located, face-to-face interactions. The reported findings suggest that how policy-makers and industry imagine community care through ATT service provision may not always reflect actual practices in technology-enabled dementia care. As previous research has also suggested, people with dementia and caregivers may make ATT work for them in contingently, rather than systematically.<sup>145-147</sup> This study, however, highlights not only the role taken by caregivers to fit these technologies into care practices, but also how their use of ATT can change the spaces and placement of care and everyday life. It shows how people's practices with ATT may shift dependencies in care arrangements as a result of actual or perceived changes or disruptions in care.<sup>147,148</sup> These findings identify limitations for ATT to enable people with dementia to 'live independently in the community' if they do not also have added support from caregivers to help adapt technologies to fit into their lives.

### *Strengths and limitations*

Study findings highlighted granular details of how people with dementia and their caregivers do and could use assistive technologies. We adopted systematic measures to ensure that the findings were trustworthy. However, these findings only exemplify practices of participants taking part in a trial and agreeing to receive this intervention. It may have limited transferability to how people with dementia and caregivers may use other current or emergent technologies. Caregivers also have diverse living arrangements and familial ties and relationships, and it was not possible to sample all of these. Nonetheless, it provides critical insights into the complexity of technology-enabled dementia care to consider in current and future design and provision of such technologies. Transparent reporting of this study's methods of data collection and analysis allows other researchers to challenge, confirm or add to understandings and implications of the findings.

## Conclusions and implications

These ethnographic findings flag up unintended and unanticipated consequences for ATT implementation and uptake in 'real-world' community-based dementia care contexts. The ethnographic approach details how people's use of ATT shifted over time. Nonetheless, even temporary use of ATT may have deferred more complex and more acute care crises for the person with dementia or caregiver. Transient effects or limited engagement with technology should not necessarily be interpreted, therefore, as a failure in its uptake or effect. It underlines the need to identify and map the context of ATT provision over time within the changing lives of people with dementia and their caregivers, and relative to service provider organisations, as revealed in these cases.

These findings have relevance for technology developers and providers in indicating how to consider more appropriate products and services that can support more sustainable technology-enabled care for people with dementia and their partners in care. Designers and service provider organisations should also work with caregivers and people with dementia, including charities representing these groups, such as Carers UK and the Alzheimer's Society, to co-produce suitable technological interventions.

This study suggests that we must more fully appreciate the importance of people's activities and relationships in continuously shaping care, including dementia care involving the implementation and uptake of technology in community settings to improve their effectiveness and sustainability.

# Chapter 8 Discussion

## Main outcomes

To the best of our knowledge, this study is the first RCT of ATT for people living with dementia in the community. Despite the large increase in available products and their promotion as effective, cost-saving ways of helping people with dementia remain at home, there has been a paucity of robust research on how beneficial these products and services can be.<sup>37</sup> The main outcomes of this trial were whether or not ATT could help keep people living at home longer and whether or not this was more cost-effective than a basic ATT package and alternative support. The answer to both questions was no: there were no significant differences found between the ATT and groups on any outcomes.

Home-based dementia care is a policy prioritised across the world,<sup>149,150</sup> including in the UK.<sup>151</sup> Remaining at home to maintain a higher quality of life is preferred by people with dementia, is more cost-effective than residential care and can provide continuity and familiarity that is beneficial to those experiencing a decline in cognitive and functional abilities.<sup>152</sup> ATT has been marketed as an aid to keeping people with dementia safely at home by providing monitoring of movement, safety and well-being; reminders for events and medication; and social support, among other things.

There have been many studies conducted around ATT, but all have been very small and/or have had poor methodology. The results of these have often been conflicting, with some viewing ATT very positively,<sup>153</sup> others finding no benefits<sup>154</sup> and some even regarding it negatively, for example although surveillance can be enabling, it can also be an invasion of privacy.<sup>8</sup> A 2017 Cochrane Review<sup>37</sup> found that there were no studies sufficiently robust to make a judgement and cited our study as being the only ongoing research that met their criteria. The lack of evidence to date makes the contribution of this study to the evidence base vital.

Dementia is an increasing challenge for health-care systems across the world, with 43.8 million cases in 2016;<sup>11</sup> this is predicted to rise to 75 million by 2030.<sup>155</sup> With no treatment for dementia, or many of its causes, currently available, and medication to slow development showing only marginal clinical improvement,<sup>156</sup> it is increasingly important to help people with dementia and their families to live well in the community for as long as is safe for them to do so. Caregivers provide 42% of the estimated US\$604B spent globally on dementia,<sup>37</sup> so supporting their role is also vital.

There are a number of possible reasons for the lack of efficacy shown in the current study. Previous research has suggested that ATT are often introduced when the cognitive decline is too great and the ability to adapt is too impaired for the user to incorporate it into their routines, and, at all stages of dementia, devices are seen as most useful when they are simple.<sup>157</sup> Aids that do not need adjusting have been considered most useful by caregivers, whereas complex interfaces and connection problems reduce the perceived utility of ATT.<sup>158</sup> However, other studies have found that a lot of ATT devices lack user-centred design approaches,<sup>159</sup> and user experience can be improved by optimising specific details of a product.<sup>160</sup>

## Conclusions from Chapter 6

Evidence from the ethnographic study (see *Chapter 7*) may also provide some insight into the lack of effects on caregiver outcomes. The ethnographic study indicates that, although technology was deployed, how it was used by caregivers and the cared-for person in the context of their own home and lifestyle may be important in determining the effectiveness and beneficial impact of the technology on their well-being. Data from the ethnographic study reported issues with reliability, situations in which the cared-for person did not use it as instructed or as intended, and that it may not have



reduced the amount of time spent caregiving, even if the caregiving was carried out remotely rather than as visits to the home.

### ***How ethnographic findings complement ATTILA trial findings***

As detailed in *Chapter 4*, the primary outcomes from the ATTILA trial demonstrated no significant effect of ATT on reducing mortality or on care home use by the person with dementia. Ethnographic findings illustrate how ATT provision could, nonetheless, provide participants, especially caregivers, with a sense of security or 'peace of mind', which they specifically valued, yet could also pose other challenges to caregivers.

These findings demonstrate the need to understand specifically how the ATT devices are incorporated into people's space and behaviours. Appreciating the specific context is important for fully understanding how ATT came to work as an intervention. Here, the technology's 'effectiveness' was influenced by participants' social relations (e.g. instructing how to use the device) and environment (e.g. in-home object placement, other occupants). This emphasises the need for complementary studies on the effectiveness of ATT as an intervention, while also appreciating the ways in which people with dementia and caregivers make sense and work to include these devices within their care practices and other arrangements. Technology takes up space on a person or in their home; this requires people to make choices about whether or not and how it fits on people's bodies and in domestic spaces. As the findings illustrated, these choices come packaged with value judgements about what care practices and interventions people find suitable in their everyday routines for people living with dementia in the community. People with dementia, caregivers and care workers may often contest the suitability of ATT, and extent to which they allow ATT to intervene in their lives.

The diverse range of experiences of living with dementia and caring for a person with dementia, and the wide variety of different ATT devices available through local authorities and on the consumer market, make it difficult to understand what may make ATT an appropriate and effective intervention for community-based dementia care. Individual caregivers and people with dementia may find that a specific ATT product helps them to manage their specific care responsibilities or ADL. Yet, these may be time bound, as care needs can rapidly fluctuate as a person experiences further limitations owing to their dementia progression, and there are fresh challenges for caregivers to negotiate, emphasising the need to incorporate a review process in providing ATT in dementia care.

### **Limitations**

There was great variation across sites in the assessment and provision of ATT, and the study was not powered or intended to examine the impact of local configurations of ATT. The trial was designed to embrace the heterogeneous nature of local ATT assessment and equipment provision for people with dementia. As discussed in *Chapter 3*, the way in which ATT was delivered locally varied considerably: two types of value networks were found to be operating in our relatively small sample of local authority areas. A mixture of models of providing and financing ATT was encountered across trial sites. The extent to which councils and providers charged user fees varied depending on the nature of local markets and on the needs profiles of ATT users. The extent of information on locally available ATT services and charges is limited in the UK; most ATT services, including ASCDs, charge fees.<sup>161</sup> We did not investigate the impact of deficiencies in service information or the presence of user charges, although such barriers might have affected the uptake of ATT and reduced the use of potentially beneficial devices.

Delivery systems were investigated and described as planned (see *Chapter 3* and *Appendix 2*), but it proved difficult to collect data from sites in a consistent manner sufficient to calculate a unit cost of ATT. The unit costs of ATT devices, installation, monitoring and response were drawn from databases of prices set by public sector procurement frameworks. This approach allowed a realistic costing of



ATT services and equipment provided by the public sector (e.g. in comparison to pricing devices via telecare providers' and online technology retailers' websites); prices paid for ATT devices and services by private individuals might be higher, and so ATT costs, which made up a very modest proportion of participants' total costs, might have been somewhat higher. Because control participants were also in receipt of at least a basic ATT package over the course of the study, their costs could equally be higher and differences in costs between groups little affected overall. We explored the feasibility of collecting providers' data on ATT devices used by participants; however, as the study was not resourced to negotiate data-sharing arrangements with all the providers involved, we relied on researcher-collected technology checklist data.

The CSRI was reliant on participant recall, which may have affected the precision and size of cost estimates. Costs were measured by asking caregivers to retrospectively report service use, so the results could be subject to recall bias. Costs of the intervals between periods with CSRI data available were estimated by carrying forward most costs, although costs of inpatient and emergency department use were estimated from the SAE data available over these times. Costs of regularly used services were thus assumed to be constant over these intervening periods. Participant-reported EQ-5D data were missing for one-quarter of intervention participants and for one-third of control participants who had participated in assessments at 104 weeks. Although difference-in-difference analyses controlled for baseline covariates (stratification variables and dependency, as measured by the BADLS) that might have accounted for differences in data availability between groups on this measure, QALY analyses drew on group mean utilities at each time point and did not adjust for baseline characteristics. Therefore, the finding that the intervention group had fewer QALYs derived from participant-reported EQ-5D data must be interpreted with some caution, as substantial numbers of missing data in that measure could be a concern. Generalisability of these findings may also be limited because all assessment data were missing from some participating dyads at the baseline and follow-up points (8% of the sample at baseline and between 16% and 19% of the community-dwelling sample still participating in the study over the follow-ups did not participate in an interview).

## Future research

An official national collection of data on local authority ATT provision, the size of contracts with provider partners and total expenditure and unit costs would shed light on the variety of delivery and financing models in place, and the relationship with expenditure. A study on the nature and size of the private ATT market (including internet of things and smart home applications) would shed light on the relative importance of public and private sectors in ATT provision.<sup>161</sup>

An observational study of telecare for dementia could be designed, which could employ a larger sample than would be achievable with an experimental design, and observe longer and continuous durations of service use. Such research could also identify processes and mechanisms of implementation (procurement, clinical and care decision-making, maintenance of technologies, call centre activities, etc.) of ATT in health and care systems to support people with dementia. If routine data from health and social care providers could be linked<sup>162</sup> to telecare providers' data, further research could examine associations between ATT (activations and device types) and hospital and care home admissions.

## Implications

This study found that a full package of ATT did not result in a significant increase in the length of time a person with dementia can remain living in the community, nor did it achieve decreases in caregiver burden, depression or anxiety. The findings of *Chapter 3* suggest that providers of assessments and providers of ATT do not always work in tandem. Work to understand why local delivery systems were producing such mismatches should be conducted with local authorities, not-for-profit providers and the

## DISCUSSION

NHS in England. Meanwhile, the use of ATT that extend beyond basic devices (including pendant alarms) as support for people with dementia should not be unconditionally adopted and should be subject to the same rigorous evaluation as other interventions. However, ATT recommended on the basis of need and installed and used as intended might be very useful for people with dementia and their caregivers. Designers and service provider organisations should work with caregivers and people with dementia and their advocates to co-produce suitable technological interventions. Alternatives to technological solutions to difficulties should also be actively sought.

# Acknowledgements

## The ATTILA trial trialists group

### *Writing Committee*

Rebecca Gathercole, Catherine Henderson, Rosie Bradley, Anna Davies, Shashivadan Hirani, Stefano Brini, Stanton Newman, Kirsty Forsyth, Matthew Lariviere, Chris Fox, Fiona Poland, Martin Knapp, Iracema Leroi, John Woolham, Richard Gray and Robert Howard.

### *Data Monitoring Committee*

Professor Ian McKeith, Institute for Ageing and Health, Newcastle University (chairperson); Professor James Lindesay, Department of Health Sciences, Leicester University Hospitals NHS Trust; and Dr Tracey Young, School of Health and Related Research, University of Sheffield.

### *Trial Steering Committee*

Dr Peter Bentham, The Barberry Centre, Birmingham and Solihull Mental Health NHS Foundation Trust (chairperson); Dr Louise Brown, Medical Research Council Clinical Trials Unit at University College London; and Mrs Gillian Harrison and Mrs Sue Tucker, Service User Representatives, Alzheimer's Society.

### *Trial Management Group*

Rebecca Gathercole, Emma Harper, Linda Kelly, Natalie Lam, Lynn Pank, Rosie Bradley and Richard Gray and Robert Howard.

### *Health Economics*

Catherine Henderson and Martin Knapp (London School of Economics and Political Science).

### *Participating centres*

South London and Maudsley NHS Foundation Trust: Robert Howard (principal investigator), Rebecca Gathercole, Heather Westwood, Bethany Scutt and Grace Lavelle.

Cambridge Community Services NHS Trust, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust: John O'Brien (principal investigator), Andrew Bateman (principal investigator), Rachel Winson, Samantha Nunn and Victoria Ordonez Montano.

Oxford and Buckinghamshire Mental Health NHS Foundation Trust: Rupert McShane (principal investigator), Sarah-Jane Cellan-Jones, Marni Moran and Rowena Johns.

Norfolk and Suffolk NHS Foundation Trust: Chris Fox (principal investigator) and Emma Talbot.

Lancashire Care NHS Foundation Trust: Iracema Leroi (principal investigator) and Emma Hooper.

Nottinghamshire Healthcare NHS Foundation Trust: Dr Anand Ramakrishnan (principal investigator) and David Trevor.

South West Yorkshire Partnership NHS Foundation Trust: Seelam Kalyan (principal investigator), Lubena Mirza and Amber Hemmingway.

## Contributions of authors

**Rebecca Gathercole** (<https://orcid.org/0000-0002-6380-2655>) (Trial Manager, Old Age Psychiatry) ran the trial, contributed to the paper, interpreted the data and wrote the initial draft paper.

**Rosie Bradley** (<https://orcid.org/0000-0002-0758-4905>) (Medical Statistician, Medical Statistics) analysed the survival data, contributed to the paper, interpreted the data and wrote the initial draft paper.

**Emma Harper** (<https://orcid.org/0000-0001-5651-6258>) (Clinical Trials Co-ordinator, Population Health) ran the trial.

**Lucy Davies** (<https://orcid.org/0000-0001-6632-7215>) (Medical Statistician, Medical Statistics) analysed the survival data.

**Lynn Pank** (<https://orcid.org/0000-0001-6398-6565>) (Administrative Assistant, Medical Statistics) and **Natalie Lam** (<https://orcid.org/0000-0001-8591-444X>) (Data Manager, Medical Statistics) provided data management support and data entry at the Clinical Trials Unit.

**Anna Davies** (<https://orcid.org/0000-0003-0743-6547>) (Senior Research Associate, Health Psychology) analysed the caregiver outcome data, contributed to the paper, interpreted the data and wrote the initial draft paper.

**Emma Talbot** (<https://orcid.org/0000-0002-7614-9683>) (Research Practitioner, Mental Health Research), **Emma Hooper** (<https://orcid.org/0000-0002-4059-6035>) (Research Practitioner, Mental Health Research), **Rachel Winson** (Research Practitioner, Mental Health Research), **Bethany Scutt** (<https://orcid.org/0000-0003-0456-2556>) (Research Worker, Old Age Psychiatry), **Victoria Ordenez Montano** (<https://orcid.org/0000-0002-3500-1922>) (Research Practitioner, Mental Health Research), **Samantha Nunn** (<https://orcid.org/0000-0002-2853-9652>) (Research Practitioner, Mental Health Research) and **Grace Lavelle** (<https://orcid.org/0000-0003-3768-1797>) (Research Worker, Old Age Psychiatry) recruited and retained participants.

**Matthew Lariviere** (<https://orcid.org/0000-0001-6901-3115>) (Research Fellow, Anthropologist of Care, Ageing and Technology) designed and analysed the ethnographic study.

**Shashivadan Hirani** (<https://orcid.org/0000-0002-1577-8806>) (Senior Lecturer, Health Services Research) and **Stefano Brini** (<https://orcid.org/0000-0002-1909-1796>) (Research Fellow, Health Services Research and Management) analysed the caregiver outcome data and contributed to the paper.

**Andrew Bateman** (<https://orcid.org/0000-0002-2547-5921>) (Clinical Manager, Neuropsychological Rehabilitation), **Peter Bentham** (<https://orcid.org/0000-0002-6443-3353>) (Consultant, Psychiatry), **Alistair Burns** (<https://orcid.org/0000-0002-9837-0645>) (Professor, Old Age Psychiatry) and **Barbara Dunk** (<https://orcid.org/0000-0002-6363-5009>) (Senior Occupational Therapist, Older Adult Memory Services) were principal investigators.

**Kirsty Forsyth** (<https://orcid.org/0000-0002-6732-1699>) (Professor, Occupational Therapy) analysed the needs assessment data and contributed to the paper.

**Chris Fox** (<https://orcid.org/0000-0001-9480-5704>) (Clinical Professor, Psychiatry) designed and analysed the ethnographic study, contributed to the paper and was a principal investigator.

**Catherine Henderson** (<https://orcid.org/0000-0003-4340-4702>) (Assistant Professorial Research Fellow, Health Policy) analysed the health economic data, contributed to the paper, interpreted the data and wrote the initial draft paper.

**Martin Knapp** (<https://orcid.org/0000-0003-1427-0215>) (Professor of Social Policy, Health Policy) analysed the health economic data and contributed to the paper.

**Iracema Leroi** (<https://orcid.org/0000-0003-1822-3643>) (Professor, Psychiatry in Ageing and Dementia) contributed to the paper and was a principal investigator.

**Stanton Newman** (<https://orcid.org/0000-0001-6712-6079>) (Professor, Health Psychology) analysed the caregiver outcome data and contributed to the paper.

**John O'Brien** (<https://orcid.org/0000-0002-0837-5080>) (Professor, Old Age Psychiatry) was a principal investigator.

**Fiona Poland** (<https://orcid.org/0000-0003-0003-6911>) (Professor, Social Research Methodology) designed and analysed the ethnographic study and contributed to the paper.

**John Woolham** (<https://orcid.org/0000-0003-3128-7756>) (Senior Research Fellow, Social Care Research) designed the trial and contributed to the paper.

**Richard Gray** (<https://orcid.org/0000-0003-4440-574X>) (Professor, Medical Statistics) designed and ran the trial, analysed the survival data, contributed to the paper, interpreted the data and wrote the initial draft paper.

**Robert Howard** (<https://orcid.org/0000-0002-3071-2338>) (Professor, Old Age Psychiatry) designed and ran the trial, contributed to the paper, was a principal investigator, interpreted the data and wrote the initial draft paper.

All authors assume responsibility for the accuracy and completeness of the data and for the overall content and integrity of the paper.

## Publications

Leroi I, Woolham J, Gathercole R, Howard R, Dunk B, Fox C, *et al.* Does telecare prolong community living in dementia? A study protocol for a pragmatic, randomised controlled trial. *Trials* 2013;14:349.

Forsyth K, Henderson C, Davis L, Roy AS, Dunk B, Curnow E, *et al.* Assessment of need and practice for assistive technology and telecare for people with dementia – The ATTILA (Assistive Technology and Telecare to maintain Independent Living At home for people with dementia) trial. *Alzheimers Dement* 2019;5:420–30.

Howard R, Gathercole R, Bradley R, Harper E, Davis L, Pank L, *et al.* The effectiveness and cost-effectiveness of assistive technology and telecare for independent living in dementia: a randomised controlled trial. *Age Ageing* 2021:afaa284.

## Data-sharing statement

All data requests should be submitted to the corresponding author for consideration. Access to available anonymised data may be granted following review.

## Patient data

This work uses data provided by patients and collected by the NHS as part of their care and support. Using patient data is vital to improve health and care for everyone. There is huge potential to make better use of information from people's patient records, to understand more about disease, develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone's privacy, and it's important that there are safeguards to make sure that it is stored and used responsibly. Everyone should be able to find out about how patient data are used. #datasaveslives You can find out more about the background to this citation here: <https://understandingpatientdata.org.uk/data-citation>.

## References

1. Leroi I, Woolham J, Gathercole R, Howard R, Dunk B, Fox C, *et al.* Does telecare prolong community living in dementia? A study protocol for a pragmatic, randomised controlled trial. *Trials* 2013;**14**:349.
2. Howard R, Gathercole R, Bradley R, Harper E, Davis L, Pank L, *et al.* The effectiveness and cost-effectiveness of assistive technology and telecare for independent living in dementia: a randomised controlled trial. *Age Ageing* 2021:afaa284.
3. Knapp M, Prince M, Albanese E, Banerjee S, Dhanasiri S, Fernandez JL, *et al.* *Dementia UK: The Full Report. A Report into the Prevalence and Economic Cost of Dementia in the UK Produced by King's College London and the London School of Economics.* London: Alzheimer's Society; 2007.
4. Lewis F, Karlsberg Schaffer S, Sussex J, O'Neill P, Cockcroft L. *The Trajectory of Dementia in the UK - Making a Difference.* London: Office of Health Economics; 2014.
5. Wanless D, Forder J. *Securing Good Care for Older People. Taking a Long-term View.* London: The King's Fund; 2006.
6. Department of Health and Social Care. *The Government's Expenditure Plans. Departmental Report 2003.* URL: <https://webarchive.nationalarchives.gov.uk/20030731053810/http://www.doh.gov.uk:80/dohreport/report2003/download.html> (accessed 26 February 2020).
7. Bebbington A, Darton R, Netten A. *Care Homes for Older People: Volume 2. Admissions, Needs and Outcomes. The 1995/96 National Longitudinal Survey of Publicly-Funded Admissions.* Canterbury: Personal Social Services Research Unit, University of Kent; 2001.
8. Department of Health and Social Care. *Living Well with Dementia: A National Dementia Strategy.* London: Department of Health and Social Care; 2009.
9. Woolham J, Frisby B, Quinn S, Moore A, Smart W. *The Safe at Home Project.* London: Hawker Publications; 2002.
10. Woolham J, Frisby B. Using Technology in Dementia Care. In Benson S, editor. *Dementia Topics for the Millennium and Beyond.* London: Hawker Publications; 2002. pp. 91–4.
11. Gitlin LN, Winter L, Dennis MP. Assistive devices caregivers use and find helpful to manage problem behaviors of dementia. *Gerontechnology* 2010;**9**:408–14. <https://doi.org/10.4017/gt.2010.09.03.006.00>
12. Woolham J. *Safe at Home: The Effectiveness of Assistive Technology in Supporting the Independence of People with Dementia: The Safe at Home Project.* London: Hawker; 2006.
13. Department of Health and Social Care. *Building Telecare in England.* London: Department of Health and Social Care; 2005.
14. Audit Commission. *Assistive Technology: Independence and Well-being 4.* London: Audit Commission; 2004.
15. Miskelly FG. Assistive technology in elderly care. *Age Ageing* 2001;**30**:455–8. <https://doi.org/10.1093/ageing/30.6.455>
16. Lansley P, McCreddie C, Tinker A. Can adapting the homes of older people and providing assistive technology pay its way? *Age and Ageing* 2004;**33**:571–6. <https://doi.org/10.1093/ageing/afh190>
17. Mitchell R. *An Evaluation of Falkirk's Mobile Community Alarms Service.* Falkirk: Falkirk Council; 1996.



18. Cash M. *At Home with AT (Assistive Technology). An Evaluation of the Practical and Ethical Implications of Assistive Technology and Devices to Support People with Dementia and their Carers*. Bristol: Dementia Voice; 2004.
19. Doughty K, Williams G. Practical solutions for the integration of community alarms, assistive technologies and telecare. *Qual Ageing Older Adults* 2001;**2**:31–47. <https://doi.org/10.1108/14717794200100006>
20. Bharucha AJ, Anand V, Forlizzi J, Dew MA, Reynolds CF, Stevens S, Wactlar H. Intelligent assistive technology applications to dementia care: current capabilities, limitations, and future challenges. *Am J Geriatr Psychiatry* 2009;**17**:88–104. <https://doi.org/10.1097/JGP.0b013e318187dde5>
21. Barlow J. *Building an Evidence Base for Successful Telecare Implementation. Updated Report of the Evidence Working Group of the Telecare Policy Collaborative Chaired by James Barlow*. London: Care Services Improvement Partnership; 2006.
22. Marshall M. *ASTRID: A Social and Technological Response to Meeting the Needs of Individuals with Dementia and their Carers; A Guide to Using Technology Within Dementia Care*. London: Hawker; 2000.
23. Frisby B, Woolham J. Building a local infrastructure that supports the use of assistive technology in the care of people with dementia. *Res Policy Plan* 2002;**20**:11–24.
24. Fisk MJ. *Social Alarms to Telecare: Older People's Services in Transition*. Bristol: The Policy Press; 2003. <https://doi.org/10.2307/j.ctt1t8951n>
25. Woolham J, Gibson G, Clarke P. Assistive technology, telecare, and dementia: some implications of current policies and guidance. *Res Policy Plan* 2006;**24**:149–64.
26. Department of Health and Social Care. *Transforming Adult Social Care*. London: Department of Health and Social Care; 2009.
27. Poole T. *Wanless Social Care Review: Telecare and Older People*. London: The King's Fund; 2006.
28. Girodano R, Clark M, Goodwin N. *Perspectives on Telehealth and Telecare: Learning from the 12 Whole System Demonstrator Action Network (WSDAN) Sites. WSDAN Briefing Paper*. London: The King's Fund; 2010.
29. Bower P, Cartwright M, Hirani SP, Barlow J, Hendy J, Knapp M, et al. A comprehensive evaluation of the impact of telemonitoring in patients with long-term conditions and social care needs: protocol for the whole systems demonstrator cluster randomised trial. *BMC Health Serv Res* 2011;**11**:184. <https://doi.org/10.1186/1472-6963-11-184>
30. Cartwright M, Hirani SP, Rixon L, Beynon M, Doll H, Bower P, et al. Effect of telehealth on quality of life and psychological outcomes over 12 months (Whole Systems Demonstrator telehealth questionnaire study): nested study of patient reported outcomes in a pragmatic, cluster randomised controlled trial. *BMJ* 2013;**346**:f653. <https://doi.org/10.1136/bmj.f653>
31. Henderson C, Knapp M, Fernández JL, Beecham J, Hirani SP, Cartwright M, et al. Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation in a pragmatic, cluster randomised controlled trial. *BMJ* 2013;**346**:f1035. <https://doi.org/10.1136/bmj.f1035>
32. Steventon A, Bardsley M, Billings J, Dixon J, Doll H, Hirani S, et al. Effect of telehealth on use of secondary care and mortality: findings from the Whole System Demonstrator cluster randomised trial. *BMJ* 2012;**344**:e3874. <https://doi.org/10.1136/bmj.e3874>



33. Hirani SP, Beynon M, Cartwright M, Rixon L, Doll H, Henderson C, *et al.* The effect of telecare on the quality of life and psychological well-being of elderly recipients of social care over a 12-month period: the Whole Systems Demonstrator cluster randomised trial. *Age Ageing* 2014;**43**:334–41. <https://doi.org/10.1093/ageing/aft185>
34. Steventon A, Bardsley M, Billings J, Dixon J, Doll H, Beynon M, *et al.* Effect of telecare on use of health and social care services: findings from the Whole Systems Demonstrator cluster randomised trial. *Age Ageing* 2013;**42**:501–8. <https://doi.org/10.1093/ageing/aft008>
35. Henderson C, Knapp M, Fernández JL, Beecham J, Hirani SP, Beynon M, *et al.* Cost-effectiveness of telecare for people with social care needs: the Whole Systems Demonstrator cluster randomised trial. *Age Ageing* 2014;**43**:794–800. <https://doi.org/10.1093/ageing/afu067>
36. Brownsell S. Measuring the ‘success’ of telehealth interventions. *J Assistive Technol* 2009;**3**:12–20. <https://doi.org/10.1108/17549450200900030>
37. Van der Roest HG, Wenborn J, Pastink C, Dröes RM, Orrell M. Assistive technology for memory support in dementia. *Cochrane Database Syst Rev* 2017;**6**:CD009627. <https://doi.org/10.1002/14651858.CD009627.pub2>
38. Knapp M, Barlow J, Comas-Herrera A, Damant J, Freddolino P, Hamblin K, *et al.* *The Case for Investment in Technology to Manage the Global Costs of Dementia*. London: Policy Innovation Research Unit; 2015.
39. Department for Constitutional Affairs. *Mental Capacity Act 2005: Code of Practice*. London: The Stationery Office; 2007.
40. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, *et al.* Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;**20**:1727–36. <https://doi.org/10.1007/s11136-011-9903-x>
41. Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, *et al.* Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. *Qual Life Res* 2013;**22**:1717–27. <https://doi.org/10.1007/s11136-012-0322-4>
42. NHS Improvement. *Reference Cost Collection: National Schedule of Reference Costs, 2016–17 – NHS Trusts and NHS Foundation Trusts*. London: NHS Improvement; 2017.
43. Curtis L, Burns A. *Unit Costs of Health and Social Care 2017*. Canterbury: Personal Social Services Research Unit, University of Kent; 2017.
44. Beecham J, Knapp M. Costing Psychiatric Interventions. In Thornicroft G, Brewin C, Wing J, editors. *Measuring Mental Health Needs*. 2nd edn. London: Gaskell/Royal College of Psychiatrists; 2001. pp. 200–24.
45. Leggett AN, Zarit S, Taylor A, Galvin JE. Stress and burden among caregivers of patients with Lewy body dementia. *Gerontologist* 2011;**51**:76–85. <https://doi.org/10.1093/geront/gnq055>
46. Hirani SP, Rixon L, Beynon M, Cartwright M, Cleanthous S, Selva A, *et al.* Quantifying beliefs regarding telehealth: development of the Whole Systems Demonstrator Service User Technology Acceptability Questionnaire. *J Telemed Telecare* 2017;**23**:460–9. <https://doi.org/10.1177/1357633X16649531>
47. Fish J. Bristol Activities of Daily Living Scale. In Kreutzer JS, DeLuca J, Caplan B, editors. *Encyclopedia of Clinical Neuropsychology*. New York, NY: Springer; 2011. pp. 452–53. [https://doi.org/10.1007/978-0-387-79948-3\\_1929](https://doi.org/10.1007/978-0-387-79948-3_1929)
48. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, *et al.* Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. *Lancet* 2004;**363**:2105–15. [https://doi.org/10.1016/S0140-6736\(04\)16499-4](https://doi.org/10.1016/S0140-6736(04)16499-4)

## REFERENCES

49. World Medical Assembly. Declaration of Helsinki (1964). *Br Med J* 1996;**313**:1448–9. <https://doi.org/10.1136/bmj.313.7070.1448a>
50. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use – Good Clinical Practice. *Code of Federal Regulations & Guidelines Vol. 1. International Committee on Harmonization*. Philadelphia, PA: Barnett International/PAREXEL; 1997.
51. Forsyth K, Henderson C, Davis L, Singh Roy A, Dunk B, Curnow E, *et al*. Assessment of need and practice for assistive technology and telecare for people with dementia – The ATTILA (Assistive Technology and Telecare to maintain Independent Living At home for people with dementia) trial. *Alzheimers Dement* 2019;**5**:420–30. <https://doi.org/10.1016/j.trci.2019.07.010>
52. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M, Medical Research Council Guidance. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008;**337**:a1655. <https://doi.org/10.1136/bmj.a1655>
53. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, *et al*. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ* 2014;**348**:g1687. <https://doi.org/10.1136/bmj.g1687>
54. Ritchie J, Lewis J. *Qualitative Research Practice : A Guide for Social Science Students and Researchers*. London: SAGE Publications Ltd; 2003.
55. Ehrenhard M, Kijl B, Nieuwenhuis L. Market adoption barriers of multi-stakeholder technology: smart homes for the aging population. *Technol Forecast Soc Change* 2014;**89**:306–15. <https://doi.org/10.1016/j.techfore.2014.08.002>
56. Kijl B, Nieuwenhuis LJ, Huis in 't Veld RM, Hermens HJ, Vollenbroek-Hutten MM. Deployment of e-health services – a business model engineering strategy. *J Telemed Telecare* 2010;**16**:344–53. <https://doi.org/10.1258/jtt.2010.006009>
57. Parkinson SFK, Kielhofner G. *User's Manual for the Model of Human Occupation Screening Tool (MOHOST)*. Chicago, IL: University of Illinois; 2002.
58. Siegel S. *Nonparametric Statistics for the Behavioral Sciences*. New York, NY: McGraw-Hill; 1956.
59. Pernecky R, Wagenpfeil S, Komossa K, Grimmer T, Diehl J, Kurz A. Mapping scores onto stages: mini-mental state examination and clinical dementia rating. *Am J Geriatr Psychiatry* 2006;**14**:139–44. <https://doi.org/10.1097/01.JGP.0000192478.82189.a8>
60. Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. *Anesth Analg* 2018;**126**:1763–8. <https://doi.org/10.1213/ANE.0000000000002864>
61. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, *et al*. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. *Value Health* 2012;**15**:708–15. <https://doi.org/10.1016/j.jval.2012.02.008>
62. Dolan P. Modeling valuations for EuroQol health states. *Med Care* 1997;**35**:1095–108. <https://doi.org/10.1097/00005650-199711000-00002>
63. National Institute for Health and Care Excellence. *Position Statement on Use of the EQ-5D-5L Valuation Set for England (Updated November 2018)*. URL: [www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l](http://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l) (accessed July 2019).
64. HM Treasury. *The Green Book: Appraisal and Evaluation in Central Government*. London: HM Treasury; 2015.

65. Wimo A, Reed CC, Dodel R, Belger M, Jones RW, Happich M, *et al*. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries – study design and baseline findings. *J Alzheimers Dis* 2013;**36**:385–99. <https://doi.org/10.3233/JAD-122392>
66. Office for National Statistics. *Annual Survey of Hours and Earnings: 2017 Provisional Results*. Newport: Office for National Statistics; 2017.
67. Koopmanschap MA, van Exel JN, van den Berg B, Brouwer WB. An overview of methods and applications to value informal care in economic evaluations of healthcare. *Pharmacoeconomics* 2008;**26**:269–80. <https://doi.org/10.2165/00019053-200826040-00001>
68. Northern Housing Consortium. *Consortium Procurement*. URL: <https://consortiumprocurement.org.uk> (accessed October 2018).
69. Billingham LJ, Abrams KR. Simultaneous analysis of quality of life and survival data. *Stat Methods Med Res* 2002;**11**:25–48. <https://doi.org/10.1191/0962280202sm269ra>
70. Gray A. *Applied Methods of Cost-effectiveness Analysis in Health Care*. Oxford: Oxford University Press; 2011.
71. Bang H, Tsiatis AA. Estimating medical costs with censored data. *Biometrika* 2000;**87**:329–43. <https://doi.org/10.1093/biomet/87.2.329>
72. Basu A, Manning WG. Estimating lifetime or episode-of-illness costs under censoring. *Health Econ* 2010;**19**:1010–28. <https://doi.org/10.1002/hec.1640>
73. Rabe-Hesketh S, Skrondal A. *Multilevel and Longitudinal Modeling Using Stata*. 3rd edn. College Station, TX: Stata Press; 2011.
74. Allison PD. *Handling Missing Data by Maximum Likelihood*. Paper 312-2012. SAS Global Forum. Haverford, PA: Statistical Horizons; 2012.
75. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. *Health Econ* 2002;**11**:415–30. <https://doi.org/10.1002/hec.678>
76. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. *Methods for the Economic Evaluation of Health Care Programmes*. 4th edn. Oxford: Oxford University Press; 2015.
77. National Institute for Health and Care Excellence. *Guide to the Methods of Technology Appraisal 2013*. London: NICE; 2013.
78. Oremus M, Aguilar SC. A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada. *Pharmacoeconomics* 2011;**29**:141–56. <https://doi.org/10.2165/11539450-000000000-00000>
79. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. *Qual Life Res* 2005;**14**:1523–32. <https://doi.org/10.1007/s11136-004-7713-0>
80. Glick H. *Economic Evaluation in Clinical Trials*. Oxford: Oxford University Press; 2007.
81. Hounsome N, Orrell M, Edwards RT. EQ-5D as a quality of life measure in people with dementia and their carers: evidence and key issues. *Value Health* 2011;**14**:390–9. <https://doi.org/10.1016/j.jval.2010.08.002>
82. Aguirre E, Kang S, Hoare Z, Tudor Edwards R, Orrell M. How does the EQ-5D perform when measuring quality of life in dementia against two other dementia-specific outcome measures? *Qual Life Res* 2016;**25**:45–9. <https://doi.org/10.1007/s11136-015-1065-9>

83. Alzheimer's Research UK. *Women and Dementia: A Marginalised Majority*. URL: [www.alzheimersresearchuk.org/about-us/our-influence/policy-work/reports/women-dementia/2015](http://www.alzheimersresearchuk.org/about-us/our-influence/policy-work/reports/women-dementia/2015) (accessed May 2019).
84. Trust C. *Key Facts About Carers and the People They Care For*. URL: <https://carers.org/key-facts-about-carers-and-people-they-care> (accessed June 2019).
85. Brodaty H, Donkin M. Family caregivers of people with dementia. *Dialogues Clin Neurosci* 2009;**11**:217.
86. NHS Digital. *Personal Social Services Survey of Adult Carers in England 2016–17*. URL: <https://digital.nhs.uk/data-and-information/publications/statistical/personal-social-services-survey-of-adult-carers/personal-social-services-survey-of-adult-carers-in-england-2016-17#resources> (accessed June 2019).
87. Allen AP, Curran EA, Duggan Á, Cryan JF, Chorcóráin AN, Dinan TG, *et al*. A systematic review of the psychobiological burden of informal caregiving for patients with dementia: Focus on cognitive and biological markers of chronic stress. *Neurosci Biobehav Rev* 2017;**73**:123–64. <https://doi.org/10.1016/j.neubiorev.2016.12.006>
88. Carers UK. *State of Caring 2018*. URL: [www.carersuk.org/for-professionals/policy/policy-library/state-of-caring-2018-2](http://www.carersuk.org/for-professionals/policy/policy-library/state-of-caring-2018-2) (accessed June 2019).
89. Mahoney R, Regan C, Katona C, Livingston G. Anxiety and depression in family caregivers of people with Alzheimer disease: the LASER-AD study. *Am J Geriatr Psychiatry* 2005;**13**:795–801. <https://doi.org/10.1097/00019442-200509000-00008>
90. Seeher K, Low LF, Reppermund S, Brodaty H. Predictors and outcomes for caregivers of people with mild cognitive impairment: a systematic literature review. *Alzheimers Dement* 2013;**9**:346–55. <https://doi.org/10.1016/j.jalz.2012.01.012>
91. Chen ML. The growing costs and burden of family caregiving of older adults: a review of paid sick leave and family leave policies. *Gerontologist* 2016;**56**:391–6. <https://doi.org/10.1093/geront/gnu093>
92. Moore MJ, Zhu CW, Clipp EC. Informal costs of dementia care: estimates from the National Longitudinal Caregiver Study. *J Gerontol B Psychol Sci Soc Sci* 2001;**56**:S219–28. <https://doi.org/10.1093/geronb/56.4.s219>
93. Dassel KB, Carr DC. Does dementia caregiving accelerate frailty? Findings from the health and retirement study. *Gerontologist* 2016;**56**:444–50. <https://doi.org/10.1093/geront/gnu078>
94. Vitaliano PP, Zhang J, Scanlan JM. Is caregiving hazardous to one's physical health? A meta-analysis. *Psychol Bull* 2003;**129**:946–72. <https://doi.org/10.1037/0033-2909.129.6.946>
95. Alzheimer's Association. 2017 Alzheimer's disease facts and figures. *Alzheimer Dement* 2017;**13**:325–73. <https://doi.org/10.1016/j.jalz.2017.02.001>
96. Prince M, Knapp M, Guerchet M, McCrone P, Prina M, Comas-Hererra A, *et al*. *Dementia UK: Update*. 2nd edn. London: Alzheimer's Society; 2014.
97. Wimo A, Winblad B, Jönsson L. The worldwide societal costs of dementia: estimates for 2009. *Alzheimers Dement* 2010;**6**:98–103. <https://doi.org/10.1016/j.jalz.2010.01.010>
98. Zarit SH, Todd PA, Zarit JM. Subjective burden of husbands and wives as caregivers: a longitudinal study. *Gerontologist* 1986;**26**:260–6. <https://doi.org/10.1093/geront/26.3.260>
99. Chiao CY, Wu HS, Hsiao CY. Caregiver burden for informal caregivers of patients with dementia: a systematic review. *Int Nurs Rev* 2015;**62**:340–50. <https://doi.org/10.1111/inr.12194>

100. Schofield H, Bloch S. *Family Caregivers: Disability, Illness and Ageing*. Sydney, NSW: Allen & Unwin; 1998.
101. Schofield H, Murphy B, Herrman HE, Bloch S, Singh BS. Carers of people aged over 50 with physical impairment, memory loss and dementia: a comparative study. *Ageing Soc* 1998;**18**:355–69. <https://doi.org/10.1017/S0144686X98006965>
102. Ashworth M, Baker AH. 'Time and space': carers' views about respite care. *Health Soc Care Community* 2000;**8**:50–6. <https://doi.org/10.1046/j.1365-2524.2000.00221.x>
103. Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. *Am J Psychiatry* 2012;**169**:946–53. <https://doi.org/10.1176/appi.ajp.2012.11101529>
104. Cooke DD, McNally L, Mulligan KT, Harrison MJ, Newman SP. Psychosocial interventions for caregivers of people with dementia: a systematic review. *Aging Ment Health* 2001;**5**:120–35. <https://doi.org/10.1080/713650019>
105. Gitlin LN, Marx K, Stanley IH, Hodgson N. Translating evidence-based dementia caregiving interventions into practice: state-of-the-science and next steps. *Gerontologist* 2015;**55**:210–26. <https://doi.org/10.1093/geront/gnu123>
106. Lindberg B, Nilsson C, Zotterman D, Söderberg S, Skär L. Using information and communication technology in home care for communication between patients, family members, and healthcare professionals: a systematic review. *Int J Telemed Appl* 2013;**2013**:461829. <https://doi.org/10.1155/2013/461829>
107. Schwabe R, Kenny C, Foster V, Wellenius B, Dokeniya A, Wheeler D, et al. *Information and Communication Technologies: A World Bank Group Strategy*. Washington, DC: World Bank Publications; 2002.
108. Lucero RJ, Fehlberg EA, Patel AGM, Bjarnardottir RI, Williams R, Lee K, et al. The effects of information and communication technologies on informal caregivers of persons living with dementia: a systematic review. *Alzheimers Dement* 2019;**5**:1–12. <https://doi.org/10.1016/j.trci.2018.11.003>
109. Davies A, Rixon L, Newman S. Systematic review of the effects of telecare provided for a person with social care needs on outcomes for their informal carers. *Health Soc Care Community* 2013;**21**:582–97. <https://doi.org/10.1111/hsc.12035>
110. Alwan M, Dalal S, Mack D, Kell SW, Turner B, Leachtenauer J, Felder R. Impact of monitoring technology in assisted living: outcome pilot. *IEEE Trans Inf Technol Biomed* 2006;**10**:192–8. <https://doi.org/10.1109/titb.2005.855552>
111. Mellors S. *Service User and Carer Views of Telecare in Derbyshire*. Matlock: Derbyshire County Council; 2009.
112. Holthe T. *Enabling Technologies for People with Dementia: National Report on Results from Norway*. 2004. URL: [www.enableproject.org/download/Enable%20-%20National%20Report%20-%20Norway.pdf](http://www.enableproject.org/download/Enable%20-%20National%20Report%20-%20Norway.pdf) (accessed 26 February 2020).
113. Woolham J. *The Safe at Home Project: Using Technology to Help People with Dementia Remain Living in their Own Homes in Northampton*. London: Hawker; 2005.
114. Molloy DW, Alemayehu E, Roberts R. Reliability of a Standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination. *Am J Psychiatry* 1991;**148**:102–5. <https://doi.org/10.1176/ajp.148.1.102>
115. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. *Gerontologist* 1980;**20**:649–55. <https://doi.org/10.1093/geront/20.6.649>



116. Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). *Br J Clin Psychol* 1992;**31**:301–6. <https://doi.org/10.1111/j.2044-8260.1992.tb00997.x>
117. Little RJA, Rubin DB. The analysis of social science data with missing values. *Soc Methods Res* 1989;**18**:292–326. <https://doi.org/10.1177/0049124189018002004>
118. Rubin DB. The calculation of posterior distributions by data augmentation: comment: a noniterative sampling/importance resampling alternative to the data augmentation algorithm for creating a few imputations when fractions of missing information are modest: the SIR algorithm. *J Am Stat Assoc* 1987;**82**:543–46. <https://doi.org/10.2307/2289460>
119. Schafer JL. Multiple imputation: a primer. *Stat Methods Med Res* 1999;**8**:3–15. <https://doi.org/10.1177/096228029900800102>
120. Neubauer S, Holle R, Menn P, Grossfeld-Schmitz M, Graesel E. Measurement of informal care time in a study of patients with dementia. *Int Psychogeriatr* 2008;**20**:1160–76. <https://doi.org/10.1017/S1041610208007564>
121. Joling KJ, van Marwijk HW, Veldhuijzen AE, van der Horst HE, Scheltens P, Smit F, van Hout HP. The two-year incidence of depression and anxiety disorders in spousal caregivers of persons with dementia: who is at the greatest risk? *Am J Geriatr Psychiatry* 2015;**23**:293–303. <https://doi.org/10.1016/j.jagp.2014.05.005>
122. Meshefedjian G, McCusker J, Bellavance F, Baumgarten M. Factors associated with symptoms of depression among informal caregivers of demented elders in the community. *Gerontologist* 1998;**38**:247–53. <https://doi.org/10.1093/geront/38.2.247>
123. Schoenmakers B, Buntinx F, Delepeleire J. Factors determining the impact of care-giving on caregivers of elderly patients with dementia. A systematic literature review. *Maturitas* 2010;**66**:191–200. <https://doi.org/10.1016/j.maturitas.2010.02.009>
124. Jütten LH, Mark RE, Sitskoorn MM. Empathy in informal dementia caregivers and its relationship with depression, anxiety, and burden. *Int J Clin Health Psychol* 2019;**19**:12–21. <https://doi.org/10.1016/j.ijchp.2018.07.004>
125. Blom MM, Zarit SH, Groot Zwaaftink RB, Cuijpers P, Pot AM. Effectiveness of an Internet intervention for family caregivers of people with dementia: results of a randomized controlled trial. *PLOS ONE* 2015;**10**:e0116622. <https://doi.org/10.1371/journal.pone.0116622>
126. Borsje P, Hems MA, Lucassen PL, Bor H, Koopmans RT, Pot AM. Psychological distress in informal caregivers of patients with dementia in primary care: course and determinants. *Fam Pract* 2016;**33**:374–81. <https://doi.org/10.1093/fampra/cmw009>
127. Sörensen S, Pinquart M, Duberstein P. How effective are interventions with caregivers? An updated meta-analysis. *Gerontologist* 2002;**42**:356–72. <https://doi.org/10.1093/geront/42.3.356>
128. Parker D, Mills S, Abbey J. Effectiveness of interventions that assist caregivers to support people with dementia living in the community: a systematic review. *Int J Evid Based Healthc* 2008;**6**:137–72. <https://doi.org/10.1111/j.1744-1609.2008.00090.x>
129. Thompson CA, Spilsbury K, Hall J, Birks Y, Barnes C, Adamson J. Systematic review of information and support interventions for caregivers of people with dementia. *BMC Geriatr* 2007;**7**:18. <https://doi.org/10.1186/1471-2318-7-18>
130. Vernooij-Dassen M, Draskovic I, McCleery J, Downs M. Cognitive reframing for carers of people with dementia. *Cochrane Database Syst Rev* 2011;**11**:CD005318. <https://doi.org/10.1002/14651858.CD005318.pub2>

131. Lins S, Hayder-Beichel D, Rücker G, Motschall E, Antes G, Meyer G, Langer G. Efficacy and experiences of telephone counselling for informal carers of people with dementia. *Cochrane Database Syst Rev* 2014;**9**:CD009126. <https://doi.org/10.1002/14651858.CD009126.pub2>
132. Olazarán J, Reisberg B, Clare L, Cruz I, Peña-Casanova J, Del Ser T, *et al.* Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy. *Dement Geriatr Cogn Disord* 2010;**30**:161–78. <https://doi.org/10.1159/000316119>
133. Kaizik C, Caga J, Camino J, O'Connor CM, McKinnon C, Oyebode JR, *et al.* Factors underpinning caregiver burden in frontotemporal dementia differ in spouses and their children. *J Alzheimers Dis* 2017;**56**:1109–17. <https://doi.org/10.3233/JAD-160852>
134. Alfakhri AS, Alshudukhi AW, Alqahtani AA, Alhumaid AM, Alhathlol OA, Almojali AI, *et al.* Depression among caregivers of patients with dementia. *Inquiry* 2018;**55**:46958017750432. <https://doi.org/10.1177/0046958017750432>
135. Hammersley M, Atkinson P. *Ethnography: Principles in Practice*. Abingdon: Routledge; 2007. <https://doi.org/10.4324/9780203944769>
136. Wenborn J, Hynes S, Moniz-Cook E, Mountain G, Poland F, King M, *et al.* Community occupational therapy for people with dementia and family carers (COTiD-UK) versus treatment as usual (Valuing Active Life in Dementia [VALID] programme): study protocol for a randomised controlled trial. *Trials* 2016;**17**:65. <https://doi.org/10.1186/s13063-015-1150-y>
137. Lewis SJ, Russell AJ. Being embedded: a way forward for ethnographic research. *Ethnography* 2011;**12**:398–416. <https://doi.org/10.1177/1466138110393786>
138. Pink S, Morgan J. Short-term ethnography: intense routes to knowing. *Symb Interact* 2013;**36**:351–61. <https://doi.org/10.1002/symb.66>
139. Knoblauch H. Focused ethnography. *Forum Qual Social Res* 2005;**6**(3). <https://doi.org/10.17169/fqs-6.3.20>
140. Burawoy M. The extended case method. *Soc Theory* 1998;**16**:4–33. <https://doi.org/10.1111/0735-2751.00040>
141. Van Velsen J. The Extended-case Method and Situation Analysis. In Epstein AL, editor. *The Craft of Social Anthropology*. Oxford: Pergamon Press; 1979. pp. 129–52. <https://doi.org/10.1016/B978-0-08-023693-3.50011-9>
142. Guba EG. Criteria for assessing the trustworthiness of naturalistic inquiries. *Educ Commun Technol J* 1981;**29**:75–91.
143. Guba EG, Lincoln YS. Competing Paradigms in Qualitative Research. In Denzin NK, Lincoln YS, editors. *Handbook of Qualitative Research*. Thousand Oaks, CA: SAGE Publications Inc.; 1994. pp. 105–17.
144. Office for National Statistics. *Towns and cities analysis, England and Wales, March 2016*. Newport: Office for National Statistics; 2016.
145. Gibson G, Dickinson C, Brittain K, Robinson L. Personalisation, customisation and bricolage: how people with dementia and their families make assistive technology work for them. *Ageing Soc* 2019;**39**:2502–19. <https://doi.org/10.1017/S0144686X18000661>
146. Greenhalgh T, Wherton J, Sugarhood P, Hinder S, Procter R, Stones R. What matters to older people with assisted living needs? A phenomenological analysis of the use and non-use of telehealth and telecare. *Soc Sci Med* 2013;**93**:86–94. <https://doi.org/10.1016/j.socscimed.2013.05.036>
147. Mort M, Roberts C, Pols J, Domenech M, Moser I, EFORTT investigators. Ethical implications of home telecare for older people: a framework derived from a multisited participative study. *Health Expect* 2015;**18**:438–49. <https://doi.org/10.1111/hex.12109>

148. Sanders C, Rogers A, Bowen R, Bower P, Hirani S, Cartwright M, *et al.* Exploring barriers to participation and adoption of telehealth and telecare within the Whole System Demonstrator trial: a qualitative study. *BMC Health Serv Res* 2012;**12**:220. <https://doi.org/10.1186/1472-6963-12-220>
149. Samus QM, Black BS, Bovenkamp D, Buckley M, Callahan C, Davis K, *et al.* Home is where the future is: the BrightFocus Foundation consensus panel on dementia care. *Alzheimers Dement* 2018;**14**:104–14. <https://doi.org/10.1016/j.jalz.2017.10.006>
150. von Kutzleben M, Schmid W, Halek M, Holle B, Bartholomeyczik S. Community-dwelling persons with dementia: what do they need? What do they demand? What do they do? A systematic review on the subjective experiences of persons with dementia. *Aging Ment Health* 2012;**16**:378–90. <https://doi.org/10.1080/13607863.2011.614594>
151. Department of Health and Social Care. *Prime Minister's Challenge on Dementia 2020: Implementation Plan*. London: Department of Health and Social Care; 2016.
152. Aminzadeh F, Dalziel WB, Molnar FJ, Garcia LJ. Symbolic meaning of relocation to a residential care facility for persons with dementia. *Aging Ment Health* 2009;**13**:487–96. <https://doi.org/10.1080/13607860802607314>
153. Tchalla AE, Lachal F, Cardinaud N, Saulnier I, Rialle V, Preux PM, Dantoine T. Preventing and managing indoor falls with home-based technologies in mild and moderate Alzheimer's disease patients: pilot study in a community dwelling. *Dementia and geriatric cognitive disorders* 2013;**36**:251–61. <https://doi.org/10.1159/000351863>
154. Brims L, Oliver K. Effectiveness of assistive technology in improving the safety of people with dementia: a systematic review and meta-analysis. *Aging and Mental Health* 2019;**23**:942–51. <https://doi.org/10.1080/13607863.2018.1455805>
155. Alzheimer's Disease International. *Dementia Statistics*. URL: [www.alz.co.uk/research/statistics](http://www.alz.co.uk/research/statistics) (accessed July 2019).
156. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, *et al.* Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. *Ann Intern Med* 2008;**148**:379–97. <https://doi.org/10.7326/0003-4819-148-5-200803040-00009>
157. Holthe T, Jentoft R, Arntzen C, Thorsen K. Benefits and burdens: family caregivers' experiences of assistive technology (AT) in everyday life with persons with young-onset dementia (YOD). *Disabil Rehabil Assist Technol* 2018;**13**:754–62. <https://doi.org/10.1080/17483107.2017.1373151>
158. Nauha L, Keränen NS, Kangas M, Jämsä T, Reponen J. Assistive technologies at home for people with a memory disorder. *Dementia* 2018;**17**:909–23. <https://doi.org/10.1177/1471301216674816>
159. Liddle J, Smith SJ. Intelligent assistive technology for people living with dementia is a rapidly growing and changing area requiring clinical consideration. *Aust Occup Ther J* 2017;**64**:510–11. <https://doi.org/10.1111/1440-1630.12434>
160. Megges H, Freiesleben SD, Rösch C, Knoll N, Wessel L, Peters O. User experience and clinical effectiveness with two wearable global positioning system devices in home dementia care. *Alzheimers Dement* 2018;**4**:636–44. <https://doi.org/10.1016/j.trci.2018.10.002>
161. Gibson G, Newton L, Pritchard G, Finch T, Brittain K, Robinson L. The provision of assistive technology products and services for people with dementia in the United Kingdom. *Dementia* 2016;**15**:681–701. <https://doi.org/10.1177/1471301214532643>



162. Momanyi K. *Enhancing Quality in Social Care Through Economic Analysis*. PhD thesis. Aberdeen: University of Aberdeen; 2018.
163. Allen C, Beecham J. Costing Services: Ideals and Reality. In Netten A, Beecham J, editors. *Costing Community Care: Theory and Practice*. Avebury: Ashgate; 1993.
164. Beecham J. *Unit Costs – Not Exactly Child's Play*. London: Department of Health and Social Care, Personal Social Services Research Unit and Dartington Social Care Research Unit; 2000.
165. Curtis L. *Unit Costs of Health and Social Care 2013*. Canterbury: Personal Social Services Research Unit, University of Kent; 2013.
166. Curtis L. *Unit Costs of Health and Social Care 2014*. Canterbury: Personal Social Services Research Unit, University of Kent; 2014.
167. Banks L, Barnes, M. *Evaluation of the East Sussex Carers' Breaks Demonstrator Site*. Brighton: University of Brighton, 2011.
168. Federation of (Ophthalmic and Dispensing) Opticians (FODO). *GOS Sight Test Fees*. 2018. URL: [www.fodo.com/resource-categories/nhs-sight-test-fees](http://www.fodo.com/resource-categories/nhs-sight-test-fees) (accessed August 2019).
169. Department of Health and Social Care. *General Ophthalmic Services: NHS Sight Test Fee, Increases to NHS Optical Voucher Values, Payments for Continuing Education and Training and Pre-registration Supervisors Grant*. London: Department of Health and Social Care; 2016.
170. Department of Health and Social Care. *General Ophthalmic Services – Increases to NHS Sight Test Fee, Continuing Education and Training Payment and Pre-registration Supervisors Grant*. London: Department of Health and Social Care; 2015.
171. Romeo R, Knapp M, Banerjee S, Morris J, Baldwin R, Tarrier N, *et al*. Treatment and prevention of depression after surgery for hip fracture in older people: cost-effectiveness analysis. *J Affect Disord* 2011;**128**:211–19. <https://doi.org/10.1016/j.jad.2010.07.026>
172. Office for National Statistics (ONS). *Consumer Prices Index including owner occupiers' housing costs (CPIH)*. 2019. URL: [www.ons.gov.uk/economy/inflationandpriceindices/timeseries/I522/mm23](http://www.ons.gov.uk/economy/inflationandpriceindices/timeseries/I522/mm23) (accessed 10 May 2019).
173. Iliffe S, Wilcock J, Drennan V, Goodman C, Griffin M, Knapp M, *et al*. Changing practice in dementia care in the community: developing and testing evidence-based interventions, from timely diagnosis to end of life (EVIDEM). *Programme Grants Appl Res* 2015;**3**(3). <https://doi.org/10.3310/pgfar03030>
174. NHS Digital. *Prescription Cost Analysis England 2017*. Leeds: NHS Digital; 2018.
175. Automobile Association. *Mileage Calculator*. URL: [www.theaa.com/driving/mileage-calculator.jsp](http://www.theaa.com/driving/mileage-calculator.jsp) (accessed 11 October 2018).



# Appendix 1 Costing the intervention

## The ATTILA trial: proposal for costing the assistive technology and telecare intervention

In this appendix, we set out the proposed plan of methods to calculate the costs of providing the ATT intervention, written while the trial was still in progress. The proposal begins with an overview of the trial as a whole and of the economic evaluation in particular, and lists the data collections that supported the economic evaluation. The costs that we proposed to collect are then summarised, and the methods for these data collections are outlined.

### Trial overview

The ATTILA trial is evaluating the impacts of ATT on people with dementia and their carers. ATT is defined for the purposes of the trial as ‘simple, battery-operated, standalone technologies and/or telecare (a range of devices and sensors that communicate and relay messages to an external call centre where an appropriate response is arranged)’ (see *Additional interviews and correspondence to support the economic evaluation: sample selection and recruitment of key informants*). The trial is designed as a pragmatic RCT. Participants randomised to the intervention will receive an ATT needs assessment, followed by the installation of ATT devices and response services deployed by the host local authority, in addition to usual health and social care services. Control group participants will receive an ATT needs assessment followed by a package of ATT that is limited to smoke/carbon monoxide detectors and pendant alarms, in addition to usual health and social care services. Thirteen sites in England (Lambeth, Southwark, Croydon, Lancashire, Oxford, Suffolk, Norfolk, Cambridgeshire, Nottingham, Blackpool, West Sussex, Barnsley and Blackburn) are currently involved in the trial. As the trial design is pragmatic, all aspects of the intervention (ATT assessment, choice of devices, or ordering and installation of devices) are determined by staff from the participating local authorities or telecare providers.

### Economic evaluation activities

The economic evaluation will investigate service use and costs associated with the introduction of the ATT intervention, and examine the relationship between service costs and other impacts. The co-primary trial outcomes are (1) time, in days, from randomisation to institutionalisation and (2) cost-effectiveness of the ATT intervention. The economic evaluation addresses the second outcome. The methods of the cost-effectiveness analysis described in the trial protocol (see *Additional interviews and correspondence to support the economic evaluation: sample selection and recruitment of key informants*) are summarised in Box 1.

### Trial data collections

Current data collections include:

- Participants and their identified carers will be visited by study research assistants to complete a battery of questionnaires covering self-reported quality of life, acceptability of the technology, ATT in situ (using a technology checklist) and service use and costs (using the CSRI<sup>44</sup>). These visits will take place at five time points: baseline and 12, 24, 52 and 104 weeks thereafter. Questionnaire packs will be sent to the Oxford Clinical Trials Service Unit for data entry or data will be entered directly into an electronic database.
- Data on ATT assessments are gathered by Kirsty Forsyth. Forms completed by assessors in order to recommend a package of ATT are rated against the MOHOST.

## BOX 1 Methods of cost-effectiveness analysis

Cost-effectiveness of the ATT intervention: costs related to the use of ATT, health-care and other service use patterns and (unpaid) caregiver inputs will be calculated for each participant using a modified version of the CSRI.

The cost-effectiveness analyses will be of two types, each conducted from two perspectives: (1) health and social care, and (2) societal, whereby the first type will measure costs only up to the point that a trial participant goes into a care home or hospital, and not beyond ('community costs'), and then examine cost-effectiveness in achieving the primary outcome (days from randomisation to institutionalisation in the 2-year period). This analysis will show the incremental cost of community-based support of each additional institutional day avoided. The second analysis type will measure costs for the whole 2-year period, including costs of care home and hospital stays ('total costs'), and then examine cost-effectiveness for which the outcome is change in EQ-5D score, over the 2-year period.

### ***Proposed methods for calculating the costs of the assistive technology and telecare intervention***

In this section, we set out options for collecting information sufficient to describe, measure and value the ATT intervention.

In the ATTILA trial, there is no funding provided alongside the trial for ATT equipment and there is no definitive list of ATT equipment to be provided across sites. ATT packages provided to ATTILA trial participants are likely to be highly heterogeneous across and between sites. It will be necessary to describe those packages to understand the relationship between participant outcomes and the intervention, but we face considerable challenges in collecting these data. Local authority budgets are under great pressure and the team is aware of the resultant constraints on frontline and senior management staff time.

We propose to calculate the ATT intervention costs as follows:<sup>163,164</sup>

- We will describe the interventions in terms of typical resource inputs and associated activities. This will entail creating descriptions of the organisations involved in producing the ATT intervention, including details of staffing and overheads.
- We will calculate a relevant service unit, in this case the weekly per-person cost of the intervention.
- We will collect cost data. Several elements make up the total cost of an ATT package –
  - Costs of ATT needs assessment.
    - Assessment costs will be calculated based on attaching a per-minute staff cost (including relevant overheads) of local authority and NHS staff to the estimated length of time spent in carrying out and writing up ATT assessments, including travel time, and allowing for travel costs. Data on average length of ATT assessments will be sought from key informants. Some providers may be able to make use of routinely collected data on time spent in ATT assessment, whereas others may provide their best estimate through less formal means.

- ATT service and equipment costs.
  - Costs of equipment.
    - Monitored equipment: ideally, sites will be able to provide lists of equipment used by each participant so that prices can be attached to establish their costs. The appropriate data-sharing agreements must be in place with the ATTILA trial team at KCL prior to requesting such lists. Price lists of standalone and networked equipment will be sought from the appropriate organisation or obtained from publicly available lists, where these exist.
    - Standalone equipment as (a).
  - Costs of ATT support.
    - Costs to the local authority. We would expect that a unit cost of a telecare package would comprise:
      - costs of installation, routine maintenance and upgrading of equipment
      - call centre infrastructure – operators’ staff costs (and on-costs), capital, premises and administrative overheads
    - Response-related costs.
      - Costs of any contracts with response service dedicated to telecare.
      - Other responders, for example emergency services – this information will be partly captured via CSRI (responses reported within the 3 month retrospective period). To avoid double-counting, these costs will be for the most part estimated by weighting units of service use as reported in the self-completed CSRI by unit costs from the PSSRU Unit Costs.<sup>165</sup>
    - Costs to carers.
      - Carers’ time spent responding to ATT-related sensor and other alerts can be captured via the CSRI question on time spent in caring tasks such as supervision (responses reported within the 3-month retrospective period).

The exact strategy for costing these elements is dependent on the extent of available financial and activity information from sites. Ideally, key informants in each site would be able to provide budgetary/ expenditure and activity data for use in calculating the unit cost of an ATT package. However it would also be acceptable to use a unit cost of a telecare package if the site has already made that calculation.

We will calculate a unit cost for the intervention.

The methods required to make this calculation again depend on the availability of financial or local authority -calculated unit cost data, of already established unit costs, and of equipment data. The total ATT package cost will be calculated by summing the costs of ATT assessment, telecare and standalone devices, and telecare support services.

The cost of the ATT assessment and of a telecare support package will be estimated at the site level; that is, all participants in that site would be considered to have incurred the same cost for these elements of the intervention. Networked and standalone devices should be available for each participant and the costs will be unique to that participant. In the case that providers cannot or decline to assemble a list of equipment provided, prices will be assigned to devices as recorded on the technology checklist administered to participants, and costs estimated on this basis.

### ***Proposed new data collections relevant to the economic evaluation***

As a first step in the proposed costing strategy, we devised a pro forma (see *Appendix 2*) to support a desk-based review of ATT assessment and provision processes in each site. The pro forma was devised by the economic evaluator and completed in co-operation with the researchers at Queen Margaret University, Edinburgh, the ATTILA trial project manager and the study's local researchers, who are embedded in each site. In this pro forma are listed any relevant documents already shared by the sites with the project team, brief descriptions of the processes for ATT assessment and provision already known to the local researchers in the execution of their role and suggestions for potential local key informants (e.g. operational managers, commissioners and managers of telecare providers). We now wish to proceed with collecting information from the following personnel in participating sites:

- Local authority operational managers – operational managers will probably have an overview of the mechanisms in place in their site for assessment and referral for ATT. These managers may also be able to advise on whether or not their local authority databases encompass telecare and standalone equipment records.
- Local authority commissioners of telecare – it is likely that the commissioners of telecare have information on the cost of telecare services within their local authority (including situations in which all telecare provision is contracted out), they may have calculated a unit cost of telecare for their local authority, and might be able to provide equipment price lists.
- Managers of telecare providers – it is likely that the providers of telecare have information on their own staff costs, premises, costs of installation/de-installation and maintenance if provided, also server costs and database maintenance. The managers would be able to advise on whether or not their databases contain records of the telecare equipment in place and might be able to provide equipment price lists.

### **Proposed activities**

- Seek NHS Research Ethics Committee permission for interviews with key informants.
- Local researchers to provide the economic evaluator with a set of current contact details for potential key informants, with their permission:
  - local authority operational/middle managers in adult services
  - local authority commissioners of telecare
  - telecare providers managers.
- Researchers from the project team to set up and carry out interviews with key informants in each site (after Research Ethics Committee approval). Contact to be made by e-mail or telephone and a list of the relevant questions sent to the potential participants, who can then decide whether or not to participate. Interviews to be carried out via site visits or over the telephone. Interviews will not be recorded but handwritten notes will be taken.
- Project team to request relevant budget/expenditure data from key informants (local authority and telecare providers' managers).
- Project team to update data-sharing agreements as required prior to requesting participants' equipment data from relevant local authority and telecare providers; project team to establish procedures for transferring these data to the project team.

## Additional interviews and correspondence to support the economic evaluation: sample selection and recruitment of key informants

### Recruitment targets for key informants

Cross-reference	Participants	Numbers	Nature of contact	Time taken	Information sought
Figure 18	Local authority commissioners of telecare	1 per site	Face-to-face interview OR Telephone interview; any follow-up enquiries by correspondence	45 minutes maximum	Costs of telecare services within their local authority
Figure 19	Local authority operational managers	1 or 2 per site	Face-to-face interview OR Telephone interview; any follow-up enquiries by correspondence	In person or by telephone: 20–30 minutes maximum	Mechanisms in place for assessment and referral for ATT; systems for recording telecare and standalone equipment provision
Table 38	Managers of telecare providers	1–5 per site <sup>a</sup>	Face-to-face interview OR Telephone interviews; any follow-up enquiries by correspondence	In person or by telephone: 45 minutes maximum	Information on staff costs, premises, costs of installation/de-installation and maintenance if provided; server costs and database maintenance; systems for recording telecare and standalone equipment provision and prices

a The exact number depends on whether or not the means of delivery varies considerably from district to district within each site.

*Pro formas*

## ATTILLA TRIAL: TELECARE ASSESSMENT AND SERVICE DESCRIPTIONS

DATE STARTED:

SITE:

RESEARCHERS PROVIDING DATA:

COLLATED BY: CATE HENDERSON (INITIALS: CH)

### PART 1: ATT NEEDS ASSESSMENT PROCESSES AND PROCEDURES

*Please give a brief description in answer to each question. If not applicable, enter N/A.*

#### ATT NEEDS ASSESSMENT PROCESS

1. Is the ATT assessment part of a general initial assessment or review assessment of needs?
2. Is the ATT assessment carried out separately from the general assessment?
3. Who carries out the assessment in which telecare and other ATT needs are identified? *(Title, organisation)*
4. Where is the assessment carried out?
5. How much time does it take to complete this assessment?
6. Who carries out an assessment of exactly which items of telecare and other ATT equipment should be provided (title, organisation)?
7. Where is that assessment carried out? *(In the home, demonstration centre)*
8. How much time does it take to complete an ATT assessment?

#### ATT NEEDS ASSESSMENT PROTOCOLS/DOCUMENTS

9. Are there written guidelines or processes for ATT needs assessments?

*If you can you obtain a copy, please attach; if there is a contact from whom it should be requested please give name and contact details.*

#### CONTACTS FOR FURTHER INFORMATION ON ASSESSMENT PROCESSES

10. If known, provide contact name(s) of social services operational/team manager who could give an overview of assessment process within Social Services

### PART 2: ATT DELIVERY PROCESSES AND PROCEDURES

*The next questions address the organisation and delivery of the intervention.*

11. What is the typical process when a potential user is identified?
12. Which organisation provides the ATT equipment to a new user?
13. Which organisation maintains the equipment (e.g. repairs equipment if faulty; replaces batteries; takes away unwanted equipment)
14. Which organisation installs the equipment?
15. Which organisation is responsible for providing training on ATT equipment to the user?



## Appendix 2 Rating of assistive technology and telecare need

ATT assessment standard				
ATTILA trial sites' key questions	ATTILA trial sites' questions	MOHOST		
		Items (partial)	Domains	Rating ATT need
Does the person's motivation put them at risk when doing daily activity?	Does the person's insight put them at higher/lower risk?	Appraisal of ability	Motivation for occupation	When doing daily activity, does this issue cause risk?
	Does what is important to the person put them at higher or lower risk?	Choices		If no ... choose either:
Do the person's routines and responsibilities put them at risk when doing daily activity?	Do the person's routines put them at higher/lower risk?	Routines	Pattern of occupation	<ul style="list-style-type: none"> <li>• 4, no risk, OR</li> <li>• 3, mostly risk free</li> </ul>
	Do the person's responsibilities put them at higher/lower risk?	Responsibilities		If yes ... choose either:
Does the person's communication skill place them at risk when doing daily activity?	Does the person's ability to have a conversation put them at higher/lower risk?	Conversation	Communication and interaction skills	<ul style="list-style-type: none"> <li>• 2, some risk OR</li> <li>• 1, significant, multiple risks</li> </ul>
	Does the person's ability to express their needs put them at higher/lower risk?	Vocal expression		
Does the person's cognitive skill place them at risk when doing daily activity?	Does memory and understanding of how to do things put the person at higher/lower risk?	Knowledge	Process skills	
	Does the ability to problem solve put the person at higher/lower risk?	Problem-solving		
Does the person's physical skill place them at risk when doing daily activity?	Does the person's mobility put them at higher/lower risk?	Posture and mobility	Motor skills	
	Does the person's grip/dexterity put them at higher/lower risk?	Strength and effort		
Do the features of the physical environment put the person at risk when doing daily activity?	Does the person's physical space put them at higher/lower risk?	Physical space	Physical environment	
	Does the person's physical resources put them at higher/lower risk?	Physical resources		
Does who is involved and how activities are completed put the person at risk when doing daily activity?	Does the support available put them at higher/lower risk?	Social groups	Social environment	
	Does the way the person completes activity put them at higher/lower risk?	Occupational demands		





ATTILA trial questions	Score	ATTILA trial scale
<ul style="list-style-type: none"> <li>Can they manage medication safely, i.e. not overdosing and reliability (not forgetting)?</li> </ul>	2	Difficulty being able to fulfil expectations and meet role obligations without support. <b>Some risk related to doing daily responsibilities</b> including difficulties managing medication, difficulty to safely do their cooking, make a hot drink/snack, difficulty to safely bathe/dress
	1	Limited ability to meet demands of activities or obligations, unable to complete role activities. <b>Significant multiple risks doing daily responsibilities</b> , for example cannot manage medication, cannot safely do their cooking, make a hot drink/snack, cannot safely bathe/dress

## Communication

ATTILA trial questions	Score	ATTILA trial scale
<i>Key question: Does the person's communication skill place them at risk when doing everyday things?</i>		
<p><b>Conversation</b></p> <p>Does the person's ability to have a conversation put them at higher or lower risk?</p> <ul style="list-style-type: none"> <li>Would the service user be able to communicate reliably via the lifeline and/or will they confabulate e.g. if their fire alarm goes off, saying there is not fire, when there is?</li> <li>Is the service user able to verbally communicate their needs effectively?</li> <li>Have the service user and carer been able to discuss different ATT options?</li> <li>Would the service user be able to communicate through the lifeline unit without becoming disorientated, considering communication and cognitive issues?</li> <li>Is the service user able to use a telephone appropriately? Is this a picture or standard phone?</li> </ul>	4	Appropriately initiates, discloses and sustains conversation (clear/direct/open). <b>Mostly risk free when doing daily activity</b> as a result of no confabulation, able to communicate their needs, ability to use a telephone or lifeline unit without becoming disorientated in conversation
	3	Generally able to use language or signing to effectively exchange information. <b>Mostly risk free when doing daily activity</b> owing to limited confabulation, mostly able to communicate their needs, mostly able to use a telephone or lifeline unit without becoming disorientated in conversation
	2	Difficulty initiating, disclosing or sustaining conversation (hesitant/abrupt/limited/irrelevant). <b>Some risk when doing daily activity</b> owing to some confabulation, only able to communicate some of their needs, some ability to use a telephone or lifeline unit without becoming disorientated in conversation
	1	Uncommunicative, disjointed, bizarre or inappropriate disclosure of information. <b>Significant multiple risks when doing daily activity</b> owing to confabulation, unable to communicate their needs, unable to use a telephone or lifeline unit without becoming disorientated in conversation
<p><b>Express needs</b></p> <p>Does the person's ability to express their needs put them at higher or lower risk?</p> <ul style="list-style-type: none"> <li>Does the service user have speech impairment? Specify how this would impact on ATT, and what adaptations and response procedures would be required to support the user?</li> <li>Has the ability to express themselves verbally limited?</li> </ul>	4	Assertive, articulate, uses appropriate tone, volume and pace. <b>Mostly risk free when doing daily activity</b> owing to no speech impairment, no word substitutions, no stammering, adequate vocabulary
	3	Vocal expression is generally appropriate in tone, volume and pace. <b>Mostly risk free when doing daily activity</b> owing to minimal speech impairment, minimal word substitutions, minimal stammering, mostly adequate vocabulary

ATTILA trial questions	Score	ATTILA trial scale
<ul style="list-style-type: none"> <li>Is there a family member/carer usually present in the property, who can communicate on behalf of the service user?</li> <li>What is the service user's preferred language? Do they speak another language? Specify if special arrangements, including a language line, are required</li> </ul>	2	Difficulty with expressing self (mumbling/pressured speech/monotone). <b>Some risk when doing daily activity</b> owing to speech impairment, as there are word substitutions for words that sound the same, stammering, function of items described rather than the names of items, limited vocabulary
	1	Unable to express self (unclear/too quiet or loud/too fast or too passive). <b>Significant multiple risks when doing daily activity</b> owing to speech impairment, an inability to express their needs, incomplete sentence structure, mute, speak in another language only

## Cognitive skills

ATTILA trial questions	Score	ATTILA trial scale
<i>Key question: Does the person's cognitive skill place them at risk when doing everyday things?</i>		
<b>Memory</b> Does memory and understanding of how to do things put the person at higher/lower risk?	4	Seeks and retains relevant information, know how to use tools appropriately. <b>No risk when doing daily activity</b> inclusive of not needing prompting, remembering to take medication, remembering to close doors/turn off taps, aware of how to use appliances, aware of how to respond to alarms
<ul style="list-style-type: none"> <li>Would the service user understand and be able to use a pendant alarm appropriately?</li> <li>Would the service user benefit from prompting to take medication?</li> <li>Does the service user have the ability to learn how to use a medication reminder device?</li> <li>Does the service user ever forget to close doors and windows?</li> <li>Does the service user leave external doors open at the wrong time of day or time of year?</li> <li>Is heating system switched on in cold weather by the service user?</li> <li>Is service user able to turn on/off taps appropriately and remember to turn them off?</li> <li>Does the person know how to safely turn on/off gas cooker and/or other appliances?</li> <li>Is there a history of unsafe use of gas or electrical appliances such as iron marks, covering the heater up, tampering with controls, cigarette burn marks or scalding?</li> <li>Would the person know how to respond if smoke, carbon monoxide or other alarms activated?</li> </ul>	3	Generally able to seek and retain information and know how to use tools. <b>Mostly risk free when doing daily activity</b> inclusive of occasionally needing prompting, occasionally forgetting to take medication, occasionally forgetting to close doors/turn off taps, mostly awareness of how to use appliances, mostly aware of how to respond to alarms
	2	Difficulty knowing how to use tools, difficulty in asking for or retaining information. <b>Some risk when doing daily activity</b> inclusive of needing some prompting, sometimes forgetting to take medication, sometimes forgetting to close doors/turn off taps, some awareness of how to use appliances, some awareness of how to respond to alarms
	1	Unable to use knowledge/tools, does not retain information, asks repeatedly for same information. <b>Significant multiple risks when doing daily activity</b> inclusive of needing prompting, forgetting to take medication, forgetting to close doors/turn off taps, no awareness of how to use appliances, no awareness of how to respond to alarms
<b>Problem-solving</b> Does the ability to problem solve put the person at higher/lower risk?	4	Shows good judgement, anticipates difficulties and generates workable solutions (rational). <b>No risk when doing daily activity</b> inclusive of never letting in strangers, always closes doors in winter, never burns food, no cigarette burn marks, gas use always safe, no tampering with controls, heating always switched on in cold weather
<ul style="list-style-type: none"> <li>Does the service user let in strangers?</li> <li>Does the service user leave water taps running, leading to flooding?</li> <li>Is there a history of service user leaving gas appliance on unlit?</li> <li>Is there evidence or history of burning food or pans during domestic activities?</li> <li>Would the service user know what to do if an alarm signal was generated, such as the activation of a smoke detector?</li> </ul>	3	Generally able to make decisions based on difficulties that arise. <b>Mostly risk free when doing daily activity</b> inclusive of rarely letting in strangers, mostly closes doors in winter, rarely burns food, one or two cigarette burn marks, gas use mostly safe, minimal tampering with controls, rarely heating not switched on in cold weather

ATTILA trial questions	Score	ATTILA trial scale
	2	Difficulty anticipating and adapting to difficulties that arise, seeks reassurance. <b>Some risk when doing daily activity</b> inclusive of sometimes letting in strangers, sometimes leaving doors open in winter, sometimes burns food, some cigarette burn marks, some flooding, sometimes gas left on despite smell, sometimes tampering with controls, heating sometimes not switched on in cold weather
	1	Unable to anticipate and adapt to difficulties that arise and makes inappropriate decisions. <b>Significant multiple risks when doing daily activity</b> inclusive of letting in strangers, leaving doors open in winter, history of burning food, cigarette burn marks, flooding, gas left on despite smell, tampering with controls, heating not switched on in cold weather

## Physical skills

ATTILA trial questions	Score	ATTILA trial scale
<i>Key question: Does the person's physical skill place them at risk when doing everyday things?</i>		
<b>Mobility</b>	4	Stable, upright, independent, flexible, good range of movement (possibly agile). <b>No risk when doing daily activity</b> as posture and stability adequate, walking indoors is safe, the person is safe using stairs, safe walking outdoors, walking is stable enough not to put person at risk of falls
Does the person's mobility put them at higher/lower risk?		
<ul style="list-style-type: none"> <li>Can the service user move around effectively during their daily routine?</li> <li>Does the service user use any mobility aids? Stick/frame/wheelchair/rails/ramps/stair lifts?</li> <li>Is the service user's mobility around the home good/poor/requires assistance?</li> <li>Is the service user's ability to negotiate stairs – good/poor/requires assistance?</li> <li>Is the service user's mobility outside the home – good/poor/requires assistance?</li> <li>Does the service user have a history of falls? Where and when did these happen? Are the causes known? What were the causes?</li> <li>Has the service user had any falls in the previous 6 months? Have the issues related to this specific fall been resolved?</li> <li>Does the service user have an unsteady gait/adequate sense of balance? Is the service user unsteady when reaching for objects e.g. reaching into cupboards or for mail at the door?</li> <li>Is the service user able to remember to use a mobility aid appropriately?</li> </ul>	3	Generally able to maintain posture and mobility in occupation, independently or with aids. <b>Mostly risk free when doing daily activity</b> as posture and stability/balance mostly adequate, walking indoors is mostly safe, mostly safe using stairs, mostly safe walking outdoors, mostly walking is stable enough not to put person at risk of falls
	2	Unsteady at times despite any aids, slow or manages with difficulty. <b>Some risk when doing daily activity</b> including some poor posture and instability/balance when walking indoors, some safety issues using stairs, some safety issues walking outdoors, walks with a shuffle or a stoop putting person at some risk of falls
	1	Extremely unstable, unable to reach and bend or unable to walk. <b>Significant multiple risks when doing daily activity</b> owing to poor posture and instability/poor balance when walking indoors, unsafe using stairs, unsafe walking outdoors, walks with a shuffle or a stoop putting person at risk of falls
<b>Grip/dexterity</b>	4	Grasps, moves and transports objects securely with adequate force/speed (possibly strong). <b>No risk when doing daily activity</b> as grip is adequate, hand strength is adequate, able to carry hot liquids, able to use grip when turning on/off domestic appliances, can operate ATT as required
Does the person's grip/dexterity put them at higher/lower risk?		
<ul style="list-style-type: none"> <li>Does the service user have adequate manual dexterity, grip, in hand manipulation of everyday objects?</li> <li>Does the person use two hands together to open packets or jars, spread butter on bread, turn gas cooker knobs?</li> <li>Can the person apply enough pressure to trigger alarm, if appropriate?</li> </ul>	3	Strength and effort are generally sufficient for most tasks. <b>Mostly risk free when doing daily activity</b> as grip is mostly adequate, hand strength mostly adequate, mostly able to carry hot liquids, mostly able to use grip when turning on/off domestic appliances, can mostly operate ATT as required



ATTILA trial questions	Score	ATTILA trial scale
<ul style="list-style-type: none"> <li>Does the person have enough grip to carry hot liquid without burning themselves?</li> <li>Does the person have enough grip/strength/dexterity to use the device (e.g., fasten/unfasten device, pull handle, push button, pull cord)?</li> </ul>	2	Has difficulty with grasping, moving, transporting objects with adequate force and speed. <b>Some risk when doing daily activity</b> due poorer grip, poorer hand strength, may drop hot liquids, some challenge effectively using domestic appliances owing to poorer grip, difficulty to operate ATT owing to poorer grip and some limitation in strength
	1	Unable to grasp, move, transport objects with appropriate force and speed (weak/frail). <b>Significant multiple risks when doing daily activity</b> owing to poor grip, poor hand strength, drops hot liquids/burn risk, cannot effectively use domestic appliances owing to poor grip, cannot operate ATT owing to poor grip and lack of strength

## Physical environment

ATTILA trial questions	Score	ATTILA trial scale
<i>Key question: Do the features of the physical environment put the person at risk when doing daily activity?</i>		
<p><b>Mobility</b></p> <p>Does the person's physical space put them at higher/lower risk?</p> <ul style="list-style-type: none"> <li>The general state of repair, including electrics, heating system, adequate lighting, working landline, level of safety of gas or electric appliances</li> <li>Is there access for emergency responses (note: bolts, chains, keys left in doors)?</li> <li>Are there trip hazards on the property (e.g. rugs, clutter, cables tidy, pets)?</li> <li>Are there risks to service user when entering any part of the property alone, e.g. stairs, kitchen or bathroom?</li> <li>Are there environmental hazards (e.g. blocked access, poisonous substances)?</li> <li>Is there anything in the vicinity that may interfere with the operation of the unit?</li> <li>Are there any special materials or conditions that need to be considered when mounting sensors (e.g. concrete/high ceilings, potential asbestos)?</li> </ul>	4	Space affords a range of opportunities, supports and stimulates valued occupations. <b>No risk when doing daily activity in the physical space</b> , e.g., clear access, appropriate flooring, no trailing cables, uses bolts/chains effectively, good state of repair, good lighting, safe on stairs, can access rooms
	3	Space is mostly adequate, allows daily occupations to be pursued. <b>Mostly risk free when doing daily activity in physical space</b> , e.g. occasional low risk i.e., blocked access, rugs, cables, bolts/chains, poor state of repair, poor lighting, negotiating stairs, accessing rooms
	2	Affords a limited range of opportunities and curtails performance of valued occupations. <b>Some risk in some aspects of the physical space when doing daily activity</b> , e.g. including blocked access, rugs, cables, bolts/chains, poor state of repair, poor lighting, negotiating stairs, accessing rooms
	1	Space restricts opportunities and prevents performance of valued occupations. <b>Significant multiple risks when doing activity in physical space</b> , e.g. blocked access, rugs, cables, bolts/chains, poor state of repair, poor lighting, negotiating stairs, accessing rooms
<p><b>Grip/dexterity</b></p> <p>Do the persons physical resources put them at higher/lower risk?</p> <ul style="list-style-type: none"> <li>Does the service user use a gas cooker? Detail the cooker type e.g. hob, freestanding, servicing</li> <li>Is there a bath, walk-in shower, over bath shower or bathing equipment?</li> <li>Are there other appliances in use by the service user (in the home/outside the home)?</li> <li>Does the service user have electrical appliances such as a kettle, microwave, electric blanket, toaster, or cooker?</li> </ul>	4	Enable occupational goals to be achieved with ease, equipment and tools are appropriate. <b>No risk when using appliances/objects to do daily activity</b> , e.g. appliances are in good repair i.e., electric fire, cookers, smoke alarm fitted, hot water not a risk for scalding, bath available and person uses safely, shower available as required
	3	Generally allow occupational goals to be achieved; may present some obstacles. <b>Mostly risk free when using appliances/objects to do daily activity</b> , e.g. mostly appliances are in good repair, that is electric fire, cookers, smoke alarm fitted, an episode of excessively hot water/risk of scalding, only bath available and person mostly uses safely

ATTILA trial questions	Score	ATTILA trial scale
<ul style="list-style-type: none"> <li>• Are there any potential fire hazards as appliances are in disrepair (e.g. evidence of burns from cooking)?</li> <li>• Is there smoke, carbon monoxide or other alarms already fitted?</li> <li>• Is the water excessively hot, with potential for scalding?</li> <li>• What is the source of hot water (immersion tank, combi-boiler, back-boiler i.e. behind gas fire, over sink heater)?</li> <li>• Risk of fall in night because of lack of night light</li> </ul>	2	Impede ability to achieve occupational goals safely, equipment and tools are inadequate. <b>Some risk in some aspect of using appliances/objects to do daily activity</b> , e.g. some appliances are in disrepair and a fire risk, that is electric fire, cookers, no smoke alarms, an episode of excessively hot water/risk of scalding, only bath available and person not safe to use, no night light when needed
	1	Have major impact on ability to achieve occupational goals, lack of tools lead to high risks. <b>Significant multiple risks when using appliances/objects to do daily activity</b> , e.g. appliances are in disrepair and a fire risk, that is electric fire, cookers, no smoke alarms, excessively hot water/risk of scalding, only bath available and person not safe to use, no night light when needed

## Social environment

ATTILA trial questions	Score	ATTILA trial scale
<i>Key question: Does who is involved and how activities are completed put the person at risk when doing daily activity?</i>		
<p><b>Social support</b></p> <p>Does the support available put them at higher/lower risk?</p> <ul style="list-style-type: none"> <li>• Does the service user live alone or with others?</li> <li>• Is the service user receiving formal care services? Does the service user have adequate social support, including medication management?</li> <li>• Who will remind/assist the service user to use the device if they need help?</li> <li>• Has emergency access been agreed (e.g. key safe, key holding)?</li> <li>• Are the primary carer's needs being met?</li> <li>• Is the service user receiving help from unpaid carers, e.g. relative's informal support, and if so, is anyone able to respond? Would there be any risks to them? Are they able to respond to sensor alerts? Are potential responders acceptable to the service user?</li> <li>• Would the service user accept an unfamiliar person visiting in response to an alert?</li> <li>• Who will be responsible for maintenance?</li> </ul>	4	Social groups offer practical support, values and attitudes support optimal functioning. <b>No risk due to carer(s) when doing daily activity</b> , e.g. appropriate family support, carer's needs being met, carer available when needed to prompt, provide emergency access or respond to an alert, accepting of a non-familiar person, clarity around who maintains ATT
	3	Generally able to offer support but may be some under or over involvement. <b>Mostly risk free due to carer(s) when doing daily activity</b> , e.g. mostly appropriate family support, carer's needs mostly being met, mostly carer available when needed to prompt, provide emergency access or respond to an alert, mostly accepting of a non-familiar person, mostly clarity around who maintains ATT
	2	Offer reduced support, or detracts from participation, some groups support but not others. <b>Some risk due to carer(s) when doing daily activity</b> , e.g. minimal family support, carer's needs not fully being met, minimal carer availability when needed to prompt, provide emergency access or respond to an alert, minimal acceptance of a non-familiar person, lack of clarity around who maintains ATT
	1	Do not support participation due to lack of interest or inappropriate involvement. <b>Significant multiple risks due to carer(s) when doing activity</b> , e.g. no family support, carer's needs not being met, no carer currently available when needed to prompt, provide emergency access or respond to an alert, no acceptance of a non-familiar person, no one to maintain ATT



ATTILA trial questions	Score	ATTILA trial scale
<p><b>The way the activity is completed</b></p> <p>Does the way the person completes activity put them at higher/lower risk?</p> <ul style="list-style-type: none"> <li>Does the person wear appropriate clothing when going outdoors?</li> <li>Does the person use their gas fire/cooker even when they are not safe? Is an alternative available?</li> <li>Does the person repeatedly go to toilet at night without putting the light on and increases risk of falls?</li> </ul>	4	Demands of activities match well with abilities, interests, energy and time available. <b>No risk due to the way the activity is being done</b> , e.g. safe when using an overhead gas grill, safe going to the toilet at night by putting light on, safe having a night-time bath, safe using stairs repeatedly in the day, evidence of wearing shoes/coat outdoors in wet weather
	3	Generally consistent with abilities, interest, energy or time available, may present challenges. <b>Mostly risk free due to the way the activity is being done</b> , e.g. mostly safe when using an overhead gas grill instead of a toaster, mostly safe going to the toilet at night by putting light on, mostly safe having a night-time bath, mostly safe using stairs repeatedly in the day, some evidence of wearing shoes/coat outdoors in wet weather
	2	Some clear inconsistencies with abilities and interest, or energy and time available. <b>Some risk due to the way the activity is being done</b> , e.g. can be unsafe when using an overhead gas grill instead of a toaster, can be unsafe going to the toilet at night owing to lack of light, can be unsafe having a night-time bath when tired, can be unsafe using stairs repeatedly in the day when physically not able, minimal evidence of wearing shoes/coat outdoors in wet weather
	1	Mostly inconsistent with abilities, construction of activity is under- or over-demanding. <b>Significant multiple risks due to the way the activity is being done</b> , e.g. unsafely using an overhead gas grill instead of a toaster, unsafely going to the toilet at night owing to lack of light, unsafely having a night-time bath when tired, using stairs repeatedly in the day when physically not able, not wearing shoes/coat outdoors in wet weather



## Appendix 3 Unit costs table

Variable name	Unit cost (£, 2016/17)	Unit	Source	Notes/assumptions
<b>Respite and care home use</b>				
Private-sector residential care for older people, cost of stay	94	Per day	PSSRU 2017, <sup>43</sup> table 1.2	Includes personal living expenses
Local authority residential care for older people, cost of stay	162	Per day	PSSRU 2017, <sup>43</sup> table 1.3	Includes personal living expenses
Private sector nursing home for older people, cost of stay	119	Per day	PSSRU 2017, <sup>43</sup> table 1.1	Includes personal living expenses
<b>Community health and social care services</b>				
GP time, home visit	88	Per visit	PSSRU 2017, <sup>43</sup> table 10.3b for costs; PSSRU 2013, <sup>165</sup> table 10.3b, for ratios	No information about home visits in PSSRU 2017. <sup>43</sup> Assumed ratio of clinic-to-home cost per minute remained the same and average duration of visit remained the same as given in PSSRU 2013. <sup>165</sup> Assumes average home visit duration of 23.4 minutes
GP time, home visit	3.7	Per minute	PSSRU 2017, <sup>43</sup> table 10.3b for costs; PSSRU 2013, <sup>165</sup> table 10.3b, for ratios	No information about home visits in PSSRU 2017. <sup>43</sup> Assumed ratio of clinic-to-home cost per minute remained the same and average duration of visit remained the same as given in PSSRU 2013. <sup>165</sup>
GP time, surgery	28	Per visit	PSSRU 2017, <sup>43</sup> table 10.3b	No direct care staff and no qualification costs, per surgery consultation of 9.22 minutes
GP time, surgery	3	Per minute	PSSRU 2017, <sup>43</sup> table 10.3b	No direct care staff and no qualification costs, per surgery consultation of 9.22 minutes
Practice nurse, face-to-face time	0.60	Per minute	PSSRU 2017, <sup>43</sup> table 10.2	Excludes qualification costs
Practice nurse, face-to-face time	9.30	Per consultation	PSSRU 2017, <sup>43</sup> table 10.2	Per 15.5-minute consultation. Excludes qualification costs
Community nursing time	0.73	Per minute	PSSRU 2017, <sup>43</sup> table 10.1	Assumes AfC band 6
Community nursing time	37	Per contact	NHS reference costs 2016/17 <sup>42</sup>	CHS tab
Nurse (mental health) time	0.73	Per minute	PSSRU 2017, <sup>43</sup> table 10.1	Assumes average hourly cost of a member of a community mental health team for older people

Variable name	Unit cost (£, 2016/17)	Unit	Source	Notes/assumptions
Nurse (mental health) time	44	Per contact	PSSRU 2017, <sup>43</sup> table 12.1	Assumes average visit duration in community mental health teams for older people, 60 minutes
Consultant: psychiatrist time	1.8	Per minute	PSSRU 2017, <sup>43</sup> table 15	Excludes qualification costs
Consultant: psychiatrist time	54	Per contact	PSSRU 2017, <sup>43</sup> table 15	Excludes qualification costs. Assumes 30-minute visit
Social worker, face-to-face time	59	Per visit	PSSRU 2017, <sup>43</sup> table 11.2	Excludes qualification costs. Assumes 1 hour of client-related work
Social worker, face-to-face time	0.98	Per minute	PSSRU 2017, <sup>43</sup> table 11.2	Excludes qualification costs. Assumes 1 hour of client-related work
Physiotherapist	0.72	Per minute	PSSRU 2017, <sup>43</sup> table 9	Assumes AfC band 61
Physiotherapist	53	Per contact	NHS reference costs 2016/17 <sup>42</sup>	CHS tab
NHS occupational therapist	0.72	Per minute	PSSRU 2017, <sup>43</sup> table 9	Assumes AfC band 61
NHS occupational therapist	76.73	Per contact	NHS reference costs 2016/17 <sup>42</sup>	CHS tab
NHS community mental health team worker for older people with mental health problems, per team member	44	Per contact	PSSRU 2017, <sup>43</sup> table 12.1	Assumes average visit duration in community mental health teams for older people, 60 minutes
Dietitian	84.85	Per contact	NHS reference costs 2016/17 <sup>42</sup>	CHS tab
Home care – average of independent and social services	0.44	Per minute	PSSRU 2017, <sup>43</sup> table 11.6	Face-to-face time: average cost of private and social services costs; weighted average of weekday and weekend costs
Home care – average of independent and social services	13.21	Per contact	PSSRU 2017, <sup>43</sup> table 11.6	Face-to-face time: average cost of private and Social Services costs; weighted average of weekday and weekend costs. Assumes 30 minute visit
Cleaner	20	Per visit		Internet search. Assumes 2-hour visit
Meals on wheels	6	Per meal	PSSRU 2014, <sup>166</sup> table 8.1.1	Upated using HCHS Pay & Prices index <sup>43</sup>
Sitting service i.e. Crossroads Care Essex (Canvey Island, UK); carer support worker	45	Per visit	<i>Evaluation of the East Sussex Carers' Breaks Demonstrator Site</i> <sup>167</sup>	Cost of short break for carers of 2.5 hours. Upated using HCHS Pay & Prices Index
Chiropodist	44.02	Per contact	NHS reference costs 2016/17 <sup>42</sup>	Activity-weighted average of podiatrist services; CHS tab
Optician – office	21.31	Per visit	Department of Health and Social Care, FODO <sup>168-170</sup>	Cost of a sight test

Variable name	Unit cost (£, 2016/17)	Unit	Source	Notes/assumptions
Optician – domiciliary	58.87	Per visit	Department of Health, FODO <sup>168-170</sup>	NHS domiciliary visit: ophthalmic service + sight test
Dentist, general dental service	85	Per visit	NHS reference costs 2016/17 <sup>42</sup>	CHS tab
Dentist, community dental service	153.88	Per visit	NHS reference costs 2016/17 <sup>42</sup>	CHS tab
Day care for older people, per session	63	Per session	PSSRU 2017, <sup>43</sup> table 1.4	
Day care in NHS facilities, per attendance	132.23	Attendance	NHS reference costs 2016/17 <sup>42</sup> CHS tab	Day care facilities regular attendances – elderly
Day care for people with mental health problems, per session	34	Per session	PSSRU 2017, <sup>43</sup> table 2.4	
Lunch club	8	Per session	Romeo <i>et al.</i> <sup>171</sup>	Uprated using HCHS Pay & Prices index
Paramedic visit, see and treat and refer	181.25	Per attendance	NHS reference costs 2016/17 <sup>42</sup>	ASS01: see and treat or refer
ATT assessment	36	Per working hour	PSSRU 2017, <sup>43</sup> table 9	Assumes the following: health and social care assessor is on AfC band 5 (cost per working hour: £33); specialist ATT assessor is on AfC band 6 (cost per working hour: £43); of assessors where assessor type was known, 70% were health and social care assessors and 30% were specialist ATT assessors
<b>ATT equipment</b>				
Activity monitoring detectors	7	Per item	NHC <sup>68</sup>	Mid-point of the range between minimum and maximum prices per device type. Annuity over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
Bed and chair sensors	11	Per item	NHC <sup>68</sup>	Mid-point of the range between minimum and maximum prices per device type. Annuity over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
Clocks and time reminders	9	Per item	NHC <sup>68</sup>	Mid-point of the range between minimum and maximum prices per device type. Annuity over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>

Variable name	Unit cost (£, 2016/17)	Unit	Source	Notes/assumptions
Enuresis sensors	9	Per item	NHC <sup>68</sup>	Mid-point of the range between minimum and maximum prices per device type. Annuitised over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
Epilepsy sensors	30	Per item	NHC <sup>68</sup>	Mid-point of the range between minimum and maximum prices per device type. Annuitised over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
GPS devices	21	Per item	NHC <sup>68</sup>	Mid-point of the range between minimum and maximum prices per device type. Annuitised over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
Networked carbon monoxide and gas monitors	9	Per item	NHC <sup>68</sup>	Mid-point of the range between minimum and maximum prices per device type. Annuitised over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
Networked flood detectors	6	Per item	NHC <sup>68</sup>	Mid-point of the range between minimum and maximum prices per device type. Annuitised over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
Networked smoke detector	5	Per item	NHC <sup>68</sup>	Mid-point of the range between minimum and maximum prices per device type. Annuitised over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
Networked temperature detectors	5	Per item	NHC <sup>68</sup>	Mid-point of the range between minimum and maximum prices per device type. Annuitised over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>

Variable name	Unit cost (£, 2016/17)	Unit	Source	Notes/assumptions
PIR movement and exit detectors	5	Per item	NHC <sup>68</sup>	Mid-point of the range between minimum and maximum prices per device type. Annuity over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
Pager units	10	Per item	NHC <sup>68</sup>	Mid-point of the range between minimum and maximum prices per device type. Annuity over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
Telecare base units and pendants	11	Per item	NHC <sup>68</sup>	Mid-point of the range between minimum and maximum prices per device type. Annuity over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
Key safes	7	Per item	NHC <sup>68</sup>	Mean price for device type. Annuity over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
Standalone smoke detectors	2	Per item	NHC <sup>68</sup>	Mean price for device-type. Annuity over 5 years at 3.5% discount rate; three-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
Standalone carbon monoxide monitors	4	Per item	NHC <sup>68</sup>	Mean price for device type. Annuity over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
Fall detectors	5	Per item	NHC <sup>68</sup>	Mean price for device type. Annuity over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
Standalone gas detectors	8	Per item	NHC <sup>68</sup>	Mean price for device type. Annuity over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
Medications reminders and dispensers	11	Per item	NHC <sup>68</sup>	Mean price for device type. Annuity over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>

Variable name	Unit cost (£, 2016/17)	Unit	Source	Notes/assumptions
Intercoms	5	Per item	NHC <sup>68</sup>	Mean price for device type. Annuited over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
Adapted telephones	2	Per item	NHC <sup>68</sup>	Mean price for device type. Annuited over 5 years at 3.5% discount rate; 3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
ATT installation	Range: 0.2-9	Per item	NHC <sup>68</sup>	3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
ATT maintenance	10	Per ATT package	NHC <sup>68</sup>	3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
Call handling/monitoring and response	40	Per networked ATT package	NHC <sup>68</sup>	3-month cost. Uprated to 2017 prices using CPIH <sup>172</sup>
<b>Equipment and adaptations</b>				
Wheelchair (average of self-/attendant propelled)	24.00	Per item	PSSRU 2017, <sup>43</sup> table 7.2	Annuited over 5 years; 3-month cost
Outdoor rail	1.35	Per item	PSSRU 2017, <sup>43</sup> table 7.2	Annuited over 10 years; 3-month cost
Stair/grab rail	0.95	Per item	PSSRU 2017, <sup>43</sup> table 7.2	Annuited over 10 years; 3-month cost
Over-bath shower adaptation	38.75	Per item	PSSRU 2017, <sup>43</sup> table 7.2	Annuited over 10 years; 3-month cost
Walk-in shower adaptation	155.00	Per item	PSSRU 2017, <sup>43</sup> table 7.2	Annuited over 10 years; 3-month cost
Perching stool	1.00	Per item	PSSRU 2013, <sup>165</sup> table 7.3.1	Annuited over 10 years; 3-month cost. Uprated using HCHS Pay & Prices index <sup>43</sup>
Commode	2.00	Per item	PSSRU 2013, <sup>165</sup> table 7.3.1	Annuited over 10 years; 3-month cost. Uprated using HCHS Pay & Prices index <sup>43</sup>
Toilet frame/raised toilet seat	4.00	Per item	PSSRU 2013, <sup>165</sup> table 7.3.1	Annuited over 10 years; 3-month cost. Uprated using HCHS Pay & Prices inflator
Chair/bed raisers	4.00	Per item	PSSRU 2013, <sup>165</sup> table 7.3.1	Annuited over 10 years; 3-month cost. Uprated using HCHS Pay & Prices index <sup>43</sup>
All four-wheeled and four-footed walking frames	9.00	Per item	PSSRU 2013, <sup>165</sup> table 7.3.1	Annuited over 10 years; 3-month cost. Uprated using HCHS Pay & Prices index <sup>43</sup>
Bath seat	10.00	Per item	PSSRU 2013, <sup>165</sup> table 7.3.1	Annuited over 10 years; 3-month cost. Uprated using HCHS Pay & Prices index <sup>43</sup>



Variable name	Unit cost (£, 2016/17)	Unit	Source	Notes/assumptions
Bed rail	4.00	Per item	PSSRU 2017, <sup>43</sup> table 7.2	Annuitised over 10 years; 3-month cost. Upated using HCHS Pay & Prices index <sup>43</sup>
Incontinence pads	88.00	Per 3-month supply		Upated from 2011 prices using the CPIH <sup>172</sup> to 2017 prices <sup>173</sup>
<b>Medications</b>				
Various	Range: 0.02–28	Standard quantity units	<i>Prescription Cost Analysis England 2017</i> <sup>174</sup>	Central nervous system prescription medications, <i>British National Formulary</i> chapter 4, Hypnotics and Anxiolytics (section 1), Drugs Used in Psychoses & Related Disorders (section 2), Antidepressant Drugs (section 3), Antiepileptic Drugs (section 8), Drugs Used in Parkinsonism/Related Disorders (section 9) and Drugs for Dementia (section 11)
<b>Unpaid carer costs</b>				
National average wage – value of lost work time	16.20	Per hour	Annual survey of hours and earnings <sup>66</sup>	Gross mean wage for all employee jobs, 2017
National average wage – value of lost leisure time	5.67	Per hour	Annual survey of hours and earnings <sup>66</sup>	35% of gross mean wage for all employee jobs, 2017
<b>Travel costs</b>				
Cost per mile of travel for carer (car running costs), per mile	0.16	Per mile	Automobile Association <sup>175</sup>	
Ambulance to A&E	247.5	Attendance	NHS reference costs 2016/17 <sup>42</sup>	AMB tab: see and treat and convey
<b>Hospital services</b>				
A&E attendances, weighted average of admitted attendances	221.25	Attendance	NHS reference costs 2016/17 <sup>42</sup>	EM tab
A&E attendances, weighted average of non-admitted attendances	127.56	Attendance	NHS reference costs 2016/17 <sup>42</sup>	EM tab
A&E attendances, weighted average of admitted and non-admitted attendances	148.36	Attendance	NHS reference costs 2016/17 <sup>42</sup>	EM tab
<b>Inpatients</b>				
Subchapter AA: nervous system procedures and disorders	477.75	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	295.42	Excess day		NEL_XS tab
Subchapter AB: pain management	563.14	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	507.96	Excess day		NEL_XS tab

Variable name	Unit cost (£, 2016/17)	Unit	Source	Notes/assumptions
Subchapter BZ: eyes and periorbital procedures and disorders	666.23	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	342.52	Excess day		NEL_XS tab
Subchapter CB: Ear, nose, mouth, throat and neck disorders	521.46	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	295.10	Excess day		NEL_XS tab
Subchapter DZ: respiratory system procedures and disorders	402.23	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	271.11	Excess day		NEL_XS tab
Subchapter EB: cardiac disorders	452.02	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	291.01	Excess day		NEL_XS tab
Subchapter ED: open cardiac procedures for acquired conditions	1368.01	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	399.24	Excess day		NEL_XS tab
Subchapter EY: interventional cardiology for acquired conditions	820.12	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	383.32	Excess day		NEL_XS tab
Subchapter FD: digestive system disorders	452.79	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	294.18	Excess day		NEL_XS tab
Subchapter FE: digestive system endoscopic procedures	517.57	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	313.94	Excess day		NEL_XS tab
Subchapter FF: digestive system open and laparoscopic procedures	825.31	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	342.91	Excess day		NEL_XS tab
Subchapter GC: hepatobiliary and pancreatic system disorders	435.85	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	288.25	Excess day		NEL_XS tab
Subchapter HC: spinal procedures and disorders	540.73	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	309.87	Excess day		NEL_XS tab
Subchapter HN: orthopaedic non-trauma procedures	731.69	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	325.66	Excess day		NEL_XS tab
Subchapter HT: orthopaedic trauma procedures	724.34	Day	NHS reference costs 2016/17 <sup>42</sup>	REHAB tab
	312.97			
Subchapter KA: endocrine system disorders	460.64	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	307.37	Excess day		NEL_XS tab
Subchapter KB: diabetic medicine	413.93	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	273.36	Excess day		NEL_XS tab
Subchapter local authority: renal procedures and disorders	415.24	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	272.35	Excess day		NEL_XS tab
Subchapter LB: urological and male reproductive system procedures and disorders	505.19	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	304.76	Excess day		NEL_XS tab

Variable name	Unit cost (£, 2016/17)	Unit	Source	Notes/assumptions
Subchapter MA: female reproductive system procedures	1172.12	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	472.35	Excess day		NEL_XS tab
Subchapter SA: haematological procedures and disorders	549.53	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	349.89	Excess day		NEL_XS tab
Subchapter VC: rehabilitation		Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
		Excess day		NEL_XS tab
Subchapter WD: treatment of mental health patients by non-mental health service providers	356.25	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	264.04	Excess day		NEL_XS tab
Subchapter WH: poisoning, toxic effects, special examinations, screening and other health-care contacts	440.99	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	274.22	Excess day		NEL_XS tab
Subchapter YQ: vascular open procedures and disorders	569.10	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	294.38	Excess day		NEL_XS tab
Inpatients, weighted average across specialties	645	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab
	299	Excess day		NEL_XS tab
<b>Day cases</b>				
Subchapter AA: nervous system procedures and disorders	563.24	Day	NHS reference costs 2016/17 <sup>42</sup>	DC tab
Subchapter AB: pain management	709.80	Day	NHS reference costs 2016/17 <sup>42</sup>	DC tab
Subchapter BZ: eyes and periorbital procedures and disorders	825.04	Day	NHS reference costs 2016/17 <sup>42</sup>	DC tab
Subchapter DZ: respiratory system procedures and disorders	606.65	Day	NHS reference costs 2016/17 <sup>42</sup>	DC tab
Subchapter EY: interventional cardiology for acquired conditions	1399.54	Day	NHS reference costs 2016/17 <sup>42</sup>	NEL tab NEL_XS tab
Subchapter FE: digestive system endoscopic procedures	539.46	Day	NHS reference costs 2016/17 <sup>42</sup>	DC tab
Subchapter HD: musculoskeletal and rheumatological disorders	386.87	Day	NHS reference costs 2016/17 <sup>42</sup>	DC tab
Day-case radiotherapy	132.69	Day	NHS reference costs 2016/17 <sup>42</sup>	RAD tab

Variable name	Unit cost (£, 2016/17)	Unit	Source	Notes/assumptions
<b>Outpatients</b>				
Service code 101: urology	102.88	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 104: colorectal surgery	109.83	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 107: vascular surgery	141.35	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 108: spinal surgery service	141.91	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 110: trauma and orthopaedics	109.78	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 120: ENT	87.94	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 130: ophthalmology	82.93	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 144: maxillo-facial surgery	116.47	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 150: neurosurgery	182.88	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 160: plastic surgery	94.52	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 170: cardiothoracic surgery	213.07	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 172: cardiac surgery	166.49	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 173: thoracic surgery	204.35	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs

Variable name	Unit cost (£, 2016/17)	Unit	Source	Notes/assumptions
Service code 191: pain management	127.87	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 301: gastroenterology	138.29	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 302: endocrinology	144.74	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 303: clinical haematology	164.74	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 304: clinical physiology	72.41	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 307: diabetic medicine	141.00	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 320: cardiology	117.34	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 324: anticoagulant service	30.04	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 330: dermatology	98.36	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 340: respiratory medicine	144.26	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 361: nephrology	148.53	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 370: medical oncology	163.93	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 400: neurology	149.30	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 410: rheumatology	134.47	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs

Variable name	Unit cost (£, 2016/17)	Unit	Source	Notes/assumptions
Service code 430: geriatric medicine	194.56	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 450: dental medicine specialties	97.03	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 502: gynaecology	130.36	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 650: physiotherapy	44.96	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 652: speech and language therapy	94.88	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 653: podiatry	41.87	Follow-up attendance	NHS reference costs 2016/17 <sup>42</sup>	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 654: dietetics	68.75	Follow-up attendance	NHS reference costs 2016/17 (NHS Improvement 2017)	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 655: orthoptics	61.02	Follow-up attendance	NHS reference costs 2016/17 (NHS Improvement 2017)	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 658: orthotics	115.18	Follow-up attendance	NHS reference costs 2016/17 (NHS Improvement 2017)	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 662: optometry	54.79	Follow-up attendance	NHS reference costs 2016/17 (NHS Improvement 2017)	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 713: psychotherapy	187.65	Follow-up attendance	NHS reference costs 2016/17 (NHS Improvement 2017)	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 715: old age psychiatry	179.66	Follow-up attendance	NHS reference costs 2016/17 (NHS Improvement 2017)	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 800: clinical oncology (previously radiotherapy)	126.39	Follow-up attendance	NHS reference costs 2016/17 (NHS Improvement 2017)	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Service code 812: diagnostic imaging	80.65	Follow-up attendance	NHS reference costs 2016/17 (NHS Improvement 2017)	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs

Variable name	Unit cost (£, 2016/17)	Unit	Source	Notes/assumptions
Service code 840: audiology	87.04	Follow-up attendance	NHS reference costs 2016/17 (NHS Improvement 2017)	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Weighted average across laboratory tests	2.032	Per test	NHS reference costs 2016/17 (NHS Improvement 2017)	DAPS tab
Haemodialysis	157.83	Per attendance	NHS reference costs 2016/17 (NHS Improvement 2017)	RENAL tab
Memory clinic	406.45	Follow-up attendance	PSSRU 2014, <sup>166</sup> table 1.10	Uprated using HCHS Pay & Prices index <sup>43</sup>
Weighted average of follow-up attendances across service codes	105.52	Follow-up attendance	NHS reference costs 2016/17 (NHS Improvement 2017)	Consultant- and non-consultant-led follow-up face-to-face attendances, CL and NCL tabs
Subchapter AA: nervous system procedures and disorders	171.70	Outpatient procedure	NHS reference costs 2016/17 <sup>42</sup>	OPROC tab
Subchapter EY: interventional cardiology for acquired conditions	147.80	Outpatient procedure	NHS reference costs 2016/17 <sup>42</sup>	OPROC tab
Subchapter FE: digestive system endoscopic procedures	202.45	Outpatient procedure	NHS reference costs 2016/17 <sup>42</sup>	OPROC tab
Subchapter JC: skin procedures	126.66	Outpatient procedure	NHS reference costs 2016/17 <sup>42</sup>	OPROC tab
Subchapter MA: female reproductive system procedures	177.28	Outpatient procedure	NHS reference costs 2016/17 <sup>42</sup>	OPROC tab

A&E, accident and emergency; AfC, Agenda for Change; CHS, Community Health Services; CL, consultant led; CPI, Consumer Prices Index; DAPS, directly accessed pathology services; DC, day case; ENT, ear, nose and throat; FODO, Federation of (Ophthalmic and Dispensing) Opticians; HCHS, Hospital and Community Health Service; NCL, non-consultant led; NEL, non-elective; NEL-XS, non elective: excess bed days; OPROC, outpatient procedures; PIR, passive infrared sensor; PSSRU, Personal Social Services Research Unit; REHAB, rehabilitation; RENAL, renal dialysis.





## Appendix 4 Baseline demographic characteristics of the sample with dyads participating in full baseline assessments

Characteristic	Trial arm, n (%)		Total, n (%)
	Intervention	Control	
Female	131 (57)	131 (58)	262 (58)
<b>Age (years)</b>			
< 65	11 (5)	3 (1)	14 (3)
65–80	83 (36)	89 (40)	172 (38)
> 80	135 (59)	132 (59)	267 (59)
<b>Risk of wandering</b>			
Low	164 (72)	167 (75)	331 (73)
Moderate	48 (21)	40 (18)	88 (19)
High	17 (7)	17 (8)	34 (8)
<b>Safety risk in the home</b>			
Low	116 (51)	113 (50)	229 (51)
Moderate	95 (41)	93 (42)	188 (42)
High	18 (8)	18 (8)	36 (8)
<b>Caregiver involvement</b>			
Visits at least once/day	51 (22)	54 (24)	105 (23)
Visits less than once/day	64 (28)	56 (25)	120 (26)
Live in	114 (50)	114 (51)	228 (50)
<b>Caregiver-participant relationship</b>			
Spouse/partner	88 (38)	82 (37)	170 (38)
Sibling/child/child-in-law	119 (52)	122 (54)	241 (53)
Other relative	18 (8)	8 (4)	26 (6)
Non-relative	4 (2)	12 (5)	16 (4)



## Appendix 5 Use of health, social and unpaid care over the previous 3 months

Use of health, social and unpaid care over the previous 3 months, intervention and control groups, for cases with economic data available at baseline and at the 12-, 24-, 52- and 104-week follow-ups.

Service/item	Units	Trial arm					
		Intervention			Control		
		Valid (n)	Users, n (%)	Mean (SE)	Valid (n)	Users, n (%)	Mean (SE)
<b>Baseline</b>		<b>Expected = 229</b>			<b>Expected = 224</b>		
<b>Community health</b>							
GP	Visits	229	159 (69)	1.82 (0.13)	223	146 (65)	1.54 (0.13)
Practice nurse	Visits	229	88 (38)	0.94 (0.16)	223	84 (38)	0.69 (0.12)
Community nurse	Visits	229	52 (23)	2.76 (0.86)	223	42 (19)	1.26 (0.45)
Physiotherapist	Visits	229	33 (14)	1.04 (0.28)	223	22 (10)	0.23 (0.06)
Occupational therapist	Visits	229	61 (27)	0.44 (0.06)	223	52 (23)	0.39 (0.06)
Dietitian	Visits	229	3 (1)	0.02 (0.01)	223	11 (5)	0.06 (0.02)
Paramedic	Visits	228	24 (11)	0.13 (0.03)	223	30 (13)	0.26 (0.07)
Specialist nurse	Visits	229	22 (10)	0.22 (0.07)	223	19 (9)	0.23 (0.08)
Dentist	Visits	229	55 (24)	0.33 (0.05)	223	45 (20)	0.26 (0.04)
Optician	Visits	229	46 (20)	0.24 (0.04)	223	43 (19)	0.23 (0.04)
Chiropodist	Visits	229	84 (37)	0.60 (0.06)	223	79 (35)	0.65 (0.15)
<b>Mental health</b>							
Mental health nurse	Visits	229	78 (34)	0.78 (0.10)	223	57 (26)	0.58 (0.10)
Psychiatrist	Visits	229	52 (23)	0.75 (0.38)	223	47 (21)	0.25 (0.03)
Psychologist	Visits	229	4 (2)	0.03 (0.02)	223	6 (3)	0.06 (0.03)
Mental health team	Visits	229	17 (7)	0.29 (0.08)	223	11 (5)	0.13 (0.06)
<b>Community care</b>							
Home care	Visits	229	91 (40)	56.79 (6.79)	223	96 (43)	59.70 (6.89)
Home care	Hours	229	91 (40)	49.69 (11.06)	223	96 (43)	64.29 (15.09)
Social worker	Visits	229	75 (33)	0.51 (0.06)	223	76 (34)	0.66 (0.12)
Cleaner	Visits	229	59 (26)	2.90 (0.37)	223	40 (18)	2.22 (0.35)
Meals on wheels	Visits	229	9 (4)	1.41 (0.66)	223	16 (7)	3.45 (1.06)
Laundry service	Visits	229	7 (3)	0.43 (0.17)	223	3 (1)	0.14 (0.09)
Sitting service	Visits	229	6 (3)	0.41 (0.19)	223	9 (4)	0.33 (0.16)
Carer support worker	Visits	229	11 (5)	0.18 (0.12)	222	12 (5)	0.07 (0.02)

Service/item	Units	Trial arm					
		Intervention			Control		
		Valid (n)	Users, n (%)	Mean (SE)	Valid (n)	Users, n (%)	Mean (SE)
<i>Day services</i>							
Day centre	Attendances	229	38 (17)	3.34 (0.76)	223	36 (16)	2.73 (0.53)
Lunch club	Attendances	229	19 (8)	0.64 (0.20)	223	26 (12)	0.99 (0.23)
Patient education	Attendances	229	11 (5)	0.38 (0.13)	223	5 (2)	0.26 (0.18)
<i>Hospital care</i>							
Emergency department	Attendances	229	29 (13)	0.14 (0.03)	223	39 (17)	0.20 (0.03)
Inpatients services	Days	229	24 (10)	1.24 (0.35)	223	36 (16)	2.39 (0.57)
Day hospital services	Days	229	2 (1)	0.01 (0.01)	223	2 (1)	0.01 (0.01)
Outpatients services	Visits	229	100 (44)	0.95 (0.11)	223	92 (41)	1.00 (0.14)
<i>Residential respite</i>							
Residential home	Days	228	1 (0)	0.00 (0.00)	223	0 (0)	0.00 (0.00)
Nursing home	Days	228	5 (2)	0.37 (0.20)	223	8 (4)	0.91 (0.43)
<i>Medications</i>							
Any medications	Units	225	144 (64)	0.94 (0.06)	221	142 (64)	0.90 (0.06)
Dementia	Units	226	116 (51)	0.56 (0.04)	221	115 (52)	0.56 (0.04)
Mental health	Units	225	71 (32)	0.39 (0.04)	222	62 (28)	0.34 (0.04)
<i>Equipment and adaptations</i>							
Equipment (health and social care providers)	Items	217	48 (22)	0.47 (0.07)	202	51 (25)	0.43 (0.06)
<i>Unpaid care; out of pocket</i>							
Equipment (private)	Items	217	9 (4)	0.04 (0.01)	202	10 (5)	0.06 (0.02)
Travel to appointment	Trips	219	111 (51)	2.50 (0.45)	202	91 (45)	1.30 (0.21)
Unpaid care	Hours	214	212 (99)	563.95 (43.71)	201	200 (100)	661.00 (46.31)
Carer cut down work	Hours	205	3 (1)	1.00 (0.69)	195	4 (2)	1.57 (1.06)
Carer stopped work	Weeks	207	1 (0)	0.02 (0.02)	199	2 (1)	0.05 (0.04)
Unpaid care other carers <sup>a</sup>	Hours	216	124 (57)	121.63 (17.86)	202	96 (48)	87.80 (14.63)
Time off work other carers <sup>a</sup>	Days	215	15 (7)	0.00 (0.00)	202	20 (10)	0.01 (0.00)
ATT devices (including basic <sup>b</sup> )	Items	223	217 (97)	2.66 (0.10)	203	187 (92)	2.01 (0.09)
<b>12 weeks</b>		<b>Expected = 189</b>			<b>Expected = 188</b>		
<i>Community health</i>							
GP	Visits	188	118 (63)	1.35 (0.12)	186	119 (64)	1.62 (0.14)
Practice nurse	Visits	188	72 (38)	0.65 (0.09)	186	72 (39)	0.91 (0.24)
Community/district nurse	Visits	188	36 (19)	3.64 (1.11)	186	32 (17)	2.10 (0.77)

Service/item	Units	Trial arm					
		Intervention			Control		
		Valid (n)	Users, n (%)	Mean (SE)	Valid (n)	Users, n (%)	Mean (SE)
Physiotherapist	Visits	188	21 (11)	0.73 (0.22)	186	20 (11)	0.32 (0.13)
Occupational therapist	Visits	188	24 (13)	0.23 (0.06)	186	29 (16)	0.23 (0.05)
Dietitian	Visits	188	3 (2)	0.02 (0.01)	186	6 (3)	0.03 (0.01)
Paramedic	Visits	188	18 (10)	0.12 (0.03)	186	20 (11)	0.20 (0.06)
Specialist nurse	Visits	188	18 (10)	0.15 (0.04)	186	15 (8)	0.19 (0.07)
Dentist	Visits	189	33 (17)	0.33 (0.07)	186	33 (18)	0.21 (0.04)
Optician	Visits	189	39 (21)	0.24 (0.04)	186	26 (14)	0.19 (0.04)
Chiropodist	Visits	189	77 (41)	0.65 (0.07)	186	67 (36)	0.57 (0.07)
<i>Mental health</i>							
Mental health nurse	Visits	188	34 (18)	0.25 (0.04)	186	31 (17)	0.41 (0.11)
Psychiatrist	Visits	188	24 (13)	0.26 (0.11)	186	24 (13)	0.19 (0.05)
Psychologist	Visits	187	2 (1)	0.04 (0.03)	186	1 (1)	0.02 (0.02)
Mental health team	Visits	188	7 (4)	0.21 (0.09)	186	12 (6)	0.18 (0.07)
<i>Community care</i>							
Home care	Visits	189	81 (43)	67.14 (8.16)	186	87 (47)	66.00 (8.22)
Home care	Hours	189	81 (43)	65.94 (14.18)	186	87 (47)	73.21 (19.04)
Social worker	Visits	188	41 (22)	0.29 (0.05)	186	55 (30)	0.43 (0.06)
Cleaner	Visits	189	54 (29)	3.16 (0.43)	186	43 (23)	2.86 (0.47)
Meals on wheels	Visits	189	11 (6)	3.41 (1.19)	186	12 (6)	3.55 (1.17)
Laundry service	Visits	189	4 (2)	0.25 (0.12)	186	6 (3)	0.45 (0.20)
Sitting service	Visits	189	8 (4)	0.29 (0.12)	186	5 (3)	0.11 (0.07)
Carer support worker	Visits	189	10 (5)	0.12 (0.05)	186	10 (5)	0.18 (0.07)
<i>Day services</i>							
Day centre	Attendances	189	42 (22)	4.62 (0.82)	186	31 (17)	3.42 (0.74)
Lunch club	Attendances	189	17 (9)	0.80 (0.27)	186	19 (10)	1.33 (0.40)
Patient education	Attendances	189	11 (6)	0.42 (0.17)	186	7 (4)	0.19 (0.09)
<i>Hospital care</i>							
Emergency department	Attendances	189	30 (16)	0.20 (0.04)	186	27 (15)	0.19 (0.04)
Inpatients services	Days	189	20 (11)	0.76 (0.28)	186	23 (12)	1.34 (0.41)
Day hospital services	Days	189	1 (1)	0.19 (0.19)	186	1 (1)	0.01 (0.01)
Outpatients services	Visits	189	74 (39)	0.79 (0.09)	186	76 (41)	0.78 (0.09)
<i>Residential respite</i>							
Residential home	Days	188	0 (0)	0.00 (0.00)	185	3 (2)	0.22 (0.16)
Nursing home	Days	188	5 (3)	0.52 (0.28)	185	7 (4)	0.59 (0.26)

Service/item	Units	Trial arm					
		Intervention			Control		
		Valid (n)	Users, n (%)	Mean (SE)	Valid (n)	Users, n (%)	Mean (SE)
<i>Medications</i>							
Medications	Units	187	122 (65)	0.98 (0.07)	186	115 (62)	0.88 (0.07)
Dementia	Units	189	104 (55)	0.61 (0.04)	186	97 (52)	0.57 (0.04)
Mental health	Units	187	58 (31)	0.40 (0.05)	186	47 (25)	0.31 (0.04)
<i>Equipment and adaptations</i>							
Equipment (HSC)	Items	184	27 (15)	0.28 (0.07)	181	28 (15)	0.22 (0.04)
<i>Unpaid care; out of pocket</i>							
Equipment (private)	Items	185	6 (3)	0.03 (0.01)	181	10 (6)	0.07 (0.02)
Travel to appointments	Trips	188	85 (45)	2.12 (0.36)	184	62 (34)	1.01 (0.18)
Unpaid care	Hours	186	186 (100)	641.24 (48.85)	182	182 (100)	721.37 (50.71)
Carer cut down work	Hours	174	1 (1)	0.14 (0.14)	174	1 (1)	0.48 (0.48)
Carer stopped work	Weeks	175	3 (2)	0.09 (0.07)	179	0 (0)	0.00 (0.00)
Unpaid care other carers <sup>a</sup>	Hours	186	99 (53)	92.16 (13.09)	184	95 (52)	108.22 (19.21)
Time off work other carers <sup>a</sup>	Days	184	9 (5)	0.00 (0.00)	183	15 (8)	0.01 (0.00)
ATT devices (including basic <sup>b</sup> )	Items	188	164 (87)	3.33 (0.18)	166	120 (72)	1.98 (0.16)
<b>Week 24</b>		<b>Expected = 178</b>			<b>Expected = 168</b>		
<i>Community health</i>							
GP	Visits	176	101 (57)	1.31 (0.17)	168	100 (60)	1.23 (0.13)
Practice nurse	Visits	177	69 (39)	1.05 (0.25)	168	57 (34)	0.51 (0.07)
Community/district nurse	Visits	177	30 (17)	2.45 (0.93)	168	33 (20)	2.73 (0.90)
Physiotherapist	Visits	177	20 (11)	0.49 (0.14)	168	17 (10)	0.21 (0.06)
Occupational therapist	Visits	177	18 (10)	0.14 (0.03)	168	20 (12)	0.14 (0.03)
Dietitian	Visits	177	4 (2)	0.02 (0.01)	168	6 (4)	0.04 (0.01)
Paramedic	Visits	177	12 (7)	0.08 (0.02)	168	8 (5)	0.06 (0.02)
Specialist nurse	Visits	176	11 (6)	0.20 (0.09)	168	15 (9)	0.46 (0.28)
Dentist	Visits	177	38 (21)	0.27 (0.05)	168	38 (23)	0.30 (0.06)
Optician	Visits	177	37 (21)	0.26 (0.04)	168	28 (17)	0.21 (0.04)
Chiropodist	Visits	177	65 (37)	0.54 (0.06)	168	52 (31)	0.52 (0.08)
<i>Mental health</i>							
Mental health nurse	Visits	177	24 (14)	0.26 (0.07)	168	25 (15)	0.26 (0.06)
Psychiatrist	Visits	177	13 (7)	0.08 (0.02)	168	17 (10)	0.13 (0.04)
Psychologist	Visits	177	1 (1)	0.02 (0.02)	168	2 (1)	0.04 (0.03)
Mental health team	Visits	177	7 (4)	0.11 (0.07)	168	10 (6)	0.15 (0.07)

Service/item	Units	Trial arm					
		Intervention			Control		
		Valid (n)	Users, n (%)	Mean (SE)	Valid (n)	Users, n (%)	Mean (SE)
<i>Community care</i>							
Home care	Visits	177	79 (45)	81.98 (9.66)	168	79 (47)	71.18 (8.49)
Home care	Hours	177	79 (45)	88.09 (20.15)	168	79 (47)	74.56 (16.77)
Social worker	Visits	177	29 (16)	0.24 (0.05)	168	35 (21)	0.33 (0.06)
Cleaner	Visits	177	47 (27)	3.20 (0.48)	168	44 (26)	2.86 (0.42)
Meals on wheels	Visits	177	10 (6)	4.05 (1.37)	168	11 (7)	3.86 (1.87)
Laundry service	Visits	177	2 (1)	0.22 (0.16)	168	8 (5)	0.86 (0.56)
Sitting service	Visits	177	8 (5)	0.61 (0.23)	168	7 (4)	0.12 (0.05)
Carer support worker	Visits	177	3 (2)	0.01 (0.01)	168	8 (5)	0.16 (0.08)
<i>Day services</i>							
Day centre	Attendances	177	36 (20)	4.33 (0.89)	168	30 (18)	3.32 (0.67)
Lunch club	Attendances	177	15 (8)	0.69 (0.21)	168	20 (12)	1.65 (0.47)
Patient education	Attendances	177	10 (6)	0.45 (0.16)	168	12 (7)	0.53 (0.17)
<i>Hospital care</i>							
Emergency department	Attendances	177	23 (13)	0.17 (0.04)	168	25 (15)	0.18 (0.04)
Inpatients services	Days	177	10 (6)	0.44 (0.20)	168	16 (10)	1.69 (0.69)
Day hospital services	Days	177	3 (2)	0.02 (0.01)	168	2 (1)	0.02 (0.01)
Outpatients services	Visits	177	62 (35)	0.78 (0.17)	168	68 (40)	0.91 (0.17)
<i>Residential respite</i>							
Residential home	Days	175	1 (1)	0.00 (0.00)	166	1 (1)	0.21 (0.21)
Nursing home	Days	175	4 (2)	0.38 (0.23)	166	3 (2)	0.13 (0.07)
<i>Medications</i>							
Any medications	Units	175	122 (70)	1.05 (0.07)	168	110 (65)	0.88 (0.06)
Dementia	Units	177	105 (59)	0.65 (0.04)	168	95 (57)	0.61 (0.04)
Mental health	Units	175	57 (33)	0.41 (0.05)	168	38 (23)	0.27 (0.04)
Equipment (health and social care providers)	Items	175	28 (16)	0.25 (0.05)	167	20 (12)	0.22 (0.06)
<i>Unpaid care; out-of-pocket</i>							
Equipment (private)	Items	175	8 (5)	0.06 (0.02)	167	3 (2)	0.02 (0.01)
Travel to appointments	Trips	177	58 (33)	1.91 (0.40)	168	66 (39)	1.24 (0.23)
Unpaid care	Hours	175	173 (99)	667.58 (53.00)	168	168 (100)	732.41 (53.61)
Carer cut down work	Hours	171	2 (1)	0.42 (0.42)	159	0 (0)	0.00 (0.00)
Carer stopped work	Weeks	169	1 (1)	0.03 (0.03)	165	0 (0)	0.00 (0.00)

Service/item	Units	Trial arm					
		Intervention			Control		
		Valid (n)	Users, n (%)	Mean (SE)	Valid (n)	Users, n (%)	Mean (SE)
Unpaid care other carers <sup>a</sup>	Hours	175	102 (58)	135.57 (20.81)	167	91 (54)	115.89 (19.44)
Time off work other carers <sup>a</sup>	Days	175	20 (11)	0.01 (0.01)	167	16 (10)	0.01 (0.00)
ATT devices (including basic <sup>b</sup> )	Items	176	148 (84)	2.91 (0.17)	157	121 (77)	2.28 (0.17)
<b>Week 52</b>		<b>Expected = 150</b>			<b>Expected = 139</b>		
<i>Community health</i>							
GP	Visits	148	96 (65)	1.41 (0.13)	137	80 (58)	1.35 (0.14)
Practice nurse	Visits	148	64 (43)	0.87 (0.16)	137	50 (36)	0.70 (0.13)
Community nurse	Visits	148	31 (21)	2.36 (0.88)	137	26 (19)	1.95 (0.77)
Physiotherapist	Visits	148	9 (6)	0.34 (0.15)	137	9 (7)	0.66 (0.48)
Occupational therapist	Visits	148	17 (11)	0.22 (0.06)	137	20 (15)	0.28 (0.07)
Dietitian	Visits	148	4 (3)	0.03 (0.02)	137	9 (7)	0.09 (0.03)
Paramedic	Visits	148	15 (10)	0.12 (0.03)	137	18 (13)	0.18 (0.05)
Specialist nurse	Visits	148	17 (11)	0.14 (0.04)	137	16 (12)	0.21 (0.07)
Dentist	Visits	148	33 (22)	0.32 (0.06)	137	38 (28)	0.40 (0.06)
Optician	Visits	148	25 (17)	0.18 (0.03)	137	31 (23)	0.30 (0.05)
Chiropodist	Visits	148	61 (41)	0.61 (0.07)	137	52 (38)	0.63 (0.08)
<i>Mental health</i>							
Mental health nurse	Visits	148	12 (8)	0.14 (0.04)	137	19 (14)	0.25 (0.07)
Psychiatrist	Visits	148	7 (5)	0.05 (0.02)	137	10 (7)	0.08 (0.03)
Psychologist	Visits	148	1 (1)	0.01 (0.01)	137	0 (0)	0.00 (0.00)
Mental health team	Visits	148	4 (3)	0.18 (0.16)	137	3 (2)	0.10 (0.08)
<i>Community care</i>							
Home care	Visits	148	77 (52)	86.19 (10.48)	137	67 (49)	92.06 (11.46)
Home care	Hours	148	77 (52)	122.81 (28.27)	137	67 (49)	77.20 (17.46)
Social worker	Visits	148	29 (20)	0.26 (0.06)	137	33 (24)	0.30 (0.05)
Cleaner	Visits	148	38 (26)	2.91 (0.46)	137	36 (26)	3.69 (0.81)
Meals on wheels	Visits	148	5 (3)	2.82 (1.26)	137	12 (9)	4.98 (1.60)
Laundry service	Visits	148	4 (3)	0.43 (0.22)	137	5 (4)	0.36 (0.17)
Sitting service	Visits	148	5 (3)	0.61 (0.36)	137	9 (7)	0.94 (0.39)
Carer support worker	Visits	148	1 (1)	0.00 (0.00)	137	6 (4)	0.15 (0.07)
<i>Day services</i>							
Day centre	Attendances	148	35 (24)	5.83 (1.18)	137	30 (22)	4.54 (0.97)
Lunch club	Attendances	148	12 (8)	0.73 (0.22)	137	16 (12)	2.28 (1.12)
Patient education	Attendances	148	7 (5)	0.48 (0.23)	137	7 (5)	0.42 (0.17)



Service/item	Units	Trial arm					
		Intervention			Control		
		Valid (n)	Users, n (%)	Mean (SE)	Valid (n)	Users, n (%)	Mean (SE)
<i>Hospital care</i>							
Emergency department	Attendances	148	25 (17)	0.18 (0.03)	137	24 (18)	0.24 (0.05)
Inpatients services	Days	148	17 (11)	0.86 (0.33)	137	17 (12)	1.69 (0.51)
Day hospital services	Days	148	0 (0)	0.00 (0.00)	137	3 (2)	0.02 (0.01)
Outpatients services	Visits	148	52 (35)	0.65 (0.10)	137	56 (41)	1.13 (0.31)
<i>Residential respite</i>							
Residential home	Days	148	1 (1)	0.00 (0.00)	137	4 (3)	0.47 (0.32)
Nursing home	Days	148	5 (3)	0.64 (0.39)	137	7 (5)	0.61 (0.24)
<i>Medications</i>							
Any medications	Units	145	101 (70)	0.99 (0.07)	137	92 (67)	0.93 (0.07)
Dementia	Units	147	85 (58)	0.63 (0.05)	137	78 (57)	0.62 (0.05)
Mental health	Units	145	45 (31)	0.37 (0.05)	137	35 (26)	0.31 (0.05)
Equipment (health and social care providers)	Items	147	22 (15)	0.24 (0.06)	137	18 (13)	0.21 (0.05)
<i>Unpaid care; out of pocket</i>							
Equipment (private)	Items	147	14 (10)	0.11 (0.03)	137	8 (6)	0.06 (0.02)
Travel to appointments	Trips	147	49 (33)	2.27 (0.55)	136	47 (35)	1.11 (0.27)
Unpaid care	Hours	145	145 (100)	653.68 (56.15)	135	135 (100)	793.88 (59.57)
Carer cut down work	Hours	146	1 (1)	0.34 (0.34)	135	3 (2)	1.03 (0.71)
Carer stopped work	Weeks	144	0 (0)	0.00 (0.00)	136	0 (0)	0.00 (0.00)
Unpaid care other carers <sup>a</sup>	Hours	147	84 (57)	100.98 (17.96)	136	78 (57)	145.61 (28.77)
Time off work other carers <sup>a</sup>	Days	146	7 (5)	0.00 (0.00)	134	16 (12)	0.01 (0.00)
ATT devices (including basic <sup>b</sup> )	Items	146	131 (90)	3.70 (0.20)	129	111 (86)	2.63 (0.17)
<b>Week 104</b>		<b>Expected = 96</b>			<b>Expected = 90</b>		
<i>Community health</i>							
GP	Visits	93	66 (71)	1.39 (0.15)	89	58 (65)	1.55 (0.18)
Practice nurse	Visits	92	28 (30)	0.55 (0.14)	89	28 (31)	0.69 (0.22)
Community/district nurse	Visits	93	20 (22)	2.35 (1.05)	89	31 (35)	4.29 (1.59)
Physiotherapist	Visits	93	7 (8)	0.56 (0.31)	89	11 (12)	0.70 (0.38)
Occupational therapist	Visits	93	8 (9)	0.12 (0.05)	89	8 (9)	0.18 (0.07)

Service/item	Units	Trial arm					
		Intervention			Control		
		Valid (n)	Users, n (%)	Mean (SE)	Valid (n)	Users, n (%)	Mean (SE)
Dietitian	Visits	93	2 (2)	0.02 (0.02)	89	6 (7)	0.12 (0.05)
Paramedic	Visits	93	10 (11)	0.15 (0.06)	89	9 (10)	0.16 (0.06)
Specialist nurse	Visits	93	11 (12)	0.23 (0.09)	89	8 (9)	0.15 (0.06)
Dentist	Visits	93	16 (17)	0.26 (0.07)	89	18 (20)	0.29 (0.07)
Optician	Visits	93	21 (23)	0.27 (0.06)	89	15 (17)	0.21 (0.06)
Chiropodist	Visits	93	37 (40)	0.66 (0.11)	89	39 (44)	0.55 (0.07)
<i>Mental health</i>							
Mental health nurse	Visits	93	6 (6)	0.11 (0.06)	89	7 (8)	0.11 (0.04)
Psychiatrist	Visits	93	1 (1)	0.01 (0.01)	89	6 (7)	0.07 (0.03)
Psychologist	Visits	93	0 (0)	0.00 (0.00)	89	0 (0)	0.00 (0.00)
Mental health team	Visits	93	0 (0)	0.00 (0.00)	89	4 (4)	0.07 (0.04)
<i>Community care</i>							
Home care	Visits	93	46 (49)	97.81 (15.06)	89	50 (56)	110.49 (16.87)
Home care	Hours	93	46 (49)	169.38 (49.12)	89	50 (56)	113.33 (28.65)
Social worker	Visits	93	11 (12)	0.24 (0.11)	89	19 (21)	0.33 (0.08)
Cleaner	Visits	93	32 (34)	4.00 (0.65)	89	25 (28)	4.68 (1.59)
Meals on wheels	Visits	93	2 (2)	1.96 (1.38)	89	8 (9)	8.13 (4.43)
Laundry service	Visits	93	1 (1)	0.14 (0.14)	89	3 (3)	0.28 (0.20)
Sitting service	Visits	93	6 (6)	1.44 (0.64)	89	7 (8)	1.10 (0.48)
Carer support worker	Visits	93	2 (2)	0.29 (0.27)	89	3 (3)	0.25 (0.20)
<i>Day services</i>							
Day centre	Attendances	93	20 (22)	7.00 (1.72)	89	22 (25)	5.46 (1.26)
Lunch club	Attendances	93	5 (5)	0.37 (0.20)	89	8 (9)	0.84 (0.39)
Patient education group	Attendances	93	3 (3)	0.18 (0.14)	89	4 (4)	0.58 (0.33)
<i>Hospital care</i>							
Emergency department	Attendances	93	8 (9)	0.11 (0.04)	89	20 (22)	0.35 (0.08)
Inpatients services	Days	93	6 (6)	1.00 (0.56)	89	16 (18)	1.33 (0.44)
Day hospital services	Days	93	1 (1)	0.01 (0.01)	89	1 (1)	0.01 (0.01)
Outpatients services	Visits	93	35 (38)	0.67 (0.12)	89	28 (31)	1.17 (0.54)
<i>Residential respite</i>							
Residential home	Days	93	0 (0)	0.00 (0.00)	89	1 (1)	0.15 (0.15)
Nursing home	Days	93	1 (1)	0.03 (0.03)	89	4 (4)	0.57 (0.31)

Service/item	Units	Trial arm					
		Intervention			Control		
		Valid (n)	Users, n (%)	Mean (SE)	Valid (n)	Users, n (%)	Mean (SE)
<i>Medications</i>							
Any medications	Units	92	61 (66)	0.99 (0.09)	89	63 (71)	0.98 (0.09)
Dementia	Units	93	50 (54)	0.61 (0.06)	89	53 (60)	0.61 (0.05)
Mental health	Units	92	29 (32)	0.39 (0.07)	89	25 (28)	0.37 (0.07)
Equipment (health and social care providers)	Items	92	10 (11)	0.15 (0.05)	89	9 (10)	0.16 (0.05)
<i>Unpaid care</i>							
Equipment (private)	Items	92	5 (5)	0.10 (0.05)	89	3 (3)	0.03 (0.02)
Travel to appointments	Trips	93	35 (38)	1.41 (0.36)	89	29 (33)	2.97 (1.02)
Unpaid care	Hours	91	88 (97)	656.30 (72.42)	88	87 (99)	776.74 (74.79)
Carer cut down work	Hours	90	1 (1)	0.56 (0.56)	89	1 (1)	0.22 (0.22)
Carer stopped work	Weeks	89	0 (0)	0.00 (0.00)	89	0 (0)	0.00 (0.00)
Unpaid care other carers <sup>a</sup>	Hours	93	53 (57)	154.89 (36.97)	89	53 (60)	118.22 (29.03)
Time off work other carers <sup>a</sup>	Days	93	3 (3)	0.01 (0.01)	88	4 (5)	0.00 (0.00)
ATT devices (including basic <sup>b</sup> )	Items	93	85 (91)	3.63 (0.24)	87	72 (83)	2.78 (0.22)
<p>a 'Other carers' = other relatives and friends who provide care.</p> <p>b 'Including basic' = all ATT devices recorded on ATT checklist including 'basic' ATT (e.g. key safes, standard smoke alarms).</p>							



## Appendix 6 Mean cumulative costs

Mean cumulative costs (SEs): intervention costs, total health and social care and societal costs (at opportunity and replacement cost valuation of unpaid carer time) from baseline to 104 weeks (£, 2016–17).

Cost	Trial arm						Intervention – control	
	Intervention			Control			Mean difference	95% CI
	n	Mean	SE	n	Mean	SE		
	<i>Expected = 229</i>			<i>Expected = 224</i>				
Intervention: ATT including baseline ATT cost <sup>a</sup>	223	408	18	203	288	16	119***	71 to 168
Intervention: ATT over 104 weeks' follow-up	223	322	18	203	214	15	109***	62 to 155
Health and social care	210	19,232	3086	201	16,073	2189	3159	-4337 to 10,655
Intervention + health and social care	205	19,649	3206	189	15,186	2102	4463	-3209 to 12,135
Societal <sup>b</sup>	208	55,209	4404	200	58,272	4473	-3064	-15,405 to 9277
Intervention + societal <sup>b</sup>	203	56,000	4579	188	53,378	4441	2622	-9953 to 15,196
<b>Sensitivity analysis</b>								
Societal <sup>c</sup>	208	128,935	8862	200	139,524	10,008	-10,589	-36,816 to 15,638
Intervention + societal <sup>c</sup>	203	129,845	9163	188	125,952	10,026	3893	-22,756 to 30,543

\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .

a ATT costs: includes the costs of the ATT assessment and ATT package installed prior to baseline assessment.

b Societal costs: participant's health and social care costs; unpaid carers' time in care and support to participant (opportunity cost valuation); expenditure by self or family on travel to appointments, equipment purchases.

c Societal costs: participant's health and social care costs; unpaid carers' time in care and support to participant (replacement cost valuation); expenditure by self or family on travel to appointments, equipment purchases.

### Note

Sample includes any participant who had participated in a baseline assessment and whose data for that cost at baseline were not missing.



## Appendix 7 Economic evaluation and caregiver data supplementary tables and figures

TABLE 30 Difference-in-difference model estimates: average 3-month costs at baseline and across the 24-week follow-up period

Costs	Time point					
	Baseline		Follow-up period		Follow-up – baseline	
	Mean	SE	Mean	SE	Mean	95% CI
<b>Health and social care</b>					<b>N = 287</b>	
Intervention	2295	250	2785	384	490	-97 to 1078
Control	2541	356	2665	434	124	-917 to 1164
<b>Societal</b>					<b>N = 284</b>	
Intervention	8152	545	8978	553	825	-172 to 1823
Control	8558	614	9133	640	574	-730 to 1878
<b>Note</b>						
Available cases at 24 weeks = cost and participant-reported EQ-5D data available from baseline and at least one follow-up point.						

TABLE 31 Difference-in-difference model estimates: average 3-month EQ-5D index scores at baseline and across the 24-week follow-up period

Costs	Time point					
	Baseline		Follow-up period		Follow-up – baseline	
	Mean	SE	Mean	SE	Mean	95% CI
<b>EQ-5D-5L-participant</b>					<b>N = 287</b>	
Intervention	0.746	0.017	0.747	0.017	0.001	-0.027 to 0.028
Control	0.792	0.020	0.804	0.017	0.012	-0.017 to 0.04
<b>EQ-5D-5L-proxy</b>					<b>N = 309</b>	
Intervention	0.546	0.014	0.546	0.013	0.000	-0.026 to 0.026
Control	0.565	0.016	0.531	0.016	-0.034	-0.066 to -0.002
<b>Note</b>						
Available cases at 24 weeks = cost and outcomes data available from baseline and at least one follow-up point.						

TABLE 32 Difference-in-difference model estimates: average 3-month costs at baseline and across the 52-week follow-up period

Costs	Time point					
	Baseline		Follow-up period		Follow-up - baseline	
	Mean	SE	Mean	SE	Mean	95% CI
<b>Health and social care<sup>d</sup></b>					<b>N = 229</b>	
Intervention	2250	291	3239	493	989	158 to 1819
Control	2504	447	2959	497	455	-706 to 1616
<b>Societal</b>					<b>N = 227</b>	
Intervention	7961	584	9665	668	1704	569 to 2838
Control	8450	709	10,038	759	1588	3 to 3174
<b>Note</b> Available cases at 52 and 104 weeks = cost and participant-reported EQ-5D data available from baseline and at least two follow-up points.						

TABLE 33 Difference-in-difference model estimates: average 3-month EQ-5D index scores at baseline and across the 52-week follow-up period

Outcomes	Time point					
	Baseline		Follow-up period		Follow-up - baseline	
	Mean	SE	Mean	SE	Mean	95% CI
<b>EQ-5D-5L-participant</b>					<b>N = 229</b>	
Intervention	0.774	0.016	0.766	0.017	-0.008	-0.038 to 0.021
Control	0.774	0.016	0.766	0.017	-0.008	-0.038 to 0.021
<b>EQ-5D-5L-proxy</b>					<b>N = 257</b>	
Intervention	0.569	0.013	0.539	0.013	-0.031	-0.057 to -0.004
Control	0.575	0.018	0.517	0.016	-0.057	-0.089 to -0.025
<b>Note</b> Available cases at 52 and 104 weeks = cost and outcome data available from baseline and at least two follow-up points.						

TABLE 34 Difference-in-difference model estimates: average 3-month costs at baseline and across 104-week follow-up period

Costs	Time point					
	Baseline		Follow-up period		Follow-up - baseline	
	Mean	SE	Mean	SE	Mean	95% CI <sup>b</sup>
<b>Health and social care<sup>d</sup></b>					<b>N = 243</b>	
Intervention	2257	295	3639	538	1381	409 to 2360
Control	2502	40	3185	526	683	-547 to 1913
<b>Societal</b>					<b>N = 241</b>	
Intervention	8037	600	10,051	696	2013	640 to 3387
Control	8536	691	10,397	735	1860	273 to 3449
<b>Note</b> Available cases at 52 and 104 weeks = cost and participant-reported EQ-5D data available from baseline and at least two follow-up points.						



TABLE 35 Difference-in-difference model estimates: average 3-month EQ-5D index scores at baseline and across the 104-week follow-up period

Outcomes	Time point					
	Baseline		Follow-up period		Follow-up - baseline	
	Mean	SE	Mean	SE	Mean	95% CI
<b>EQ-5D-5L-participant</b>					<b>N = 243</b>	
Intervention	0.767	0.016	0.752	0.017	-0.015	-0.043 to 0.012
Control	0.807	0.018	0.808	0.015	0.001	-0.026 to 0.027
<b>EQ-5D-5L-proxy</b>					<b>N = 266</b>	
Intervention	0.567	0.014	0.524	0.013	-0.064	-0.095 to -0.033
Control	0.573	0.018	0.509	0.015	-0.043	-0.07 to -0.017

**Note**  
Available cases at 52 and 104 weeks = cost and outcome data available from baseline and at least two follow-up points.




FIGURE 13 Cost-effectiveness acceptability curve: institutionalisation-free days and total costs at the 104-week follow-up.




FIGURE 14 The CEAC at the 24-week follow-up: EQ-5D-proxy index scores and health and social care costs. MCID, minimal clinically important difference. MCID = 0.74.




FIGURE 15 The CEAC at 52-week follow-up: EQ-5D-proxy index scores and health and social care costs. MCID, minimal clinically important difference. MCID = 0.74.




FIGURE 16 The CEAC at 104-week follow-up: EQ-5D-proxy index scores and health and social care costs. MCID, minimal clinically important difference. MCID = 0.74.




FIGURE 17 Cost-effectiveness acceptability curve: person with dementia QALY derived from the EQ-5D-proxy and total costs at the 24-week follow-up.




FIGURE 18 Cost-effectiveness acceptability curve: person with dementia QALY derived from the EQ-5D-proxy and total costs at the 52-week follow-up.




FIGURE 19 Cost-effectiveness acceptability curve: person with dementia QALY derived from the EQ-5D-proxy and total costs at the 104-week follow-up.

TABLE 36 Mean costs (SEs): unpaid care and total costs from the societal perspective with unpaid care valued at replacement cost over the previous 3 months, at baseline and at the 12-, 24-, 52- and 104-week assessments (£, 2016–17)

Cost	Trial arm						Intervention – control	
	Intervention			Control			Mean difference	95% CI
	n	Mean	SE	n	Mean	SE		
<b>Baseline</b>	<b>Expected = 229</b>			<b>Expected = 224</b>				
Unpaid care <sup>a</sup>	217	18,270	1240	202	20,106	1334	-1836	-5410 to 1739
Intervention + societal <sup>b</sup>	203	20,502	1285	188	23,102	1493	-2600	-6457 to 1256
<b>Week 12</b>	<b>Expected = 189</b>			<b>Expected = 188</b>				
Unpaid care <sup>a</sup>	186	19,802	1332	183	22,229	1511	-2427	-6384 to 1530
Intervention + societal <sup>b</sup>	181	22,569	1371	160	25,187	1696	-2618	-6869 to 1632
<b>Week 24</b>	<b>Expected = 178</b>			<b>Expected = 168</b>				
Unpaid care <sup>a</sup>	175	21,685	1528	168	22,830	1602	-1144	-5497 to 3208
Intervention + societal <sup>b</sup>	170	24,769	1575	151	25,719	1716	-951	-5527 to 3625
<b>Week 52</b>	<b>Expected = 150</b>			<b>Expected = 139</b>				
Unpaid care <sup>a</sup>	147	20,117	1517	136	25,180	1791	-5063*	-9661 to -464
Intervention + societal <sup>b</sup>	143	24,582	1633	128	28,512	1914	-3930	-8854 to 995
<b>Week 104</b>	<b>Expected = 96</b>			<b>Expected = 90</b>				
Unpaid care <sup>a</sup>	93	21,337	2035	89	23,652	2103	-2316	-8088 to 3457
Intervention + societal <sup>b</sup>	92	27,125	2527	84	29,122	2161	-1998	-8620 to 4624

\* $p < 0.05$ .

a Unpaid carers' time in care and support to participant valued at the cost of a home care worker.

b Societal costs: participant's health and social care costs; unpaid caregivers' time in care and support to participant valued at the cost of a home care worker; expenditure by self or family on travel to appointments, equipment purchases.

TABLE 37 Difference-in-difference estimates at 104 weeks: differences in between-group differences on participant and proxy-rated EQ-5D scores and 3-month costs (unpaid care valued at replacement cost)

	Difference	95% CI <sup>a</sup>	ICER <sup>b</sup> (difference in costs/MCID)
<b>Person with dementia-reported</b>			
	N = 241		
EQ-5D <sup>c</sup>	-0.019	-0.06 to 0.017	316/-0.262 = -1209
Societal <sup>d</sup>	316	-3457 to 3978	
<b>Person with dementia proxy-reported</b>			
	N = 266		
EQ-5D-proxy <sup>c</sup>	0.021	-0.022 to 0.06	-288/0.281 = -1024
Societal <sup>d</sup>	-281	-3930 to 3249	

MCID, minimal clinically important difference.

a 95% CIs, bootstrapped estimates (5000 replications).

b Cost per gain of 0.074 in EQ-5D.<sup>78,79</sup>

c Estimates from outcome equation: covariates are allocation to ATT, BADLS categories and stratifiers.

d Estimates from costs equation: covariates are allocation to ATT, BADLS categories and stratifiers.

**Note**

Available cases: cost and outcome data available from baseline and at least two follow-up points.

TABLE 38 Institutionalisation-free days and societal costs (unpaid care valued at replacement cost) at 104 weeks (£, 2016–17) (n = 450)

	Trial arm		Control <sup>a</sup>		Intervention - control		Cost per institutionalisation-free day <sup>a</sup>
	Intervention <sup>a</sup>		Mean	95% CI <sup>b</sup>	Mean difference	95% CI <sup>b</sup>	
	Mean	95% CI <sup>b</sup>					
Societal costs (£)	131,847	119,111 to 146,973	133,781	119,333 to 149,963	-1934	-19,986 to 16,892	-1934/7.898 = -245
Institutionalisation-free days	597.075	572.464 to 620.939	589.177	563.373 to 614.062	7.898	-26.438 to 42.425	

a Difference in QALYs rounded to the third decimal place.  
b 95% CIs, bootstrapped estimates (25,000 replications).

TABLE 39 Societal costs and QALYs (unpaid care valued at replacement cost) at 104 weeks (£, 2016–17) (n = 450)

	Trial arm		Control <sup>a</sup>		Intervention - control		Cost per QALY
	Intervention <sup>a</sup>		Mean	95% CI <sup>b</sup>	Mean difference	95% CI <sup>b</sup>	
	Mean	95% CI <sup>b</sup>					
Societal costs (£)	131,847	119,111 to 146,973	133,781	119,333 to 149,963	-1934	-19,986 to 16,892	
QALY - EQ-5D-participant	1.201	1.127 to 1.271	1.306	1.234 to 1.376	-0.105*	-0.204 to -0.007	-1934/-0.105 = 18,371
QALY - EQ-5D-proxy	0.828	0.762 to 0.894	0.798	0.733 to 0.861	0.030	-0.058 to 0.117	-1934/0.030 = -63,587

\**p* < 0.05.  
a Difference in QALYs rounded to the third decimal place.  
b 95% CIs, bootstrapped estimates (25,000 replications).

TABLE 40 Principal component analysis of caregivers' responses on the ZBI

Negative appraisal of caring	Adequacy as a care partner	Care partner burden and strain
zarit12_rg.1	zarit20_rg.1	zarit18_rg.1
zarit8_rg.1	zarit21_rg.1	zarit5_rg.1
zarit2_rg.1	zarit15_rg.1	zarit9_rg.1
zarit17_rg.1		zarit19_rg.1
zarit11_rg.1		zarit16_rg.1
zarit14_rg.1		zarit4_rg.1
zarit3_rg.1		zarit22_rg.1
zarit1_rg.1		
zarit6_rg.1		

**Notes**  
Extraction method: principal component analysis.  
Rotation method: oblimin with Kaiser normalisation.

## Item loadings

Item	Item code	Component		
		1	2	3
Do you feel your social life has suffered because you are caring for the person you care for?	zarit12_rg.1	0.823		
Do you feel that the person you care for is dependent on you?	zarit8_rg.1	0.715		
Do you feel that because of the time you spend with the person you care for that you do not have enough time for yourself?	zarit2_rg.1	0.710		
Do you feel that you have lost control of your life since the illness/disability of the person you care for?	zarit17_rg.1	0.597		
Do you feel that you do not have as much privacy as you would like because of the person you care for?	zarit11_rg.1	0.595		
Do you feel that the person you care for seems to expect you to take care of him/her as if you were the only one he/she could depend on?	zarit14_rg.1	0.576		
Do you feel stressed between caring for the person you care for and trying to meet other responsibilities for your family or work?	zarit3_rg.1	0.425	0.313	
Do you feel that the person you care for asks for more help than he/she needs?	zarit1_rg.1	0.424		
Do you feel that the person you care for currently affects your relationships with other family members or friends in a negative way?	zarit6_rg.1	0.404		
Do you feel your health has suffered because of your involvement with the person you care for?	zarit10_rg.1	0.387		-0.378
Do you feel you should be doing more for the person you care for?	zarit20_rg.1		0.855	

Item	Item code	Component		
		1	2	3
Do you feel you could do a better job in caring for the person you care for? Values	zarit21_rg.1		0.806	
Do you feel that you do not have enough money to take care of the person you care for in addition to the rest of your expenses?	zarit15_rg.1	0.361	0.415	
Are you afraid what the future holds for the person you care for?	zarit7_rg.1	0.340	0.346	
Do you wish you could leave the care of the person you care for to someone else?	zarit18_rg.1			-0.758
Do you feel angry when you are around the person you care for?	zarit5_rg.1			-0.713
Do you feel strained when you are around the person you care for?	zarit9_rg.1			-0.674
Do you feel uncertain about what to do about the person you care for?	zarit19_rg.1			-0.613
Do you feel that you will be unable to take care of the person you care for much longer?	zarit16_rg.1			-0.602
Do you feel embarrassed over the behaviour of the person you care for?	zarit4_rg.1			-0.584
Overall, how burdened do you feel in caring for your relative?	zarit22_rg.1			-0.576
Do you feel uncomfortable about having friends over because of the person you care for?	zarit13_rg.1	0.369		-0.391

TABLE 41 The ZBI scores for co-resident caregivers, by time point and trial arm

	F-value	df		p-value
		1	2	
<b>Total score</b>				
Time	1.233	2	24754846	0.291
Group	0.646	1	561897	0.422
Interaction	0.466	2	89862616	0.628
<b>Component 1: negative appraisal</b>				
Time	1.552	2	1562062	0.212
Group	0.504	1	483265	0.478
Interaction	0.816	2	6865985	0.442
<b>Component 2: adequacy as a care partner</b>				
Time	0.582	2	407414	0.559
Group	0.111	1	92008	0.739
Interaction	0.849	2	195724	0.428
<b>Component 3: burden and strain</b>				
Time	2.027	2	608124	0.132
Group	1.237	1	1260074	0.266
Interaction	0.838	2	1370133	0.433
df, degrees of freedom.				



TABLE 42 The ZBI mean and component scores for co-resident caregivers, by time point and trial arm

Time point	Trial arm	Mean	SE	95% CI
<b>Total score</b>				
Baseline	Control	25.0	2.84	19.4 to 30.5
	ATT intervention	25.1	2.92	19.4 to 30.8
Week 12	Control	25.5	2.91	19.8 to 31.2
	ATT intervention	26.3	2.98	20.5 to 32.2
Week 24	Control	25.2	2.93	19.4 to 30.9
	ATT intervention	27.1	2.98	21.2 to 32.9
<b>Component 1: negative appraisal</b>				
Baseline	Control	11.6	1.34	9.0 to 14.2
	ATT intervention	11.6	1.38	8.9 to 14.3
Week 12	Control	12.3	1.38	9.6 to 15.0
	ATT intervention	11.8	1.41	9.0 to 14.5
Week 24	Control	11.9	1.40	9.2 to 14.7
	ATT intervention	12.8	1.41	10.0 to 15.5
<b>Component 2: adequacy as a care partner</b>				
Baseline	Control	3.5	0.53	2.4 to 4.5
	ATT intervention	3.5	0.54	2.5 to 4.6
Week 12	Control	3.2	0.54	2.1 to 4.2
	ATT intervention	3.8	0.55	2.7 to 4.8
Week 24	Control	3.3	0.55	2.2 to 4.4
	ATT intervention	3.4	0.55	2.4 to 4.5
<b>ZBI Component 3: Burden and strain</b>				
Baseline	Control	6.1	1.08	4.0 to 8.2
	ATT intervention	6.3	1.10	4.1 to 8.4
Week 12	Control	6.3	1.11	4.2 to 8.5
	ATT intervention	7.2	1.13	5.0 to 9.4
Week 24	Control	6.0	1.12	3.8 to 8.2
	ATT intervention	7.0	1.13	4.8 to 9.2

TABLE 43 The STAI-6 and CES-D-10 for co-resident caregivers, by time point and trial arm

	F-value	df		p-value
		1	2	
<b>STAI-6</b>				
Time	1.388	2	25730363	0.250
Group	2.290	1	6245543	0.130
Interaction	0.489	2	15591551	0.613
<b>CES-D-10</b>				
Time	0.246	2	503980	0.782
Group	0.016	1	370269	0.899
Interaction	0.159	2	916269	0.853

df, degrees of freedom.

TABLE 44 The Anxiety and Depression mean scores for co-resident caregivers, by time point and trial arm

Time point	Trial arm	Mean	SE	95% CI
<b>STAI-6</b>				
Baseline	Control	37.5	2.51	32.6 to 42.5
	ATT intervention	39.2	2.55	34.2 to 44.2
Week 12	Control	38.7	2.61	33.6 to 43.9
	ATT intervention	40.0	2.64	34.8 to 45.2
Week 24	Control	38.4	2.65	33.2 to 43.6
	ATT intervention	41.9	2.64	36.7 to 47.1
<b>CES-D-10</b>				
Baseline	Control	8.8	1.05	6.7 to 10.9
	ATT intervention	8.3	1.07	6.2 to 10.4
Week 12	Control	8.7	1.08	6.6 to 10.8
	ATT intervention	8.1	1.10	6.0 to 10.3
Week 24	Control	8.6	1.09	6.5 to 10.8
	ATT intervention	8.5	1.10	6.4 to 10.7

TABLE 45 The ZBI scores for spousal caregivers, by time point and trial arm for total burden and principal components

	F-value	df		p-value
		1	2	
<b>Total score</b>				
Time	0.372	2	74615089	0.690
Group	0.007	1	404895	0.931
Interaction	0.150	2	119338508	0.861
<b>Component 1: negative appraisal</b>				
Time	0.816	2	7177464.9	0.442
Group	0.019	1	1066716	0.890
Interaction	1.038	2	20626935	0.354
<b>Component 2: adequacy as a care partner</b>				
Time	0.755	2	456838.93	0.470
Group	0.251	1	136990.12	0.617
Interaction	0.767	2	236804.1	0.465
<b>Component 3: burden and strain</b>				
Time	1.491	2	523331.74	0.225
Group	0.237	1	1210269	0.626
Interaction	0.672	2	2791857	0.511
df, degrees of freedom.				

TABLE 46 The ZBI mean and component scores for spousal caregivers, by time point and trial arm

Time point	Trial arm	Mean	SE	95% CI
<b>Total score</b>				
Baseline	Control	31.7	1.69	28.4 to 35.1
	Intervention	31.3	1.76	27.8 to 34.7
Week 12	Control	32.5	1.76	29.0 to 35.9
	Intervention	31.8	1.82	28.2 to 35.4
Week 24	Control	32.0	1.79	28.5 to 35.5
	Intervention	32.2	1.83	28.6 to 35.8
<b>Component 1: negative appraisal</b>				
Baseline	Control	15.5	0.801	13.9 to 17.1
	Intervention	15.5	0.832	13.9 to 17.1
Week 12	Control	16.3	0.843	14.6 to 17.9
	Intervention	15.3	0.871	13.6 to 17.0
Week 24	Control	15.9	0.864	14.2 to 17.6
	Intervention	16.1	0.877	14.3 to 17.8
<b>Component 2: adequacy as a care partner</b>				
Baseline	Control	3.5	0.29	2.9 to 4.1
	Intervention	3.6	0.30	3.0 to 4.2
Week 12	Control	3.4	0.31	2.8 to 4.0
	Intervention	3.7	0.32	3.1 to 4.3
Week 24	Control	3.6	0.32	2.9 to 4.2
	Intervention	3.4	0.32	2.7 to 4.0
<b>Component 3: burden and strain</b>				
Baseline	Control	7.9	0.62	6.7 to 9.1
	Intervention	7.6	0.64	6.4 to 8.9
Week 12	Control	8.1	0.65	6.8 to 9.3
	Intervention	8.4	0.67	7.1 to 9.7
Week 24	Control	7.7	0.66	6.4 to 9.0
	Intervention	8.1	0.67	6.8 to 9.4

TABLE 47 The CES-D-10 and STAI-6 scores for spousal caregivers, by time point and trial arm

	F-value	df		p-value
		1	2	
<b>CES-D-10</b>				
Time	1.668	2	941283.6	0.189
Group	0.977	1	1667711	0.323
Interaction	1.564	2	1978748	0.209
<b>STAI-6</b>				
Time	2.583	2	52141891	0.076
Group	3.061	1	6614194	0.080
Interaction	0.986	2	13038219	0.373

df, degrees of freedom.

TABLE 48 The Anxiety and Depression mean scores for spousal caregivers, by time point and trial arm

Time point	Trial arm	Mean	SE	95% CI
<b>CES-D-10</b>				
Baseline	Control	11.1	0.63	9.9 to 12.4
	Intervention	10.9	0.65	9.6 to 12.2
Week 12	Control	10.9	0.67	9.6 to 12.3
	Intervention	10.6	0.69	9.2 to 11.9
Week 24	Control	10.7	0.69	9.3 to 12.0
	Intervention	11.6	0.69	10.2 to 12.9
<b>STAI-6</b>				
Baseline	Control	41.1	1.45	38.3 to 43.9
	Intervention	42.4	1.49	39.4 to 45.3
Week 12	Control	41.8	1.57	38.7 to 44.8
	Intervention	42.7	1.60	39.6 to 45.9
Week 24	Control	41.7	1.63	38.6 to 44.9
	Intervention	45.5	1.63	42.3 to 48.7



EME  
HS&DR  
**HTA**  
PGfAR  
PHR

Part of the NIHR Journals Library  
[www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

*This report presents independent research funded by the National Institute for Health Research (NIHR).  
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the  
Department of Health and Social Care*

***Published by the NIHR Journals Library***